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Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of Adult T-cell Leukemia 
(ATL), a lymphoproliferative disorder with a very poor prognosis. While approximatively 5% of 
individuals infected with HTLV-1 develop ATL within twenty years of first infection, the 
molecular mechanism that the virus uses to induce ATL is not entirely understood. microRNAs 
are posttranscriptional regulators involved in a wide range of biological processes. Based on 
biological functions, alteration of their expression can potentially contribute to tumor initiation 
and progression. The purpose of this thesis is to study changes in miRNA expression and their 
role in the deregulation of cellular pathways essential in HTLV-1-transformed and ATL cells.  
Moreover, the absence of an effective treatment for patients led to investigation of potential 
therapeutic strategies for ATL. Since previous findings show that DNA repair is impaired in 
HTLV-1-transformed cells, this thesis is focused on targeting DNA repair as a new therapeutic 
option in ATL. More specifically, the aim is the study of antiproliferative effects and cytotoxicity 
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In recent years, retroviruses have received increased attention, not only for their importance as 
human pathogens but also for their exceptional value as experimental objects. Their unique 
replication leads to distinctive biological characteristics.  
Retroviruses display a large variety of interaction with hosts, ranging from benign infections to 
fatal pathogenesis, however, among this family, major pathogens of all vertebrates are included. 
Human Immunodeficiency Virus type I, HIV, belongs to this family and is responsible for 
Acquired Immunodeficiency Syndrome (AIDS), which has caused more deaths than all 
pathogens in contemporary history [1-3]. Retroviruses have a genome encoded for Reverse 
Transcriptase and Integrase, which quickly become useful tools for nucleic acid manipulation in 
vitro and in vivo, and they can also be used to insert therapeutic genes into target cells [4, 5]. 
Currently, retroviruses serve modern medicine as a valuable tool for gene therapies. Moreover, 
retrovirus sequences can be utilized as a marker of evolutionary history. The insertion of the 
provirus in the germ line can be used as a Mendelian tag to study speciation, migration, and 
divergence of species [6].  
 
Retrovirus structure 
The retrovirus family includes a large number of viruses, primarily of vertebrates, which are 
responsible for different diseases, including human malignancies, neurological disorders and 
immunodeficiencies. Retrovirus structure is similar to general virions, enveloped in a 100 nm 
diameter. The surface presents a single protein structure, generally assembled in a trimer of two 
protein subunits, encoded by the Env gene. The nucleocapsid, also named core, can be spherical 
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or conical made by three to four protein products encoded by the Gag genes. Additionally, in the 
nucleocapsid are located catalytic proteins involved in the replication of the virus, including 
protease and the products of the pol gene – reverse transcriptase and integrase. The reverse 
transcriptase converts the viral genetic information from single strand RNA to double strand 
DNA (provirus); on the other hand, the integrase is required to join the provirus to the host 
cellular DNA. The retrovirus genome consists of two copies, generally identical, of a single 
strand RNA ranging from 7-10 kb, reminiscent to cellular RNA, including 3` polyadenylation 
and 5` capping. The genome encoded for Gag, Pol, and Env [7, 8].  
The cleavage of Gag, Pol, and Env gene products leads to the formation of the mature virions. 
These proteins are called by two letters as follows: CA - capsid, NC - nucleocapsid, PR - 
proteinase, DU - dUTPase, RT - reverse transcriptase, IN -  integrase, SU - surface protein, and 











Figure 1. Schematic representation of structure and composition of a retrovirus 
The core contains the viral genome and the RT - reverse transcriptase, IN - integrase, and the PR 
- protease. The core is enclosed by the envelope, which presents transmembrane - TM and 
receptor binding - SU. 
 
Retrovirus replication  
In the replication of retroviruses two steps can be distinguished. The first phase includes the 
entry of the nucleocapsid into the cytoplasm, synthesis of double strand DNA using viral single 
strand RNA as a template, transfer of the provirus into the nucleus, and its integration into the 
host genome (Figure 2). This process is mediated by different viral enzymes, such as reverse 
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transcriptase and integrase. The second phase is characterized by synthesis and processing of the 
viral genome (by cellular RNA polymerases and translation machinery), and virus assembly by 
encapsulation of the genome by gag and gag/pol fusion proteins with the cell membrane, which 
lead to the release of the new viruses by budding [9, 10] (Figure 2). 
The retrovirus life cycle requires the following events:  
• receptor binding and membrane fusion 
• internalization and uncoating 
• reverse transcription of the RNA viral genome into double strand DNA (provirus) 
• integration of the provirus in the host genome 
• transcription of the provirus 
• splicing and nuclear export of the RNAs 
• translation of the RNAs to viral proteins 
• assembly of the virion and packaging of the genome 
• budding and release of the viral progeny 
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Encyclopedia Britannica, 2009 
Figure 2. Representation of retrovirus life cycle 
Top Left: In the early phase of the life cycle, the virus replicates its genome in the cytoplasm of 
the host cells. Subsequently, the provirus undergoes integration into the host genome. In the late 
stage of the life cycle, viral progeny is produced and released. 
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The HTLV family 
Human T-cell Leukemia Virus type -1 and -2 have been studied in the past decades based on 
their association with specific pathological conditions, such as hematopoietic malignancies and 
neuropathy [11-15].  
Adult T-cell leukemia, also named ATL, was described for the first time in 1977 in Japan. After 
that, HTLV-1 was reported in other geographic areas. Seroepidemiological studies allow for 
identification of the etiological role of HTLV-1 in ATL. Interestingly, an association between the 
virus and the hematopoietic malignancy was described in patients affected by ATL [16-22].  
HTLV-1 was first identified in T-lymphoblastic cell lines, HUT 102, which was established from 
a patient affected by cutaneous T-cell lymphoma. In an independent study from 1981 HTLV-1 
virus was isolated from MT-1 cell lines established from an ATL patient. The two viruses 
isolated from these cell lines were later identified as the same virus, HTLV-1, and associated 
with ATL and other diseases. It is now well-established that HTLV-1 is the etiological agent of 
ATL and neuropathies, including tropical spastic paraparesis (TSP) and HTLV-1-associated 
myelopathy (HAM) [23, 24].  
In 1978, HTLV-2 was identified for the first time in a T-cell line, Mo-T, established from the 
splenic tissue of a patient affected by hairy-cell leukemia. Based on serological cross-reactivity, 
the virus isolated was found to be similar to HTLV-1, and was then called HTLV-2. HTLV 
viruses both infected and transformed T cells in vitro. Only a few patients infected by HTLV-2 
have been studied and characterized and limited pieces of evidence are provided from these 
studies investigating the association between HTLV-2 and hairy-cell leukemia. Moreover, few 
clinical cases of neurological diseases have been described in HTLV-2-infected individuals. The 
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reduced number of subjects infected with HTLV-2 affected by specific diseases preclude 
demonstrating the etiological role of HTLV-2 in human pathogenesis [25-28].  
 
HTLV structure and gene products 
As a retrovirus, HTLV encodes for proteins typical of every retrovirus, which includes structural 
and enzymatic proteins: Gag, Pol, and Env. In addition to that, a unique region was described at 
the 3` end of the viral genome; this portion was named X-region because its role was unknown. 
The X-region presents four open reading frames (ORFs), two of which are now well 
characterized, and they encode for the viral regulatory proteins Tax, Rex and HBZ. Tax is 
essential for the cellular transformation and for this reason is reported as a viral oncoprotein [29-
33]. The Tax gene encodes for a protein responsible for the transcriptional activation of LTR, 
long terminal repeat. On the other hand, Rex is involved in the expression of the viral proteins 
and partially overlaps the oncoprotein Tax in the alternative reading frame. The full-length 
messenger RNA, mRNA, synthesizes for gag and pol gene products and is packed into the 
virions. The reverse transcriptase uses the cellular tRNA-Pro as a primer for the viral genomic 
RNA and produces a single spliced subgenomic mRNA that encodes for the Env gene, a doubly 
or complementary spliced subgenomic mRNA that has two introns removed and encodes for Rex 
and Tax genes. The Env initiation codon is the same as Tax and is located in the second exon of 
Tax/Rex mRNA. In contrast, the Rex start codon is located in the same exon, more precisely 50 
nucleotides upstream [34-38]. Many minor alternative spliced mRNA species have been reported 
by using RNase protection assay or RT-PCR in cells isolated from ATL or HAM/TSP patients. 
Figure 3 shows the arrangement of the ORFs, gene products and HTLV-1 genome. 
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Matsuoka M et al. Nature Reviews Cancer 2007 
Figure 3. Schematic representation of the HTLV genome 
The top figure illustrates the structure and organization of the HTLV genome and the gene 
products. In the HTLV genome, Gag, Pol, and Env genes are flanked by 5' and 3' long terminal 
repeats (LTRs). Interestingly, the 5' LTR is reported to be deleted or methylated in some ATL 
patients; however, the 3' LTR invariably remains intact in all cases. The figure illustrates that the 
pX region, located at the 3`side of the genome, encodes for several proteins - Tax, Rex, p21, p12, 




Generally, in retroviruses the gag protein is translated as a polyprotein precursor; HTLV-1 is not 
an exception. Gag polyprotein p55 undergoes a proteolytic cleavage, which leads to the release 
of 19 kD matrix - MA, 24 kD capsid - CA, and 15 kD nucleocapsid - NC. Consistent with other 
retroviruses, p19 undergoes transcriptional modification, which results in the addition of myristic 
acid to the N-terminus of the protein. Myristoylation targets the precursor polyprotein Gag to the 
inner layer of the cellular membrane. This molecular event is particularly important in the 
assembly and budding of virus from the infected cells [37, 39, 40].  
Moreover, additional viral Gag-related proteins have been described in an HTLV-1 context, 
which includes species with 28, 29, 37, 55 and 70 kD. Further analysis has shown that these 
species are immature precursors of three different Gag proteins. For instance, p29 and p55 have 
determinants related to the mature p19 and p24. However, pulse-case experiments clearly show 
that p55 is the precursor molecule. The 3` end of Gag open reading frame overlaps with the 5` 
part of Pol, which encodes for the protease. Gag polyprotein precursor carries out the synthesis 
of the protease by ribosomal frameshift. The role of the protease in an HTLV-1 context has been 
well documented; its function is to process the Gag products. Moreover, by catalyzing its self-
cleavage, the protease induces the activation of its mature form [41-44].  
 
Pol 
The polymerase region can potentially encode for 982 and 896 amino acid products in HTLV-1 
and HTLV-2, respectively, although a frameshift event is required to express the Pol gene, 
leading to an 863 amino acid open reading frame in HTLV-1 and 864 in HTLV-2. Moreover, the 
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pol gene encodes for reverse transcriptase and integrase genes, which are located in the 5` part of 
the Pol gene [45].  
 
Env 
The Env gene encodes for a glycoprotein of 61-69 kD; the size varies in the different cell lines. 
The precursor of the Env genes is reported to be detectable on the cellular surface of HTLV-1-
infected cells. The precursor envelope protein undergoes proteolytic cleavage, which leads to 
reliance on the mature forms: SU (gp46), the 46 kD surface glycoprotein, and TM (p21), the 21 
kD transmembrane protein. Interestingly, the culture media of HTLV-1-infected cells presents a 
significant level of free gp46, which are released from the cellular surface [46]. 
 
Tax 
The regulatory protein Tax and Rex are unique to the HTLV family and are involved in virus 
replication and cellular transformation. The HTLV-1 Tax gene encodes for a 40 kD 
phosphoprotein (Tax-1); on the other hand, in an HTLV-2 context the Tax gene encodes for a 37 
kD phosphoprotein (Tax-2). The homology between these two proteins is very high, around 77-
85%, and both localize in the nucleus of infected cells, with RNA polymerase II, slicing complex 
and specific transcription factors. Structural and functional analyses have shown that the Tax 
protein presents at least four domains. At the amino-terminal of the Tax protein from the residue 
2 to 50 is localized an activation domain, which performs its function mostly in the nucleus [30-
33, 47, 48].  
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Moreover, amino-terminal presents another domain, a zinc binding domain, also named zinc 
finger, from the residues 23 to 49, which is believed to be involved in protein-protein interaction. 
From the residues 161 to 211, the Tax protein contains a structural domain, and from the residues 
289 to 322 an activation domain. At the Serines residue 300 and 301 of the carboxyl terminus of 
Tax-1 are localized the major phosphorylation sites. The phosphorylation of one or both Serines 
results in the localization of Tax in the nucleus and mediated Tax-transcriptional activation. Tax 
activates the transcription and it promotes its initiation from the promoter in the 5` of LTR of the 
provirus genome [47, 48]. The oncoprotein Tax has an essential role in HTLV replication and T-
cell immortalization and its function is discussed in more detail in section 6. 
 
Rex 
In the HTLV-1 genome, the Rex gene encodes for 21 or 27 kD protein, whereas in HTLV-2 it 
encodes for a 26 or 27 kD product. The larger p24 and p26 are phosphorylated, which is 
considered essential for their function. The larger Rex products have been reported to be 
involved in the control of HTLV gene expression, however, the role of smaller Rex proteins, 
such as p21, p20/p22, are not entirely understood. Rex is necessary for virus replication and 
transcriptionally regulates viral gene expression. Moreover, the Rex protein increases the ratio of 
incomplete or complete splicing of mRNA in the cytoplasm of HTLV-infected cells [49, 50].  
Rex activity is mediated by specific cis-acting sequences in the LTR promoter. Rex requires two 
different cis-acting sequences, one named Rex-responsive element, RxRE, which is located at 
the 3` LTR in HTLV-1, and the other one called cis-acting repressing sequence, CRS, localized 
in the U5 region of LTR. RxRE allows overcoming the repression induced by CRS. The 
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phosphorylated Rex proteins are located in the nucleus, more precisely in the nucleoli of HTLV-
1/HTLV-2 infected cells. Functional studies of Rex have shown that it presents three different 
regions. The first domain contains an arginine-rich region and it mediated the RNA binding by a 
direct interaction with RxRE. The second region is located near the RNA-binding domain and is 
necessary for the assembly of multimeric Rex complex onto RxRE. Finally, the third action 
domain presents a short leucine-rich sequence, which interacts with Rab and additional 
nucleoporin-like factors to mediate the nuclear export [51, 52].  
The molecular mechanism by which Rex/RxRE interaction leads to the expression of structural 
and enzymatic viral proteins is still unclear; however, it has been reported that Rex-1 enhances 
the transport of incompletely spliced HTLV-1 and HIV RNA. An additional study found that 
Rex-1 induced the significant increase of unspliced viral RNA by reducing intron excision and 
degradation in the nucleus. Experimental evidence shows that Rex-2 promotes the stability of the 
unsliced Gag/Pol RNA and the transport of spliced RNAs from the nucleus to the cytoplasm. The 
increased rate of incomplete spliced RNA was found to be associated with a decrease of 
complete sliced Tax/Rex RNA. Moreover, evidence suggests that Rex -1 improves the stability 
of Interleukin 2 receptor IL-2R alpha chain (IL-2R) mRNA and might be consequently involved 
in the cellular transformation of infected cells. Based on Rex’s essential role in HTLV-1 
replication, it is hard to investigate its contribution to cellular transformation. In HTLV-1 and -2, 
between the termination of the Env genes and the third exon of the Tax and Rex genes, a region 
of approximately 600 nucleotides has been described. This sequence was named pX, and it was 
initially referred to as an untranslated region because the ORF within this region was not found 
in infected cells. The pX region is conserved in the HTLV family, although the homology in 
HTLV-1 and -2 is low compared to the rest of the viral genome [53, 54].  
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HBZ 
The oncoprotein Tax has an essential role in HTLV replication and T-cell immortalization. 
While the transcripts of the Tax gene are detected in nearly 40% of ATL cells, HBZ RNA is 
ubiquitously expressed in ATL cells. The distinct expression of HBZ and Tax suggests that these 
proteins have a different role in HTLV-1 pathogenesis. 
The HTLV-1 genome encodes for an antisense transcript termed the HTLV-1 bZIP factor, HBZ. 
Recent evidence has shown that the HBZ gene presents two transcription isoforms: the unspliced 
form, termed usHBZ, and a spliced form, named sHBZ. These transcripts display different 5′ 
UTRs; however, the usHBZ and sHBZ forms have high similar sequences except for the first 
amino acids - MVNFVSA for usHBZ and MAAS for sHBZ form - and they have similar 
functions [55-60].  
HBZ is a nuclear protein, which presents an activation domain, called AD, located at the N-
terminus, a central domain, CD, and a basic leucine zipper, bZIP, domain localized in the C-
terminus. The N-terminus of HBZ has been reported to have a transactivating potential when it is 
fused with the DNA-binding domain of GAL4 and for this reason is named AD. This HBZ 
domain has two LXXLL-like motifs that bind to the KIX domain of CBP/p300, a transcription 
coactivator involved in a broad range of cellular functions. These motifs also participate in the 
activation of TGF-β/Smad signaling, which is essential for HBZ-induced Foxp3 expression. The 
bZIP domain of HBZ undergoes heterodimerization with cellular bZIP proteins of the AP1 
superfamily, including CREB2 , c-Jun , JunB , JunD , CREB, MafB and ATF3. Mainly, 
HBZ/AP1 Heterodimerization leads to an impaired association of AP1 with their responsive 
DNA elements, however, in some cases, it promotes the DNA binding, for example for JunD. 
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The HBZ viral protein can undergo phosphorylation, acetylation or methylation; however, recent 
evidence has shown that none of these modifications affects its function [60]. 
The HBZ viral protein possesses cell proliferative function by interacting with CREB, CREB-2, 
CREM-Ia, ATF-1, c-Jun, JunB, and JunD. Importantly, thanks to its bZIP domain, HBZ 
suppresses Tax-mediated viral transcription and inhibits the canonical NF-κB pathway by 
compromising the DNA binding of p65 and promoting its degradation. Tax, in contrast, activates 
both the canonical and non-canonical NF-κB pathway, which has an antiapoptotic function in 
lymphoma cell lines [60, 61]. 
A further study suggested that the HBZ transcripts are also essential for the proliferation of 
HTLV-1-infected cells. Consistently, the HTLV-1 molecular clone with a mutation in the leucine 
zipper domain of HBZ displays reduced proviral load compared to wild-type when inoculated 
into rabbits. Importantly, HBZ enhances the activity of the human telomerase reverse 
transcriptase (hTERT) gene. Altogether this evidence supports the idea that HBZ is involved in 
viral replication and cellular proliferation. A possible interpretation of the 'antagonist' activity of 
Tax and HBZ is that the first is required to initiate transformation while the latter is needed to 
maintain the transformed phenotype in the late stage of the disease. It is still unclear if HBZ is 
also involved in the pathogenesis of HTLV-1-associated HAM/TSP [58, 62-66]. 
 
pX region ORFs I and II 
Different studies were performed to investigate the splice into ORFs located in the pX region in 
HTLV-1 and -2. Based on these studies three alternative splicings were described in HTLV-1 
that potentially encode for proteins from the pX sequence called ORF I and II (ORF III and IV 
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encode for Rex and Tax). By using mRNA from ORF I and II, scientists demonstrated that ORF 
I preferentially produced 12 kD protein and p12I, however, p27 kD products can be encoded. 
p12I presents four minimal SH3 binding motifs (PXXP) and is highly hydrophobic and localized 
in the cellular endomembranes. Evidence suggests that p12I can bind the beta and gamma chain 
of the IL-2 receptor. In contrast, ORF II in HTLV-1 encodes for two proteins: a full-length p 30 
II and truncated p13 II, which derived from the initiation of the first methionine codon in ORF II 
(that correspond at the carboxyl terminal of 87 residues of p30 II). Moreover, ORF II in 
alternative reading frame extends into the last exon of Tax and Rex. P30 II is localized in the 
nucleus and p13 II in the mitochondria. Segregation of ORF II suggests that p30 II and p13 II 
might have regulatory properties. Interestingly, p30 II has high homology with POU-M1, Pit1, 
Oct1 and -2. T cells transformed with the HTLV-1 virus that displays a mutation in p13 II 
present a different pattern of phosphorylation Vav, a signal transduction adaptor protein. 
Moreover, it has been reported that ATL patients frequently show early stop codons, suggesting 
that ORF II is probably not involved in the maintenance of the leukemia status. Based on what is 
known, the pX seems not to be involved either in the virus replication or cellular transformation 
in an HTLV-1 context [67-69]. However, additional studies are needed to better investigate the 
role of this region in HTLV pathogenesis.  
 
LTR 
The structure of the LTR promoter region is conserved in retroviruses. As in another retrovirus, 
three different parts, called U3, R and U5, characterize HTLV-1 LTR. The U3 region is 
responsible for the control of the transcription of the provirus genome. More specifically, three 
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21-nucleotides repeat, named Tax-responsive elements 1, TRE1, and are required for Tax 
transcriptional activation. Importantly, the U3 region presents a sequence involved in the 
termination of the polyadenylation of the messenger RNA. The polyadenylation site in the U3 
region is far away from the polyadenylation signal of R, at nearly 250 nucleotides. The 5` 
termination encodes for the end of the carboxyl terminus of Tax protein. Comparison analysis of 
LTR elements in HTLV-1 and -2 clearly show that these regions are essential for the regulation 
of viral gene expression, as they are consistently conserved in the HTLV family. The R and U5 
sequences are found to be longer when compared with other retroviruses [70-73].  
Multiple factors bind different sites of the HTLV LTR region to regulate viral gene transcription. 
Tax induces the transcription indirectly, without binding the LTR element. The most significant 
interaction occurs at the 21-nucleotides repeats, or TRE-1, of the LTR with the cyclic AMP 
response element protein/ activating transcription factor family, CREB/ATF. Several technical 
methods have been used to identify the proteins that interact with TRE-1 elements at the LTR 
promoter, which includes CREB homodimer, CREB/ATF-1 heterodimer, ATF-1 homodimer and 
others reported in Figure 2. The viral protein Tax does not interact directly with LTR. However, 
it stabilizes the binding of these factors. The Tax responding element, TRE-2, also called Ets 
response region, ERR-1, is localized between the two proximal TRE-1 domains. This element 
presents binding sites for Tif-1, Myb, Sp1, and Ets-1. Moreover, an additional Ets binding 
element has been reported, named ERR-2. Tax was found to interact with other transcription 




Genetic Variation in HTLV family 
HTLV-1 and HTLV-2 display high homology, nearly 65% of the nucleotides sequence. The 
similarity is greater in the Rex and Tax genes and lower in the 5` pX region and LTR. The 
variability among the genome isolated from different HTLV-1 viruses was found to be limited. 
The sequence of HTLV-1 isolated in Japan show from 97 to 99% homology; a similar 
percentage was found in isolated virus from other geographic areas, such as the Caribbean and 
Africa. Interestingly, phylogenetic studies identify four different HTLV-1 subtypes, named A, B, 
C, and D. The subtype A, also called Cosmopolitan, is the most diffuse and isolated in many 
different populations. This subtype comprises four groups: Transcontinental, North African, 
West African and Japanese. This distribution is not surprising and is consistent with the large-
scale migration of the infected population, which includes the slave trade from Africa to the 
Americas. Subgroups are also described in subclone B, the Central African clade. Subclone C, 
also named Australo-Melanesia clade, was shown to be present in the Solomon Islands and 
Papua New Guinea. In contrast, the subtype D, termed Central African Pygmies clade, was 
isolated in subjects in Gabon, Cameroon, and the Central African Republic.  
The origin of the HTLV-1 virus in not fully understood, however evidence suggests that it arises 
from the related simian virus, STLV-1, which has been present in Africa and Asia for thousands 
of years. The interaction between STLV-1-infected monkeys and humans and consequent 
evolution in the new host might be responsible for the origin of HTLV-1.  
The absence of genetic variability in the HTLV family is probably associated with the low level 
of virus replication. Genome replication occurs by clonal expansion of infected cells rather that 
reverse transcription. The frequency of mutations is significantly lower when the HTLV genome 
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is replicated during cell division compared to during reverse transcription, which introduces a 
high level of mutations. Importantly, cell-associated replication allows immune escape from the 
antibody response. Consistently, HTLV Env gene does not tolerate a high rate of mutation 
without becoming un-functional. This evidence might be involved in the conservation of the 
HTLV genome through the evolutionary process.  
 
HTLV-1 infectivity 
Efficient transmission of HTLV-1 requires cell-to-cell contact. However, infection with the cell-
free virus might occur. Usually, in vitro infection of target cells with HTLV is achieved by co-
culturing them with gamma-irradiated and mitomycin-C-treated HTLV-producing cells. 
Infection of HTLV has a slow course and is considered inefficient compared to other 
retroviruses. A possible explanation might be connected to the positive and adverse regulation 
mediated by Tax and Rex, respectively. Only T cells are reported to be transformed by HTLV-1 
infection, but it is well established that HTLV-1 can infect but not transform a wide range of cell 
types. For example, B cells and macrophages can be infected by HTLV-1 in vitro [79-81].  
Cases of ATL patients that present a central nervous system (CNS) involvement are rare, but a  
few cases are reported with a direct infection in the CNS. In vivo studies show that infection of 
HTLV-1 in dendritic cells can occur and might play a role in antigen presentation, immune 
activation, and neurological diseases. In ATL patients the HTLV-1-positive cells are 
CD4+/CD25+ T lymphocytes. Consistently, in vitro study shows that HTLV-1 transcription is 
enhanced in CD4+ T cells. In contrast, CD8+ T lymphocytes are predominantly infected by 
HTLV-2 [82-84].  
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Figure 4. HTLV-1 transmission requires the formation of a virological synapse 
Unlike many other viruses, cell-free HTLV-1 viral particles are poorly contagious. The figure 
illustrates HTLV-1 infection, which requires cell–cell contact between infected and uninfected T 
cells and the formation of a virological synapse. The viral genome is transmitted from one cell to 
another thanks to the synapse. In this molecular event, the lymphocyte function-associated 
antigen 1, LFA1, and intercellular adhesion molecule 1, ICAM1, are involved in the cell–cell 
contact, as shown in the figure. Importantly, the viral protein Tax contributes to the formation of 




As previously discussed, the HTLV-1 virus can infect different cell types. Accordingly, glucose 
transporter one protein, GLUT1, has been reported to be the receptor, mediating the entry of the 
virus. Moreover, additional evidence has shown that surface heparin proteoglycan serves as a 
receptor for HTLV-1 [85]. Heparin proteoglycan and GLUT1 were found to be ubiquitously 
expressed on the surface of a wide range of cell types. Both CD4+ and CD8+ T cells can be 
infected by HTLV-1, however, in vivo studies demonstrated that the infection occurs in CD4+ T 
cells. A possible explanation might be that HTLV-1 is capable of infecting different cell types; 
however, the infection selectively increases the abundance of a particular subset of cell types, 
possibly because of the action of virus accessory proteins [80, 85, 86]. 
 
Role of Tax in T-cell immortalization  
In vitro, both HTLV-1 and -2 can transform and immortalize primary peripheral blood T cells. 
Immortalization is achieved when cells proliferate in the presence of IL-2 in the culture media 
(IL-2-dependent). After a period, which ranges from 2 months to years, the cells became fully 
transformed and can grow in the absence of IL-2 in the culture media. 
HTLV-1-transfomed cells constitutively expressed a high proportion of proliferating cell nuclear 
antigens, such as erg-1 and erg-2, and the oncogenes c-myc, c-fos, c-jun and c-sis. Moreover, it 
is reported that the viral protein Tax repressed the transcription of β-polymerase and Bax, which 
accelerate the apoptosis. Tax indirectly activates different promoters and leads to the activation 
of several cellular pathways that promote the proliferation and survival of the infected cells, such 
as CREB/ATF, NF-KB/Rel, serum response factor (SRF), NF-AT, and basic helix-loop-helix 
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proteins (bHLH). Tax activates HTLV-1 gene transcription through the interaction with 
CREB/ATF proteins and the transcriptional coactivators CREB binding protein p300, CBP, 
which leads to the binding of those factors to the three 21-bp repeats present in the LTR [87-91].  
In addition, Tax activates NF-KB/Rel target genes by interacting with the member of this family 
and their inhibitors, like p50, RelA, p100/NF-KB2, and p105/NF-KB2. The NF-KB family 
members are sequestrated in the cytoplasm by the high-affinity binding inhibitors, IKBa and 
IKBb, which, following their ubiquitination degradation, result in the translocation in the nucleus 
of the NF-KB family members. Tax is involved in specific sites of phosphorylation of IKBa and 
IKBb, which leads to the degradation and nuclear translocation of the active NF-KB subunit. The 
phosphorylation involved different complexes containing the viral protein Tax, such as IkB 
kinases (IKK); IKKg/NEMO, IKKa, and IKKb; mitogen-activated kinases kinase 1 (MEKK1); 
NF-kB-inducing kinase (NIK); NF-kB/Rel, and IkBa or IkBb [92, 93].  
Mutants of Tax1 and Tax2 have been identified that specifically abrogate the ability of Tax to 
activate the NF-kB pathway or CREB/ATF pathway. These mutants are of particular importance 
because they can be used to understand which cellular pathway is involved in the interplay 
between Tax and transcription factors and cellular transformation [91, 94-100].  
Positive and negative regulators control cell cycle progression. HTLV-1 viral proteins affect this 
regulation by promoting cellular growth. Tax is reported to influence the p53 pathway and Bax. 
More specifically, Tax stabilizes p53 and inhibits its transactivation function, leading to the 
suppression of Bax expression. Tax enhances the transition between G0/G1 and S phase by 
interfering with the activity of Cyclin D, Cyclin-dependent kinases, cdk4 and cdk6, p21WAF and 
p16INK4A. Deregulation of the cell cycle progression might be involved in HTLV-1-mediated 
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cellular transformation. Moreover, it has been shown that Tax viral protein can interact with 
MAD1, mitotic checkpoint protein, leading to multinucleated cells and chromosomal 
abnormality [47, 101-113].  
 
Adult T-cell Leukemia 
Several stages can be identified in an ATL context: (a) asymptomatic carriers, (b) pre-leukemia 
stage, pre-ATL, (c) chronic/smoldering ATL, (d) lymphoma type, and (e) acute ATL. The vast 
majority of HTLV-1-infected individuals are asymptomatic carriers; only 3-5% develop ATL 
after 20-30 years. Asymptomatic carriers can transmit the virus because the viral HTLV-1 
genome is integrated into the host cells. Infected individuals have a 1% possibility of developing 
ATL during their lifetime; however, the cases of HTLV-1-associated conditions range from 5-
10% [13, 114-116].  
Adult T-cell leukemia is frequently diagnosed during adulthood, at least 20-30 years after 
infection. Some patients display pre-leukemia ATL, which is asymptomatic in most cases. 
HTLV-1 can be identified in infected individuals by using PCR amplification; the provirus can 
be detected in abnormal T cells by using Southern blot. These alterations indicate the early stage 
of the disease, which might progress to malignancy. Approximately 50% of patients with pre-
ATL undergo spontaneous repression of lymphocytosis. In the remaining 50% the lymphocytosis 
persists and some will develop acute ATL. Nearly 30% of patients with clinical symptoms will 
develop a chronic/smoldering ATL condition, which is less aggressive than the acute form of the 
disease, and is characterized by skin lesions, a low level of leukemic cells in the blood stream, 
and absence of visceral involvement [117-119].  
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Figure 5. The natural history of HTLV-1 inducing ATL 
Cell–cell transmission of HTLV-1 requires early expression of the viral protein, which is 
essential for the cellular transformation. On the other hand, HBZ is continuously expressed in 
infected cells. In the figure cells that contain '+' in the nucleus represent the HTLV-1-infected 
cells. The uninfected T cells are represented with an empty nucleus. The formation of a 
virological synapse is created by cell-to-cell contact with an infected cell. The clonal expansion 
of infected cells is enhanced by Tax and other HTLV-1 accessory proteins. After 20 to 40 years 
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of an asymptomatic period, ATL cells, also called flower cells for the characteristic shape of the 
nucleus, emerge in 5% of infected individuals. 
 
Patients with smoldering ATL display skin lesions and bone marrow involvement; on the other 
hand, patients with the chronic form of the disease present a high level of circulating ATL cells. 
Patients affected by smoldering/chronic ATL might progress into the acute form within a few 
months. Pre-ATL and smoldering/chronic ATL represent a transitional phase in the development 
of the more lethal and aggressive stage of the disease: acute ATL. In acute ATL a malignant and 
dominant clone of ATL cells is present. Consistently, single rearrangement of the T-cell antigen 
receptor and rearrangement of one or a few proviruses is found in the ATL cell populations. 
Typically, acute ATL patients show an elevated white blood cell count and abnormal T cells. 
Moreover, hepatosplenomegaly and skin lesions are frequent in acute ATL patients and might 
depend upon ATL cell infiltration. These patients manifest alteration of lactate dehydrogenase 
(LDH), hyperbilirubinemia, and hypercalcemia. Hypercalcemia is the result of increased lytic 
bone lesions in the skull and long bones. The hypercalcemia conditions depend upon the 
production of IL-1a and a parathyroid hormone by HTLV-1-infected cells. ATL patients are 
immunocompromised and display opportunistic infection. The only significant prognostic factor 
reported in ATL patients is the presence of ascites, which is associated with a poor prognosis. 
Median survival with acute ATL is six months, even with chemotherapy treatment [120, 121].  
ATL cells present a lobulated nucleus, also called flower shape nucleus, however the degree of 
this irregularity might vary. The characteristic shape of the nuclei of HTLV-2-transformed cells 
is consistent with the pleiotropic effect of the viral protein Tax, which includes chromosomal 
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abnormality and formation of micronuclei. ATL patients might present infiltration of lymph 
nodes, but nodal histopathology does not correlate with the prognosis or the response to 
treatment. Immunological study of ATL cells derived from patients shows that these cells are 
CD4+ and CD25+, showing that ATL cells are activated T cells. ATL rarely expressed a CD8 
marker; however, another specific marker of ATL cells is the increased expression of the IL-2Ra 
chain, which is attributed to the Tax pleiotropic effect [122-124]. 
When HTLV-1-infected T cells are present at high levels in the blood stream, Southern Blot 
analysis can be used to detect the viral sequence. This type of analysis highlights the integration 
of the HTLV-1 sequence in the host genome, and typically the integration is mono or 
oligoclonal. Rarely in healthy carriers and smoldering ATL is the integration polyclonal. 
Interestingly, cases of subjects that present similar ATL pathogenesis in the absence of HTLV-1 
infection are reported. The phenomenon can be explained by the loss of the HTLV-1 genome or 
by alternative factors that lead to development of a similar disease. It is well established in the 
field that HTLV-1 infects a polyclonal population of T lymphocytes, which undergo selective 
pressures leading to the evolution of a clone responsible for the malignancies. The chromosomal 
abnormalities are documented in ATL cells and correlate significantly with the severity of the 
malignancies. Consistently, the acute form of the disease displays a high rate of chromosomal 
abnormalities, which are less frequent in the smoldering/chronic form of ATL. As explained 
below, HTLV-1 transformed a pool of T cells that are oncogenic, but they might result in the 
evolution of a malignant clone responsible for the disease. This phenomenon requires an 
extended period, which goes from the infection to the manifestation of the disease. Tax, thanks to 
its pleiotropic effect, might contribute to this event [125, 126]. 
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In acute ATL patients, when the number of ATL cells are elevated in the blood stream, the 
HTLV-1 genome can be detected and is monoclonal based on the integration side. However, 
some patients display a polyclonal characteristic based on the integration side, which was found 
to be in different chromosomes. The integration of HTLV-1 is not in specific regions of the host 
genome, which often occurs in animal retroviruses wherein they randomly integrate into 
particular cellular oncogenes. 
One of the most typical characteristics of ATL cells is that even if all ATL cells present an 
integrated copy of the HTLV-1 genome, most of them display absent expression of HTLV-1 
genes. If ATL cells are cultured in vitro, they shortly express the HTLV-1 genes, suggesting that 
the lack of activation is not related to intrinsic defects of the viral genome. The absence of 
expression of the HTLV-1 genes might depend upon virus latency or an immune selection that 
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Figure 6. Adult T-cell leukemia 
(a) Typical morphology of ATL cells, showing multilobed nuclei, flower cells. (B) Elevated 
number of osteoclasts are noted in the bone of a hypercalcemic ATL patient. 
 
HTLV-1-associated myelopathy/tropical spastic paraparesis 
In 1985 a group of West Indian patients affected by tropical spastic paraparesis was found to be 
positive for HTLV-1. Consistently, in Japan patients with myelopathy and pyramidal disorder 
were found to be positive for HTLV-1. These pieces of evidence lead to the identification of 
another HTLV-1-associated disease, named HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP). The risk to develop HAM/TSP in HTLV-1-infected individuals is 
around 1%, similar to ATL. Neurological symptoms of HAM/TSP include weakness and 
spasticity of the extremities, hyperreflexia, Babinski sign, urinary/fecal incontinence and 
peripheral sensory loss. The cerebrospinal fluid, CSF, for the patients typically contained 
increased levels of protein and lymphocytic pleocytosis. The number of lymphocytes is 
frequently normal in HAM/TSP patients. However, some cases display morphological alteration 
of T cells, similar to ATL patients, in the peripheral blood or CSF. Magnetic resonance shows 
that HAM/TSP patients present lesions in the white matter and periventricular regions. 
Interestingly, autopsy studies highlighted the presence of abnormalities in the thoracic spinal 
cord, including demyelination, capillarity proliferation, and perivascular cuffing related to 
lymphocytic infiltration [53, 125, 130-132].  
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Figure 7. HTLV-1-associated myelopathy/tropical spastic paraparesis 
Schematic representation of the natural history of HTLV-1-associated myelopathy/tropical 
spastic paraparesis, which is a progressive disease of the Central Nervous System characterized 
by weakness and/or paralysis of the legs, urinary symptoms, and lower back pain. HTLV-1-
associated myelopathy/tropical spastic paraparesis induces chronic disability. HAM/TSP has 
limited therapeutic strategies because antiretroviral drugs have a limited effect on the infection. 
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Other HTLV-associated diseases 
Several studies have indicated a possible association between HTLV-1 infection and T-cell non-
Hodgkin`s lymphoma, T-prolymphocytic leukemia, Sezary`s syndrome and mycosis fungoides, 
small cell carcinoma and large granular lymphocytic leukemia. However, the limited data present 
in the studies make it difficult to determine a real association between the infection and these 
clinical conditions. HTLV-1 might have a role in some chronic lymphocytic leukemia, CLL, 
with B-cell origins. Consistently, in Jamaica where the virus is endemic the rate of HTLV-1 
infection in patients with B-cell CLL is significantly increased compared to the general 
population, suggesting that HTLV-1 is a risk for this type of hematopoietic malignancy.  
Clinical studies show that rare complications of HTLV-1 infection are uveitis and arthropathy. 
Moreover, lines of transgenic mice for HTLV develop chronic arthritis, showing that the virus 
might be one of the etiological agents of chronic arthritis in patients.  
ATL patients and some HTLV-1 carriers display defects in cellular immune response, which 
leads to parasitic infection. Consistently, immunosuppression is commonly associated with 
opportunistic infections [133-139].  
Interestingly, epidemiological studies show that a small group of subjects are positive for HTLV-
1 and HIV. This phenomenon typically happens in the intravenous drug abuser, IVDA, 
community, wherein contaminated needles are shared leading to infection with both viruses. 
These studies show that coinfection leads to acceleration of AIDS progression. It is probable that 
HTLV-1 can generate envelope pseudotyped with HIV particles, which promote the tropism of 
the virus and diffusion of the infection; however, this was not confirmed in vivo [138, 139].  
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HTLV-2 related diseases 
HTLV-2 infection has been reported worldwide, but primarily among IVDA in Amerindian 
populations in North, Central, and South America and in Africa. The role of HTLV-2 in the 
pathogenesis of leukemia and neurodegenerative disorder is still unclear since the number of 
clinical cases is not sufficient to clear epidemiological analysis. A better understanding of the 
role of HTLV-2 in human hematopoietic malignancies is needed, but more recent evidence 
shows that HTLV-2 might play a role in human diseases. Comparison studies between the 
different HTLV viruses might be useful to investigate the similarity and difference among this 
family [25, 140]. 
 
Immune response in ATL 
All ATL patients produce antibodies against different HTLV-1 antigens, Gag, Env and Tax. Sera 
derived from infected subjects recognized Gag proteins, p15, p19, and p24. Moreover, antibodies 
against envelope glycoprotein gp46 and transmembrane proteins, such as p21, have been 
detected in infected individuals. Many subjects also present antibody against non-structural 
proteins, for example, against the regulatory protein Tax. This is likely because the nuclear Tax 
is released from the nucleus after the lysis of infected cells, exposing this antigen to the immune 
system. Time course evaluation of seroconversion of infected individuals after transfusion with 
infected blood shows that antibodies against Gag proteins are produced in these subjects in the 
post-transfusion period. It is interesting to note that anti-p14 appears before anti-p19. The first 
antibody detected against Env proteins is anti-p21, while anti-gp46 and anti-gp61 are produced 
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later. Consistently, anti-Tax antibodies are the last to appear, several months after the transfusion 
[141, 142]. 
 
Epidemiology of HTLV infection 
HTLV-1 virus infection was identified for the first time in Japan and has now been found to be 
worldwide. Several pieces of evidence have shown HTLV-1 to be endemic in particular 
geographic areas in southwestern Japan, the Caribbean, Central Africa, parts of South America, 
the Middle East and Melanesia. The number of infected individuals around the world is found to 
be between 15 and 20 million. Initially, the association between HTLV-1 infection and ATL was 
discovered in southwestern Japan, which provides the first evidence of the etiologic relationship. 
Since then several clinical and epidemiological studies were performed to estimate the number of 
infected individuals in that country better. More recent evidence shows that the number of 
HTLV-1-infected subjects in Japan is over a million in a population of 121 million. A variety of 
the rate of HTLV-1 infection is reported in different regions: 35% in Okinawa, which is the area 
with the highest percentage, 8-18% in Kyushu Province, and 0-1.2% in the non-endemic area. 
Infection with HTLV-1 commonly occurs early in life. However, it was estimated that 30,000-
50,000 Japanese individuals had been infected through blood transfusion [143, 144].  
Recent studies show that the incidence of HTLV-1 infection is increasing worldwide, especially 
in the United States and Western Europe. The estimated percentage of HTLV-1 infection is 9% 
in Ghana, 8% in Kyushu district in Japan, 8% in Uganda, 3.2% in Zaire, 3% in Mashhad, Iran, 
2% in the Dominican Republic, and 0.003-0.04% in the United States of America. However, a 
serological study shows a prevalence of 9%, 18% and 41% of HTLV-1, HTLV-2, and HIV, 
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respectively, among intravenous drug abusers in New York City [145-150]. These data show that 
in populations exposed to both HTLV and HIV, HTLV-1 spreads less efficiently compared to 
HIV.  
 
Transmission of HTLV-1 
There are three routes of HTLV-1 transmission: from mother to child, through sexual contact, 
and from exposure to contaminated blood. Transmission of the HTLV-1 virus occurs similarly to 
HIV, with the only exception being that cell-free body fluids cannot transmit HTLV-1 because 
free viral particles are poorly infected. Consistently, co-cultivation of HTLV-1-positive cells 
with uninfected cells is required to infect target cells. An HTLV-1-infected mother can transmit 
the virus to the unborn or newborn child. The transmission can occur through transplacental 
passage or T cells present in breast milk. The percentage of HTLV-1 in children born from 
infected mothers is 16%. However, the prevalence in newborn children breastfed for over three 
months is significantly higher at 27%. And the percentage is 5% in children breastfed for less 
than three months. Several studies show that HTLV-1 is present in peripheral blood and breast 
milk, but rarely in cord blood. For this reason, transmission through the transplacental route is 
rare; postpartum transmission through breastfeeding is the primary transmission mode. For this 
reason, the HTLV-1-positive mother should refrain from breastfeeding to reduce the incidence of 
transmission [151-154].  
The second mode of HTLV-1 transmission occurs by sexual contact from an infected man to 
sexual partner, as HTLV-1-infected cells are found in semen. This was confirmed in Japanese 
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macaques infected by STLV-1, a retrovirus genetically similar to HTLV-1. It is possible that the 
transmission happens from women to men, however the efficiency is very low [155].  
The transmission of HTLV-1 can also occur through exposure to contaminated blood or 
transfusion, however, the transmission requires the presence of lymphocytes. The HTLV-1 
screening of blood donors started in 1988 in the United States of America. Before that, the 
incidence of HTLV-1 was higher that HIV, 0.043% compared to 0.013%, respectively [156]. 
This evidence shows the importance of a routine screening of blood donors for HTLV-1. 
However, only a few European countries perform the testing at the present day.  
 
Diagnosis of HTLV infection 
Several methods can be used for the diagnosis of HTLV-1, such as detection of antibodies and 
nucleic acid. HTLV-1 antibodies are relatively low compared to HIV-infected individuals. 
However, the level is sufficient for detection with ELISA assay or particle agglutination. In 
primary screening, ELISA/agglutination test is performed and then the results are confirmed 
using Western blot, radioimmunoprecipitation or PCR. To avoid the risk of a false positive a 
second validation is required. These depend upon the variability of the serological response to 
the virus and limit number of circulating antibodies in some subjects.  
In infected individuals, the development of antibodies against HTLV-1 can require some time; in 
these cases detection of the HTLV-1 genome might represent a good alternative. In ATL patients 
the large majority of T cells have an integrated copy of the HTLV-1 genome and in these cases 
the virus can be detected by using Southern Blot. However, asymptomatic carriers display a 
small percentage of cells infected by the HTLV-1 virus. In this case, the cells can be cultured for 
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3 to 5 weeks, leading to virus replication and amplification of the HTLV-1 genetic materials. 
Then the virus can be detected by using Southern hybridization or in situ hybridization to HTLV 
RNA. However, this method is not suitable for clinical screening because it is time-consuming 
and expensive [157-159].  
PCR amplification of specific sequences represents the most efficient way for the diagnosis of 
HTLV-1. The PCR technique can be used to detect a single provirus of HTLV-1 or HTLV-2. 
The false-positive results represent the negative aspect of this methodology, related to sample 
contamination. Target inactivate protocol are used to reduce the risk of a false positive. The PCR 
method is commonly used nowadays for the diagnosis of HTLV-1 and HTLV-2 [158].  
 
Differential diagnosis of HTLV viruses 
Initially, the serological analysis of HTLV-1 antibodies does not allow for discrimination 
between HTLV-1 and HTLV-2. To avoid that problem, radioimmunoassay and ELISA have 
been developed. The vast majority of monoclonal antibodies against the Gag protein p19 and p24 
react against both viruses. However, few of them can distinguish between HTLV-1 and HTLV-2. 
Western Blot analysis can be used to distinguish between HTLV-1 and HTLV-2, however the 
best method for the differential diagnosis is PCR amplification of specific sequence. PCR is 
commonly used in routine screening because it provides a rapid, inexpensive and sensitive tool 




Treatment of HTLV diseases 
Only a small percentage of HTLV-1-infected individuals develop HTLV-1-related diseases; for 
this reason exclusively subacute and acute ATL patients undergo treatment. ATL is aggressive 
with limited therapeutic options. The acute form of ATL displays an average survival of less than 
one year. The standard combination of chemotherapy frequently used in aggressive non-
Hodgkin`s lymphoma or acute lymphoblastic leukemia (ALL) has a limited effect on ATL 
patients. It has been reported that deoxycoformycin might be effective, however clinical trials 
show a variable efficacy.  
Moreover, administration of β-interferon and γ-interferon has been used to treat ATL patients. 
Interestingly, anti-Tac antibodies have been used because of the elevated level of IL-2R in ATL 
tumor cells. These therapeutic options have been shown to lead to remission in some ATL cases. 
Treatment with zidovudine and α-interferon used independently or in combination has also 
proven to be promising in patients [160].  
HAM/TSP patients are treated with corticosteroids, but efficiency was found to be limited. 
Administration of a high dose of intravenous gamma globulin has a beneficial effect for a limited 
period. Interestingly, the therapeutic effect of α-interferon on HAM/TSP patients has been 
investigated and found to be useful in a reduced number of cases. That study demonstrated that 
the treatment induces immunomodulation and consequent reduction of HTLV-1 proviral load. 
Consistently, clinical benefits were noted in HAM/TSP patients treated with anti-Tac antibodies. 
However, additional studies are needed to find better therapeutic strategies to cure HTLV-1-




Among HTLV-1-infected individuals, the percentage of HTLV-1-associated diseases is 5%, 
including HAM/TSP and ATL, which leads to consideration of the development of a suitable 
vaccine. There are several advantages to establishing a vaccine for HTLV-1: (i) HTLV-1 
presents limited antigen variability, (ii) natural immunity occurs in humans, and (iii) vaccination 
with envelope antigens has been shown to be successful in animal models. Recombinant DNA is 
used to develop potential new vaccines for HTLV-1, and envelop proteins synthesized in bacteria 
culture were used to immunize cynomolgus monkeys. In the study, several animals display 
sufficient antibody titers and were capable of withstanding an HTLV-1 infection [162].  
Studies with subunit vaccinia have shown to induce immunization for STLV in monkeys. 
Marmosets can be infected with the virus by feeding with breast milk derived from HTLV-1-
infected women. Moreover, rabbits can be infected by HTLV-1 when the transmission of the 
virus is obtained by using rabbit cells. Interestingly, in some cases the HTLV-1-infected rabbits 
develop tumors. A rabbit animal model has demonstrated that passive immunization can protect 
rabbits from the virus. Few studies have found that exposure to synthetic proteins corresponding 
to HTLV-1 1/-2 Env neutralization regions induces protection in rabbits. Other have shown that 
humoral immunity to HTLV-1 Env is direct against conformation epitopes. The rabbit model 
appears to be an ideal model for testing HTLV-1 vaccine prior to human trials. A long-term 
immunization for HTLV-1 probably requires induction of a neutralizing antibody and specific 
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Chapter II "The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis"  














Human T-cell leukemia virus (HTLV)-1 is a human retrovirus and the etiological agent of adult 
T-cell leukemia/lymphoma (ATLL), a fatal malignancy of CD4/CD25+ T lymphocytes. In recent 
years, cellular as well as virus-encoded microRNA (miRNA) have been shown to deregulate 
signaling pathways to favor virus life cycle. HTLV-1 does not encode miRNA, but several 
studies have demonstrated that cellular miRNA expression is affected in infected cells. Distinct 
mechanisms such as transcriptional, epigenetic or interference with miRNA processing 
machinery have been involved. This article reviews the current knowledge of the role of cellular 
microRNAs in virus infection, replication, immune escape and pathogenesis of HTLV-1. 
Keywords: human, HTLV-I infections, T-lymphotrophic virus 1, leukemia-lymphoma, adult T-
cell, microRNAs, virus replication, cell line, cell transformation, gene expression regulation. 
 
Introduction 
The transmission of the human T-cell leukemia virus (HTLV-1) retrovirus requires close contact 
with infected T cells, and occurs from mother to child, predominantly through breastfeeding as 
well as through sexual contact and blood transfusion [1,2]. The HTLV-1 infection is also 
associated with other diseases, such as: a chronic and progressive neurologic disorder named 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), polymyositis, infective 
dermatitis, HTLV-1-associated arthropathy, and HTLV-1-associated uveitis [2,3]. According to 
the Shimoyama classification, adult T-cell leukemia/lymphoma (ATLL) can be distinguished 
into four subtypes: smoldering, chronic and acute leukemic forms and ATLL lymphoma [4]. The 
overall survival of ATLL with different regimens of chemotherapy is poor, ranging between 5.5 
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and 13 months in patients presenting acute leukemia or lymphoma [5]. HTLV-1 mediates T 
lymphocyte transformation using a multistep process in which the virus promotes genomic 
instability, accumulation of genetic defects, and chronic proliferation of infected cells [6]. The 
genome of HTLV-1 encodes common retrovirus structural and enzymatic proteins, Gag, Pro, 
Pol, and Env, and additional accessory and regulatory proteins such as Tax, Rex, P30, p12, p13, 
and HTLV-1 basic leucine zipper factor protein (HBZ). Tax and HBZ regulatory proteins have 
been reported to play a central role in regulation of viral and cellular genes that lead to 
proliferation of infected cells [7]. Tax is a transcriptional trans-activator that promotes the 
expression of genes linked to the 5′ long terminal repeat promoter (LTR) element of the HTLV-1 
genome [8]. Tax induces genomic instability [9] and promotes cell-cycle progression, survival 
and growth of HTLV-1-positive T cells [10]. HBZ is involved in the proliferation of infected 
cells in vitro and in vivo and plays an essential role in oncogenesis mediated by HTLV-1 in late 
stages of the disease when Tax is not expressed [11]. Consistently, HBZ was found to be 
expressed in ATLL cells through the whole period of ATLL development, suggesting that it 
might be involved in maintenance of HTLV-1-transformed cells [12]. Rex is a post-
transcriptional regulator of viral expression, which activates viral replication in the early phase of 
HTLV-1 infection by promoting the nuclear export of HTLV-1 mRNA [13]. Several studies have 
shown altered expression of microRNAs (miRNAs) in HTLV-1/ATLL cell lines and primary 
peripheral blood mononuclear cells (PBMCs) from ATLL patients, suggesting that miRNA 
deregulation is involved in HTLV-1 infection and adult T-cell leukemia/lymphoma pathogenesis. 
MicroRNAs play an essential role in a wide range of biological processes, including 




MicroRNAs (miRNAs) are small, non-coding RNA molecules that transcriptionally regulate 
gene expression. The first miRNA identified in animals is Lin-4, discovered in 1993 by Ambros 
and colleagues. Lin-4 was identified as heterochronic genes in Caenorhabditis elegans involved 
in cell fate [17,18]. Subsequent studies have shown the involvement of miRNAs in different 
biological processes, including tumorigenesis by targeting oncogenes or tumor suppressor genes 
[16]. MiRNA sequences are localized in different genomic contexts. Some miRNAs are encoded 
by exon; however, the majority are encoded by the intronic region of non-coding and coding 
transcripts [19]. MiRNAs are transcribed by the RNA polymerase II or III into the nucleus as 
primary miRNAs (pri-miRNAs). Pri-miRNAs are normally over 1 kilobase and contain a local 
steam-loop structure in which mature miRNA sequences are included. The nuclear RNase III 
Drosha recognized and processed pri-miRNAs into a hairpin-shaped RNA of nearly 65 
nucleotides in length, named precursor miRNAs (pre-miRNAs). After transport to the cytoplasm 
by the RanGTP-dependent dsRNA-binding protein Exportin 5, pre-miRNAs are processed by the 
cytoplasmic RNase III Dicer, liberating a mature 20–24 nucleotide long duplex. Argonaute 
family proteins, AGO, and Trans-Activation Responsive RNA-Binding Protein (TARBP2), 
together with the duplex form a complex named RNA-Induced Silencing Complex (RISC) 
[19,20]. One strand of the duplex, called guide strand, is incorporated into the RISC complex 
while the other strand, named passenger strand, is targeted for degradation [21]. Apart from the 
canonical miRNA biogenesis described above, different alternative mechanisms, which bypass 
Drosha processing, were described [22]. MiRNAs can be generated through non-canonical 
pathways, wherein the precursor miRNAs are cleavaged by Dicer. Mirtrons represent an example 
of miRNA processed by a non-canonical pathway. They are generated from intron lariats serving 
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as pri-miRNAs, which is processed by Spliceosome that function as Drosha, to release pre-
miRNAs [22,23]. MiRNAs bind complementary sequences usually localized at 3′UTR of 
messenger RNA and guide RISC to target mRNA. MiRNAs used different mechanisms to 
regulate post-transcriptional gene expression: inhibition of translation and/or messenger RNA 
degradation. The repression of many miRNA targets is frequently associated with their 
destabilization. Degradation of target mRNA is characterized by gradual shortening of the 
mRNA poly-Adenine tail, which is catalyzed by the exosome or exonuclease XRN1. MiRNAs 
might also induce gene silencing by interfering with protein translation [24]. Several pieces of 
evidence show that miRNA silencing is observed with either no change in the mRNA level or 
with a significantly smaller decrease of mRNA compared to the protein level [25,26]. 




Figure 1. Human T-cell leukemia virus HTLV-1 interferes with cellular miRNA machinery 
MiRNAs are transcribed by the RNA polymerase II or III into the nucleus as primary miRNAs 
(pri-miRNAs) from coding or non-coding part of genes. The nuclear RNase III Drosha 
recognized and processed pri-miRNAs into a hairpin-shaped RNA, named precursor miRNAs. 
Pre-miRNAs are transported to the cytoplasm by Exportin 5, and processed by the cytoplasmic 
RNase III Dicer in the mature miRNA duplex. The duplex forms a complex named RNA-
Induced Silencing Complex (RISC). MiRNAs bind complementary sequences usually localized 
at 3′UTR of messenger RNA and this binding results in the inhibition of translation and/or 
messenger RNA degradation. HTLV-1 deregulates the cellular miRNA pathway by suppressing 
the function of Drosha and Dicer. Tax directly interacts with Drosha and the binding leads to 
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Drosha degradation mediated by proteasome complex. The regulatory protein, Rex, is reported to 
directly interact with Dicer. Rex suppresses the ribonuclease-directed processing activity of 
Dicer, protecting against the cleavage Rex-mRNA. 
 
MiRNA Profile in HTLV-1-Transformed Cell Lines and ATLL Patients 
Four studies have characterized miRNA expression profiles in HTLV-1/ATLL cell lines and 
ATLL patients. Pichler [27] and colleagues chose the phenotype of regulatory T cells (Treg) as a 
starting point to study miRNA expression in HTLV-1-transformed cells. The authors have 
selected and analyzed the expression of a set of miRNAs characteristic of murine Treg and 
downregulated in different tumors. The analysis identified five deregulated miRNAs: miR-21, 
miR-24, miR-146a, and miR-155 were found upregulated, whereas miR-223 was downregulated. 
Bellon [28] and colleagues analyzed miRNA profiles from ATLL patients compared to HTLV-1-
negative donors by using microarray. The results were confirmed by Real Time (RT)-PCR of 
mature miRNAs in uncultured ATLL cells and HTLV-1-transformed cell lines. Microarray 
analysis and RT-PCR demonstrated downregulation of miR-181a, miR-132 and miR-125a and 
upregulation of miR-155 and miR-142-3p. This study identifies two miRNAs differently 
expressed in vitro and in vivo. MiR-150 and miR-223 were both upregulated in uncultured 
ATLL cells and downregulated in HTLV-1-transformed cell lines. Yeung [29] and colleagues 
examined miRNA profiles in several ATLL-derived cell lines and primary peripheral blood 
mononuclear cells (PBMCs) from acute ATLL patients using miRNA microarray. Several 
HTLV-1/ATLL cell lines and four ATLL patients were studied. Thirteen miRNAs were found to 
be upregulated and thirty downregulated among the different cell lines. In parallel, 22 
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upregulated and 22 downregulated miRNAs were identified in acute ATLL patients. Among 
those, miR-9, miR-17-3p, miR-20b, miR-93, miR-130b and miR-18a were found to be induced; 
in contrast, miR-1, miR-144, miR-126, miR-130a, miR-199a, miR-338, miR-432, miR-335 and 
miR-337 were found to be downregulated. Yamagishi and colleagues [30] studied the miRNA 
expression signature in primary ATL cells by using microarray analysis compared to CD4+ T 
cells from healthy donors. The results show that 59 of the miRNAs tested were found with a 





Figure 2. MiR-28-3p targets the HTLV-1 genome.  
The figure illustrates a natural feedback loop that regulated cellular miRNA expression in 
response to virus infection. MiR-28-3p suppresses HTLV-1 expression by targeting a sequence 
localized within the viral gag/pol HTLV-1 sequence. MiR-28-3p expression leads to abortive 





HTLV-1 Interferes with Cellular miRNA Machinery 
The dysregulation of miRNA pathways has been reported across several viruses, including HIV, 
Ebola, Epstein–Barr, Influenza, HBV, HCV, Adenovirus, and HTLV-1 
[31,32,33,34,35,36,37,38]. Drosha was reported to be downregulated in HTLV-1-infected cell 
lines, HTLV-1-transfected cells, and infected primary cells [38]. Van Duyne [38] and colleagues 
proposed that HTLV-1 deregulates the cellular RNAi pathway, including miRNAs, by 
suppressing the function and degrading Drosha (Figure 1). 
The authors have demonstrated a direct interaction between the Tax oncoprotein and Drosha, 
which is responsible for its downregulation. The N-terminal region of Tax presents two putative 
motifs, the Zinc finger motif and leucine-zipper-like region, which interact with Drosha. The 
Tax N-terminal region is reported to interact with the proteasome complex. Van Duyne and 
colleagues demonstrated that the binding between Tax and Drosha leads to its degradation 
mediated by proteasome complex. In addition, Drosha increases HTLV-1 replication and is not 
efficient in processing miRNAs when Tax is expressed, suggesting that the dysregulation of 
miRNA machinery might be involved in the rate of HTLV-1 infection [38]. The HTLV-1 
regulatory protein, Rex, is reported to directly interact with Dicer. Abe [39] and colleagues have 
demonstrated that Rex suppresses the ribonuclease-directed processing activity of Dicer, 
protecting against the cleavage Rex-mRNA (Figure 1). Inhibition of Dicer activation might 




Figure 3. MiRNAs promote cell proliferation 
MiR-155 and miR-146a were found elevated in HTLV-1-infected cells in vitro. Tax induces the 
transcription factors NF-κB and AP-1, which promote miR-155 expression by binding the 
miRNA promoter. This binding resulted in an increased expression of the B-cell integration 
cluster (BIC) gene whose transcript is processed into miR-155. The interferon regulatory factor-
4, IRF4, which is induced in HTLV-1-infected cells, promotes BIC/miR-155 expression. NF-κB 
also mediates miR-146a transactivation; both miRNAs enhance cellular growth in HTLV-1-
infected cells. MiR-150 and miR-223 are differentially regulated in ATLL samples and in 
HTLV-1-transformed cells. MiR-150 and miR-223 were found upregulated in acute ATLL 
patients and downregulated in HTLV-1-transformed cell lines. MiR-150 and miR-223 target the 
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STAT1 3′UTR. Inhibition of STAT1 expression, through miR-150, miR-223 reduced 
proliferation of HTLV-1-transformed and ATLL-derived cell lines. MiR-150 and miR-223, by 
decreasing STAT1 expression and dampening STAT1-dependent signaling in human T cells, 
regulated proliferation in an HTLV-1 context. 
 
MiRNAs Target the HTLV-1 Genome 
The cellular environment has an essential role in virus infection and replication. Many cellular 
genes prevent replication and virus dissemination by acting as innate immunity factors. 
However, viruses have evolved strategies to avoid activation of an antiviral state: virus-derived 
miRNAs can enhance viral gene expression, replication, and infectivity [40] or suppress the IFN 
response [41]. The genome of the Epstein–Barr virus (EBV), Kaposi sarcoma-associated 
herpesvirus (KSHV), human cytomegalovirus (hCMV) and bovine leukemia virus (BLV) 
encodes for virus-derived miRNAs [42,43,44,45]. BLV shares many characteristics in disease 
pathogenesis with HTLV-1 and is associated with the development of B-cell tumors. Kincaid and 
colleagues [45] show that BLV is capable of producing miRNAs in vitro. A subsequent study 
demonstrated that BLV encodes a conserved cluster of miRNAs located in a specific BLV 
proviral region, which is essential for in vivo infectivity [46]. BLV has different common 
features in genomic organization with HTLV-1, however HTLV-1-encoded miRNAs have not 
been reported. Cellular miRNAs can promote virus replication or negatively regulate virus 
expression and infectivity [47]. MiR-28, miR-125b, together with miR-150, miR-223 and miR-
382 target 3′ ends of HIV-1 messenger, promoting viral latency [47]. Bai and colleagues 
identified a binding site in the HTLV-1 genome for miR-28-3p and demonstrated a mechanism 
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used by a cellular miRNA to prevent HTLV-1 gene expression and viral transmission (Figure 2) 
[48]. 
MiR-28-3p was found to target a sequence localized within the viral gag/pol HTLV-1 mRNA 
and reduced viral replication and gene expression. MiR-28-3p-expressing cells are characterized 
by reduced levels of HTLV-1 gag p19 and p24 products and they are resistant to infection. MiR-
28-3p expression leads to abortive infection by inhibiting HTLV-1 reverse transcription and 
preventing the formation of the pre-integration complex. MiR-28-3p suppresses HTLV-1 
expression and infection; this is consistent with the high levels of miR-28-3p reported in resting 
T cells and their inability to be infected by HTLV-1 without prior activation. Bai and colleagues 
[48] demonstrated a natural feedback loop that regulated miR-28-3p expression in response to 
virus infection. It is well established that de novo infection in T cells activates the interferon anti-
viral response. MiR-28-3p expression was found to be induced after IFN-α or - γ stimulation, 
suggesting that miR-28-3p might contribute to restricting virus expansion to neighboring cells by 
reducing local inflammation and the initial establishment of latent infection. The miR-28-3p site 
is highly conserved in HTLV-1 subtypes B and C, at nearly 90%. However, the subtype 1A, 
Japanese ATK-1, presents a natural polymorphism (T to C substitution) within the miR-28-3p 
target site. The mutation is silent and more resistant to miR-28-3p inhibition of viral replication. 
Bai and colleagues [48] proposed a model where the modulation of miR-28-3p expression 
affected HTLV-1 virus spreading. Virus particles can transiently activate resting T cells by 
reducing miR-28-3p expression and favoring infection. Because IFN response is a potent inducer 
of miR-28-3p expression, the initial antiviral response might backfire, helping to protect newly 
infected cells from being eliminated by the immune system. 
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Figure 4. MiRNAs induce resistance to apoptosis 
MiR-31 is one of the most profoundly repressed miRNAs in primary ATLL cells. The Polycomb 
protein complex is overexpressed in ATLL cells and suppresses miR-31 expression. MiR-31 
negatively regulates NF-κB-inducing kinase (NIK) and leads to apoptosis resistance. MiR-130b 
and miR-93 are upregulated in HTLV-1 cell lines and ATLL patients and both target Tumor 
protein p53-inducible nuclear protein (TP53INP1). TP53INP1 is a tumor suppressor gene that 
has anti-proliferative and pro-apoptotic activities via both p53-dependent and p53-independent 
means. TP53INP1 has in its 3′ UTR two binding sites for miR-93 and two sites for miR-130b. 
 
 76 
MiRNAs Promote Cell Proliferation 
MiR-146a 
MiR-146a has a central role in the regulation of immune response and its expression is induced 
by NF-κB signaling. MiR-146a is deregulated in different cancers. A high level of expression 
was reported in papillary thyroid carcinoma, anaplastic thyroid cancer, breast cancer, 
glioblastoma and cervical cancer [49,50,51,52,53]. In contrast, low-expressing levels were 
described in pancreatic carcinoma, gastric cancer, prostate cancer, acute myeloid leukemia 
(AML), myeloblastic syndrome and chronic myeloid leukemia (CML) [54,55,56,57,58,59]. MiR-
146a was found to be upregulated in HTLV-1-transformed cell lines [27]. Ectopic expression of 
Tax in HTLV-1-negative T cells, Jurkat, induced miR-146a expression. Promotor analysis 
showed a 15-fold activation of miR-146a by Tax [60], suggesting that HTLV-1 infection might 
be involved in the regulation of miR-146a expression. Pichler [27] and colleagues used a 
mutated form of Tax and dominant active NF-κB inhibitor to show that miR-146a transactivation 
is mediated by NF-κB (Figure 3). 
Tomita et al. [60] also reported an NF-κB binding site on the miR-146a gene. In addition, it has 
been described as having a suppressive effect of miR-146a on NF-κB signaling [51]. This might 
represent a negative feedback loop, which seems to be ineffective in HTLV-1-infected cells. 
MiR-146a has also been shown to induce proliferation in several human cancers, including 
cervical cancer [53], breast cancer cells [61], gastric cancer cells [62] and mesenchymal stem 
cells (MSCs) [63]. Consistent with this report, treatment with an anti-miR-146a inhibitor 
suppressed the proliferation of HTLV-1-transformed cell lines but not uninfected T-cell lines. In 
addition, overexpression of miR-146a increased the growth of HTLV-1-transformed cell lines 
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[27]. Because overexpression of miR-146a has also been described in an EBV context, Tomita 
[60] and colleagues suggested that miR-146a up-regulation might represent a common 
mechanism in the pathogenesis of persistent viruses. Wang et al. [64] identified 622 putative 
target genes of miR-146a that are predicted by using different prediction programs. Gene 
ontology analysis shows that these genes are involved in the inhibition of cell growth and 




MiR-155 has been implicated in normal hematopoiesis [65], immune response [66], and in the 
carcinogenesis of different human tumors [67,68]. Mouse studies have reported that transgenic 
overexpression of miR-155 results in the increased frequency of tumor formation [69]. 
Overexpression of miR-155 was found in breast cancer [70], pancreatic cancer [71], lung cancer 
[72], B-cell lymphoma [67], MALT lymphoma [73] and acute myeloid leukemia (AML) [74]. 
MiR-155 was found elevated in HTLV-1-infected cells in vitro and in vivo [28,75], suggesting 
that this miRNA might play an important role in the biology and pathogenesis of HTLV-1. Babar 
[76] and colleagues used an inducible knock-in mouse model to show that miR-155 induction in 
the lymphoid tissue led to disseminated lymphoma. In contrast, reduction of miR-155 resulted in 
the decrease of tumor size. In humans, Calin [77] and colleagues identified a miRNA signature 
associated with progression and prognosis in chronic lymphocytic leukemia (CLL) and showed 
an association between miR-155 upregulation and poor prognosis. Several lymphoma-associated 
viruses, including the Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus and Marek’s 
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disease virus, are characterized by overexpression of miR-155 [73,78], suggesting that HTLV-1 
infection might be responsible for the induction of miR-155 in infected T cells. MiR-155 
upregulation has been reported in HTLV-1 cell lines and ATLL patients [28,75]. Tomita [75] and 
colleagues demonstrated that transcription factors NF-κB and AP-1 induced miR-155 expression 
by binding the miRNA promoter in an HTLV-1 context (Figure 3). This binding resulted in an 
increased expression of the B-cell integration cluster (BIC) gene whose transcript is processed 
into miR-155 (Figure 3). Tomita and colleagues demonstrated that miR-155 overexpression 
enhanced the growth in HTLV-1-transformed cells. Consistently, treatment with anti-miR-155 
reduced the proliferation of these cells and had no effect on HTLV-1-negative T cells. Wang [79] 
and colleagues demonstrated that interferon regulatory factor-4, IRF4, which is reported to be 
oncogenic [80], induces BIC/miR-155 expression in HTLV-1-transformed cells (Figure 3). In 
normal lymphocytes, IRF4 is involved in cellular proliferation and differentiation [80]. In mature 
human CD4+ T cells, IRF4 is essential for cytokine production and survival [81,82]. Several 
studies show that IRF4 is overexpressed in HTLV-1-transformed and primary ATLL/L cells and 
associated with poor prognosis [81,82,83], suggesting that IRF4 might be involved in HTLV-1 
pathogenesis. Wang and colleagues show that depletion of IRF4 drastically reduced cell 
proliferation of HTLV-1-transformed cell lines, suggesting that the IRF4/miR-155 pathway 
might play a central role in the malignant proliferation of HTLV-1-infected cells [80]. In 
addition, miR-155 is reported to target Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) 
in liver cancer stem cells [84], which promotes cell cycle arrest and apoptosis, suggesting a 




MiR-150 and MiR-223 
MiR-150 and miR-223 were reported to be differentially regulated in HTLV-1-transformed cells 
and in ATLL samples. MiR-150 and miR-223 were found upregulated in acute ATLL patients 
and downregulated in HTLV-1-transformed cell lines, suggesting that different selective 
pressure in vitro and in vivo might regulate the expression of those miRNAs. MiR-150 can have 
either oncogenic or tumor suppressor activity in different human tumors. It is overexpressed in 
chronic lymphocytic leukemia (CLL) [85,86] and downregulated in chronic myeloid leukemia 
(CML) [87,88], acute lymphoblastic leukemia (ALL) [89] and mantle cell lymphoma (MCL) 
[90]. Additional studies show that miR-150 promotes the proliferation and migration in lung 
cancer by targeting SRC kinase signaling inhibitor 1 (SRCIN1) and SRC activity [91]. In 
contrast, miR-150 expression was reported to inhibit cell migration and invasion in breast cancer 
[92,93]. C-MYB, NOTCH3, CBL, EGR2, AKT2 and DKC1 are established targets of miR-150 
[94,95,96,97,98]. MiR-223 was reported to be differentially regulated in human cancers; it is 
downregulated in hepatocellular carcinoma, B-cell chronic lymphocytic leukemia (B-CLL), 
acute myeloid leukemia (AML), gastric MALT lymphoma and recurrent ovarian cancer 
[99,100,101,102,103]. In contrast, miR-223 is upregulated in T-cell acute lymphocytic leukemia 
(T-ALL), EBV-positive diffuse large B-cell lymphoma, and metastatic gastric cancer 
[104,105,106,107,108]. FBXW7/Cdc4, RhoB, STMN1, E2F1, STAT3, C/EBPβ, FOXO1 and 
NFI-A are validated targets of miR-223 [106,107,108,109,110,111]. It has previously been 
shown that E2F1 represses the miR-223 promoter [110,111,112]. Interestingly, viral HBZ 
mRNA increases the expression and transcriptional activity of E2F1. HBZ expression is 
consistently increased in ATLL cells in vivo [11]. These observations can partially explain the 
differential regulation of miR-223 in vitro and in vivo. MiR-150 and miR-223 target the STAT1 
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3′UTR in an HTLV-1 context (Figure 3). STAT1 plays an essential role in immune modulatory 
functions, anti-viral responses, apoptosis and anti-proliferative responses [113]. In addition, 
several studies have shown that STAT1 can also act as a potent tumor promoter for leukemia 
development [114] and that many T-ALL leukemic cells are dependent upon the TYK2-STAT1-
BCL2 pathway for continued survival [115]. Inverse correlation between STAT1 expression and 
miR-150 and miR-223 was identified in HTLV-1-transformed and IL-2-independent ATLL-
derived cells [116]. IL-2-dependent ATLL cells display a high level of miR-150 expression, but 
low miR-223, suggesting that miR-150 might be regulated through the IL-2 signaling pathway. 
Absence of IL-2 signaling results in miR-150 downregulation in IL-2-dependent ATLL cells. In 
contrast, IL-2 stimulation in IL-2-independent ATLL-derived cells leads to miR-150 induction. 
This evidence suggests that miR-150 is regulated by the IL-2 signaling pathway. It was reported 
that ATLL tumor cells in vivo produce IL-2 or IL-15 and express IL-2 receptor alpha chain, 
CD25. These observations partially explain the higher levels of miR-150 in ATLL patients 
compared with HTLV-1 cell lines. Despite the miR-150 and miR-223 overexpression in freshly 
isolated ATLL samples, STAT1 was found to be induced in a majority of ATLL samples, 
suggesting that miR-150 and miR-223 cannot efficiently suppress STAT1 expression in ATLL 
patient cells. STAT1 has been reported to have tumor promoting activities. Inhibition of STAT1 
expression, through miR-150, miR-223 or directly by shRNA targeting, reduced proliferation of 
HTLV-1-transformed and ATLL-derived cell lines. MiR-150 and miR-223, by decreasing 
STAT1 expression and dampening STAT1-dependent signaling in human T cells, regulated 
proliferation in an HTLV-1 context. 
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Figure 5. MiR-149 and miR-873 promote chromatin remodeling 
The Tax protein promotes HTLV-1 gene expression by its interaction with the long terminal 
repeat (LTR) or U3 region of the viral promoter. To activate the transcription, Tax recruits the 
p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), which bind 
two different regions of Tax, resulting in histone acetylation and chromatin remodeling. MiR-
149 and miR-873 are downregulated in HTLV-1-transformed cell lines and target the chromatin 




MiRNAs Induce Resistance to Apoptosis 
MiR-31 
Yamagishi [30] and colleagues identified miR-31 as one of the most profoundly repressed 
miRNAs in primary ATLL cells. MiR-31 is reported as a tumor suppressor and correlates 
inversely with metastasis in breast cancer [117]. MiR-31 in vivo targets several genes, such as 
Fzd3, ITGA5, MMP16, RDX, RhoA, WAVE3 and integrin α5 subunit, that contribute to cell 
migration and metastatic invasion [117,118]. The Polycomb protein complex has been reported 
to be a strong suppressor of miR-31 in breast cancer and adult T-cell leukemia [30,117]. 
Polycomb group proteins are overexpressed in ATLL cells [119] and have an important role in 
cellular development and regeneration by controlling histone methylation, especially at histone 
H3 Lys27 (H3K27), which induces chromatin compaction. The Polycomb family is associated 
with cancer phenotypes and malignancy in breast cancer, prostate cancer, bladder tumors, and 
other neoplasms [120,121]. MiR-31 negatively regulates NF-κB-inducing kinase (NIK) 
expression and activity in adult T-cell leukemia and other cancers [30]. NIK has an important 
role in tumor progression and the aggressive phenotypes of various cancers. It is well established 
that the NIK level directly regulates NF-κB activity in various cell types [122]. Constitutive 
activation of the nuclear factor NF-κB is observed in the ATLL cell lines and primary isolated 
tumor cells from ATLL patients [123]. NF-κB activation contributes to cell propagation and anti-
apoptotic responses in ATLL [124]. An inverse correlation has been reported between the 
expression level of miR-31 and NIK in ATLL patients. Rescue of miR-31 represses NF-κB 
expression and leads to increased proliferation and apoptosis resistance. The inhibition of NF-kB 
promotes tumor cell death in HTLV-1-transformed cells and primary ATLL cells. The model 
proposed by Yamagishi and colleagues show that the Polycomb group regulates miR-31 
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expression and leads to NF-κB activation via NIK-miR-31 regulation and apoptosis resistance in 
HTLV-1 context (Figure 4). The downregulation of miR-31 might play an important role in 
ATLL pathogenesis. 
 
MiR-130b and MiR-93 
Microarray analyses demonstrated that miR-130b and miR-93 were consistently upregulated in 
HTLV-1 cell lines and ATLL patients and both target Tumor protein p53-inducible nuclear 
protein, TP53INP1 [29]. MiR-130b was found to be deregulated in several human cancers. 
Overexpression of miR-130b has been reported in colorectal cancer, gastric cancer, bladder 
cancer, cutaneous malignant melanoma, and head and neck squamous cell carcinoma 
[125,126,127,128]. In contrast, miR-130b is downregulated in papillary thyroid carcinoma, 
ovarian cancer and endometrial cancer [129,130,131,132]. Identified targets of miR-130b are 
STAT3, PTEN and TGF-b1 [133,134,135]. MiR-93 belongs to the miR-106b-25 cluster, which 
also includes miR-106b and miR-25 [136]. The miR-106b-25 cluster is overexpressed in 
neuroblastoma, multiple myeloma, and lung, prostate and gastric tumors [136,137,138]. 
Reported targets of miR-93 are PTEN, VEGF, ITGB8, DAB2 and LATS2 
[139,140,141,142,143]. TP53INP1 is a tumor suppressor gene that has anti-proliferative and pro-
apoptotic activities via both p53-dependent [144] and p53-independent means [145]. TP53INP1 
has in its 3′ UTR two binding sites for miR-93 and two sites for miR-130b. Yeung [29] and 
colleagues have shown that transfection of antagomirs against miR-93 and miR-130b into an 
HTLV-1-transformed cell line increased the expression of TP53INP1 and decreased cellular 
viability by promoting apoptosis (Figure 4). These results show that TP53INP1 has anti-
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proliferative properties and can be regulated by miR-130b and miR-93. Transfection of miR-93 
or miR-130b in HTLV-1-negative T-cell lines reduced TP53INP1 expression and increased 
cellular proliferation. It has been reported that loss of TP53INP1 correlates with the development 
of cancers [146,147] and its induction promotes G1 cell cycle arrest and apoptosis 
[144,145,148]. This evidence suggests that up-regulation of miR-130b and miR-93 reduces 
TP53INP1 levels in ATLL cells and promotes cellular proliferation. TP53INP1 is also able to 
reduce cell migration in pancreatic cancer cells [149] and this might be significant because it is 
well established that HTLV-1 infection promotes T-lymphocyte migration [150]. 
 
MiRNAs Promote Chromatin Remodeling 
The Tax protein promotes HTLV-1 gene expression by its interaction with the long terminal 
repeat (LTR) or U3 region of the viral promoter [151,152]. To activate the transcription, Tax 
recruits the p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), 
which bind two different regions of Tax, resulting in histone acetylation and chromatin 
remodeling (Figure 5) [153,154,155,156,157,158]. Rahman [157] and colleagues identified the 
chromatin remodeling factors, p300 and p/CAF, as a target of miR-149 and miR-873. MiR-149 
has been reported to have a role as an oncogene and tumor suppressor in different human cancers 
[158,159]. Downregulation of miR-149 has been described in prostatic cancer, astrocytomas and 
renal carcinoma [160,161,162]. In contrast, miR-873 was found to be suppressed in colorectal 
cancer, glioblastoma and breast cancer [163,164,165]. Recent evidence has established the role 
of miR-873 in cell proliferation, tumor growth and tamoxifen resistance in breast cancer [165]. 
MiR-149 and miR-873 were found to be profoundly downregulated in HTLV-1-transformed cell 
 85 
lines, MT-2, compared to an uninfected control, Jurkat [157]. To verify that miR-149 and miR-
873 could target p/CAF and p300, the authors over-expressed these miRNAs in HTLV-1-
transformed cells and observed a significant reduction in the expression of chromatin-remodeling 
enzymes. In addition, the cell culture supernatant was analyzed for viral protein p19 before and 
after transfection. The results show a decrease in the levels of viral progeny production in cells 
transfected with miR-149 and miR-873, suggesting that these miRNAs, by targeting chromatin 










Figure 6. MiRNAs induce genetic instability  
MiR-17 and miR-21 are upregulated in an HTLV-1 context. HBZ inactivates OBFC2A via miR-
17 and miR-21, promoting genetic instability and cell proliferation. OBFC2A encodes for 
hSSB2, which is involved in the ATM signaling pathway, the activation of the cell cycle 





MiRNAs Induce Genetic Instability 
MiRNA expression analysis in CD4+ lymphocytes, derived from HAM/TSP patients, has 
identified a high expression level of miR-17 and miR-21 [166]. Spry 1, Spry 2, PTEN, TPM1 
and Pdcd4 have been reported to be miR-21 targets, suggesting its central role in cell 
proliferation, apoptosis, and invasion [167,168,169,170,171]. MiR-17, instead, is the main 
effector of the miR-17-92 cluster component, which has been identified as a member of the 
miRNA signature in solid tumors [172]. MiR-17 regulates E2F1 and c-Myc, p21, PTEN and 
BIM expression [173,174,175,176], suggesting its potential functions in cell migration, invasion 
and proliferation. Vernin [166] and colleagues identified OBFC2A as a potential target of miR-
17 and miR-21 in an HTLV-1 context. OBFC2A encodes for hSSB2, which is involved in the 
ATM signaling pathway, the activation of the cell cycle checkpoint and promotes DNA repair. 
The down-regulation of OBFC2A and a positive correlation between miR-17, miR-21 and HBZ 
expression has been reported in HTLV-1-infected cells [166]. Vernin and colleagues suggested 
that HBZ inactivates OBFC2A via miR-17 and miR-21, promoting genetic instability and cell 
proliferation (Figure 6). 
The authors have shown that ectopic expression of HBZ does not decrease cellular growth in 
DNA-damaged cells. HBZ-expressing cells continued to proliferate when treated with a DNA-
damaging agent, neocarzinostatin. This phenotype can be reversed by ectopic expression of 
OBFC2A, which leads to a decrease of proliferation rates and restores the DNA damage 
response. This evidence suggested a potential role of miR-17 and miR-21 in genetic instability 
and cell proliferation in HTLV-1-infected cells. 
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Conclusions and Prospective 
The role of miRNAs in HTLV-1 infection and ATLL pathogenesis is beginning to emerge. 
Available evidence shows a complex interplay between cellular miRNA machinery and virus 
infection. HTLV-1 inhibits proteins involved in biogenesis and maturation of cellular miRNAs, 
resulting in a perturbation of the expression profile of host miRNAs. In this review, we focused 
on miRNAs, which are involved in virus production, establishment of latency, tumor cell 
transformation and proliferation. A potential role of MiRNA modulation could represent a 
therapeutic approach for ATLL patients. The combination delivery of miRNAs with 
chemotherapy drugs might provide a promising strategy to overcome chemo-resistance. 
Different studies have shown that co-delivery of miRNA and chemotherapeutic agents are 
effective to inhibit tumor growth by targeting genes, which are involved in tumor cell 
proliferation and/or survival [177,178,179]. In addition, in combination with antitumor drugs, 
miRNAs might have an important role by targeting genes involved in drug resistance, thus 
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Small non-coding microRNAs (miRNAs) are epigenetic regulators that target specific cellular 
mRNA to modulate gene expression patterns and cellular signaling pathways. miRNAs are 
involved in a wide range of biological processes and are frequently deregulated in human 
cancers. Numerous miRNAs promote tumorigenesis and cancer progression by enhancing tumor 
growth, angiogenesis, invasion and immune evasion, while others have tumor suppressive effects 
[1, 2]. The expression profile of cancer miRNAs can be used to predict patient prognosis and 
clinical response to treatment [3]. The majority of miRNAs are intracellular localized, however 
circulating miRNAs have been detected in various body fluids and represent new biomarkers of 
solid and hematologic cancers [4, 5]. This review describes the clinical relevance of miRNAs, 
lncRNAs and snoRNAs in the diagnosis, prognosis and treatment response in patients with 
chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic 
leukemia (ALL), acute myeloid leukemia (AML) and acute adult T-cell leukemia (ATL). 
 
Chronic lymphocytic leukemia (CLL) 
Chronic lymphocytic leukemia (CLL) is characterized by slow growth and the accumulation of 
incompetent CD5+, CD19+ and CD23+ B lymphocytes in blood, marrow, and other lymphoid 
tissues. This disease can be distinguished into aggressive and indolent subtypes with deletion of 
chromosome 13q14 being the most common genetic alteration found at diagnosis. 
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miRNA signature in CLL 
The miR-15/16 cluster, miR-34b/c, miR-29, miR-181b, miR-17/92, miR-150, and miR-155 
represent the most frequently deregulated miRNAs reported in CLL and these microRNAs have 
been associated with disease progression, prognosis, and drug resistance [6]. Nearly two-thirds 
of CLL cases presented a down-regulation of miR-15a/16-1 expression. In fact, miR-15a and 
miR-16-1 are located in the locus 13q14.3, a genomic region frequently deleted in CLL patient 
samples [7]. However, additional mechanisms, such as overexpression of histone deacetylases 
(HDACs), also down-regulate expression of miR-15 and miR-16 [8]. Another point to highlight 
is that there is an inverse correlation between miR-15a/16-1 and BCL2 expression reported in 
CLL, as inhibition of this microRNA expression in leukemic cell lines leads to increased BCL2 
expression and resistance to apoptotic signals. In addition, comparative microarray analysis in 
CLL patients with high or low levels of miR-15a/16-1 identified a gene signature that contains 
the anti-apoptotic BCL2 family member MCL-1, which is associated with B-CLL cell survival 
and chemotherapy resistance [9-11]. Down-regulated miR-15a and miR-16-1 in CLL patients is 
associated with a good prognosis, consistent with previous reports that correlate 13q14.3 
deletions with a favorable course of CLL [12]. On the other hand, the miR-29 family, which 
includes miR-29a, miR-29b and miR-29c, is significantly down-regulated in a subset of CLL 
patients and is associated with an unfavorable prognosis. miR-29b targets DNA 
methyltransferase (DNMT) isoforms and inhibition of miR-29b expression may lead to 
hypermethylation and epigenetic silencing of several tumor suppressors [12]. In addition, 
evidence shows that miR-29 targets the oncogene T-cell leukemia 1 gene, TCL1A. This TCL1 
oncogene is involved in translocations and inversions characteristic of mature T-cell 
prolymphocytic leukemia (PLL) and is overexpressed in patients with unmutated 
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immunoglobulin heavy chain variable regions (IgVH). Transgenic mice that overexpressed 
TCL1 in B cells display a similar phenotype to aggressive forms of human CLL [12]. Another 
genomic region frequently deleted in CLL patients is found in the 11q region where a miR-34 
cluster is located. In fact, down-regulation of miR-34a in CLL is associated with p53 
inactivation, impaired DNA damage response, and apoptosis resistance [13-15]. Since miR-34a 
also inhibits E2F1 and B-Myb [16], loss of miR-34a expression may increase tumor cell 
proliferation. Alternatively, the miR-17/92 polycistronic microRNA cluster is overexpressed in 
several lymphoid malignancies and studies have shown that miR-17/92 inhibited the expression 
of the pro-apoptotic factor Bim and the tumor suppressor PTEN [17]. In addition, STAT3-
induced IL-6 stimulates the expression of miR-17 and miR-19a, resulting in lower expression of 
TLR7 and TNFα. Also of interest, CLL patient cells expressing zeta-chain-associated protein 70 
kDa (ZAP-70) demonstrate significantly lower levels of miR-150 when compared with ZAP-70-
negative CLL cells. In CLL cells miR-150 targets forkhead box P1 (FOXP1) and GRB2-
associated binding protein 1 (GAB1), thereby reducing B-cell receptor signaling [18]. 
Another STAT3-activated microRNA, miR-155[19], is overexpressed in cells and in circulating 
microvesicles in CLL samples [19]. Induction of the onco-miR-155 in the plasma of CLL 
patients correlates with poor response to treatment and disease progression. Consistently, 
patients who achieved complete remission presented low levels of miR-155 in the plasma [6]. In 
addition, the expression of miR-155 is increased with disease progression from monoclonal B-
cell lymphocytosis (MBL) to CLL and is higher in MBL and CLL than normal controls [20]. 
High expression of miR-155 is associated with a more aggressive disease and a poor clinical 
prognosis in CLL [21, 22]. Another miRNA, miR-181b, is frequently down-regulated in CLL 
patients with disease progression [23, 24]. Important targets of miR-181b include MCL-1 and 
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BCL2 [23], which, as stated before, are important for cancer cell survival, and low expression of 
miR-181b is associated with poor prognosis as indicated by treatment-free survival [23, 24]. 
 
miRNA expression and drug response in CLL patients 
Higher expression of miR-650 and miR-708 is associated with a favorable CLL prognosis [25] 
and affects B-cell proliferation [26]. On the other hand, overexpression of miR-21, miR-148a, 
miR-155 and miR-222 in CLL patients is associated with poor therapeutic response and 
prognosis [20-22, 27, 28]. For example, the expression of miR-155 is higher in CLL patients that 
failed to achieve a complete response to a chemo-immunotherapy combination of fludarabine 
[28, 29], cyclophosphamide, and rituximab (FCR) [20] and, as stated in the previous section, it is 
associated with poor clinical prognosis in CLL [21, 22]. The relapsed patients have higher miR-
155 expression compared to baseline despite reduced expression at the beginning with response. 
Importantly, when the gene expression profile is analyzed, p53 down-stream genes are only 
detected in fludarabine-responsive patients, but not resistant patients [30]. The mutation of TP53 
in CLL is associated with unfavorable treatment response and clinical outcome [31], and in some 
CLL patients inactivation of TP53 correlates with reduced miR-34 expression, which is 
associated with an unfavorable prognosis [32]. In addition, miR-132 and miR-212 expression is 
lower in progressive CLL patients compared with stable CLL patients [33]. Gene expression 
profiling showed that the miRNAs miR-132 and miR-212 affect the Rb or TP53 signaling 
pathway, which may explain the clinical observation [33]. 
The expression of miRNAs can also be used as a biomarker to monitor CLL progression. For 
example, there is reduced expression of miR-181b, miR-29c and miR-223 with disease 
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progression in CLL patients and this correlates with unfavorable prognosis, such as shorter 
progression-free survival and overall survival [27, 34-36]. miR-150 is highly expressed in both 
cellular and serum samples of CLL patients [37]. It is interesting to note, though, that low 
cellular but high serum expression of miR-150 is associated with poor prognosis as indicated by 
tumor burden, treatment-free survival (TFS) and overall survival (OS) [37]. This could be 
because lower expression of cellular miR-150 may enhance cell survival and proliferation in 
response to BCR signaling stimulation, which worsens the patient prognosis [37]. Furthermore, 
high serum miR-150 is correlated with high lymphocytosis, which contribute to high tumor 
burden and poor clinical outcome [37]. 
 
Chronic myeloid leukemia (CML) 
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by abnormal 
expansion of immature hematopoietic progenitor cells in the bone marrow and increased levels 
of myeloid cells in the peripheral blood. The genetic hallmark of CML is a t(9;22)(q34;q11) 
reciprocal translocation, also called 'Philadelphia chromosome'. This translocation results in a 
BCR-ABL fusion gene that leads to constitutive tyrosine kinase activation [38]. 
 
miRNA signature in CML 
The most frequently down-regulated miRNAs in chronic myeloid leukemia include miR-10a, 
miR17–92, miR-150, miR-203, and miR-318 [39]. Several oncogenic miRNAs such as the 
miR17–92 cluster have been found to facilitate cellular transformation and to be up-regulated by 
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the BCR-ABL fusion protein in CML [40]. Induction of this miRNA cluster is usually observed 
in the chronic phase of CML, but not in the blast crisis phase [41]. Similarly, loss of miR-328 is 
observed in blast crisis CML in a BCR/ABL dose- and kinase-dependent manner. Ectopic 
expression of miR-328 in cell lines restores differentiation of leukemic blasts by induction of the 
survival factor PIM1 and inhibition of the hnRNP E2 interaction with the hematopoietic 
transcription factor CEBPA. Down-regulation of miR-328 is essential in CML blast crisis [39]. 
The differentiation arrest observed during the blastic phase of CML requires the activity of 
hnRNP E2, a poly(rC)-binding protein, which behaves as a translational regulator. Finally, 
expression of miR-130a and miR-130b controlled by BCR-ABL down-regulates the expression 
of CCN3, a growth inhibitory protein [42], whereas some miRNAs inhibit BCR-ABL 
expression. For instance, miR-203 and miR-451 act as tumor suppressors in CML and suppress 
ABL and BCR-ABL protein expression [43]. Consistent with this notion, miR-203 is frequently 
silenced by monoallelic loss and hypermethylation of the remaining allele [44]. Another 
consistency found in CML patients is the reduction of miR-150 and miR-10a expression [45, 46]. 
CML patients display inverse expression levels of miR-150 and the transcriptional activator 
MYB, which correlates with BCR-ABL (fusion gene) transcript levels [47], while miR-10a is 
associated with increased proliferation by targeting the upstream stimulatory factor 2 (USF2) 
[45]. Finally, recently miR-362-5p was found to act as an oncomiR by down-regulating 





miRNA expression and drug response in CML patients 
As discussed with CLL, the expression of miRNAs can be used as a biomarker to monitor CML 
progression as well. For example, the expression of miR-15a and miR-145 is higher in CML 
patients at chronic phase than in normal controls, but lower at acute phase than chronic phase 
[49]. The expression profile of some miRNAs can predict the Imatinib therapy response in CML 
patients[50]. For example, expression of miR-26a, miR-29c, miR-130b and miR-146a is lower in 
patients with an Imatinib response than in patients with Imatinib-resistant treatment [49]. A loss 
of or reduced expression of miR-23a, miR-30a, miR-30e, miR-203, miR-320 and miR424 have 
been associated with resistance to Imatinib in CML, and re-expression of these miRNAs targets 
BCR-ABL and restores sensitivity to Imatinib treatment [51-55]. In contrast, loss of miR-217 
and miR-199b correlates with resistance to ABL tyrosine kinase inhibitors [56, 57]. It should be 
noted that the tyrosine kinase inhibitor (TKI) Dasatinib affected miR-let-7d, miR-let-7e, miR-
15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while Imitanib affected miR-15a 
and miR-130a levels [49]. Consistent with the notion that miR-130a can act as a tumor 
suppressor by targeting BCL2 and MCL-1 expression, lower expression of miR-130a is 
associated with poor prognosis as indicated by shorter overall survival and treatment-free 
survival in CML patients [58]. Importantly, a low expression of miR-148b is found in a subset of 
CML patients with stable complete molecular responses after stopping Imatinib treatment[59]. 
These studies suggest that expression or lack thereof of some miRNA may predict the ability of 




Table 1. microRNAs deregulated and associated with clinical outcome in human Leukemia 
The figure represents a summary of miRNAs associated with a poor or a favorable prognosis in 
CLL, CML, ALL, AML and ATL. Highlighted in red and green are the miRNAs that are found 
most frequently associated with an unfavorable or favorable outcome, respectively, across 






Acute lymphoblastic leukemia (ALL) 
ALL is a lymphoid malignancy affecting the B or T lineages. Distinct microRNA signatures are 
reported in different ALL subtypes and can be used for the diagnosis and classification of ALL. 
ALL can be divided into T-cell, MLL-rearranged, TEL-AML1-positive, E2A-PBX1-positive, 
hyperdiploid ALL, BCR-ABL-positive, and “B-other” ALLs. Studies of the distinct microRNA 
signatures of ALL subtypes can be used for the diagnosis and classification of the disease [60].  
 
miRNA signature in ALL 
The B and T lineages of ALL can be distinguished by miR-148, miR-151, miR-424,miRNA-425-
5p, miRNA-191, miRNA-146b, miRNA-128, miRNA-629, and miRNA-126. In addition, 
miRNA-708 was found highly expressed in TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid, 
and B-other cases[60, 61]. The miRNA signature in hyperdiploid and TEL-AML1-positive 
patients partly overlap, suggesting a common underlying biology. Mavrakis et al. identified five 
miRNAs – miRNA-19b, miRNA-20a, miRNA-26a, miRNA-92, and miRNA-223 involved in T-
ALL development in a mouse model. These five miRNAs have been shown to target T-ALL 
tumor suppressors such as IKAROS, PTEN, BIM, PHF6, NF1 and FBXW7 [62]. The expression 
pattern of these miRNAs can be used as a biomarker to distinguish the B and T lineages of ALL. 
Higher expression of miR-128b and lower expression of miR-223 has independently been 
reported for human ALL cell lines and ALL cells isolated from pediatric patients [63]. In a 
different study, single nucleotide polymorphisms (SNPs) analyses of precursor miRNAs (pre-
miRNA) and miRNA-processing genes revealed eleven SNPs associated with ALL susceptibility 
[64]. Among them, eight are located at miRNA biogenesis pathway genes (TNRC6B, DROSHA, 
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DGCR8, EIF2C1, CNOT1, and CNOT6) and three at miRNA genes (miR-612, miR-499, and 
miR-449b). Interestingly, miRNA-612 and miRNA-499 have significant correlations with ALL 
susceptibility [60]. In addition, miRNA profiles can be useful to distinguish myeloid or lymphoid 
lineages of leukemia. De Leeuw et al. identified miRNA-23a, miRNA-27a, miRNA-199b, 
miRNA-221, and miRNA-223 as the most lineage-discriminative miRNAs between AML and 
ALL [65]. AML patients present down-regulation of let-7b and miRNA-223 and overexpression 
of miRNA-128a and -128b compared to ALL. Consistently, Wang et al. [66] identified miR-23a, 
miR-27a, miR-27b, miR-150, miR-199a, miR-199b, miR-221 and miR-340 as miRNAs 
differentially expressed in patients with ALL compared to AML. 
 
miRNA expression and drug response in ALL patients 
Epigenetic deregulation is one of the mechanisms that accelerates ALL progression. miR-124a is 
methylated in 59% of ALL patients and down-regulation of miR-124a increased the expression 
of its target CDK6 resulting in phosphorylation of retinoblastoma (Rb), which is involved in cell 
proliferation. As a result, hypermethylation of miR-124a in ALL patients is correlated with a 
higher relapse and mortality rate and can be used as an independent prognostic factor for disease-
free survival (DFS) and overall survival (OS) in the multivariate analysis [67]. microRNA 
analysis shows that expression of miR-10a, miR-134, miR-214, miR-221, miR-128b, miR-484, 
miR-572, miR-580, miR-624 and miR-627 are significantly correlated with a favorable clinical 
outcome [63, 66, 68]. In contrast, deregulation of the expression of miR-9, miR-33, miR-92a, 
miR-142-3p, miR-146a, miR-181a/c, miR-210, miR-215, miR-369-5p, miR-335, miR-454, miR-
496, miR-518d, and miR-599 are associated with an unfavorable long-term clinical outcome in 
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ALL patients [66, 68-74]. Low expression of miR-151-5p and miR-451, and high expression of 
miR-1290 or a combination of all three, predicted inferior relapse-free survival (RFS) in 
pediatric B-ALL [75]. Importantly, activation of NOTCH intracellular domain (NCID) signaling 
leads to transcriptional repression of miR-451 and miR-709, two tumor suppressor microRNAs 
in T-ALL [76]. Furthermore, different independent analyses identified relapse-related miRNAs. 
When globally analyzed the relapse-related miRNAs – miR-7, miR-100, miR-216 and let-7i – 
were up-regulated, and miR-486, miR-191, miR-150, miR-487 and miR-342 were down-
regulated in early relapse ALL patients[77]. In addition, overexpression of miR-708, miR-223 
and miR-27a is associated with lower relapse-free survival in patients [78], possibly through 
regulation of FOXO3, BMI1 and E2F1. Expression of miR-126, miR-345, miR-222, and miR-
551a are reduced in ALL patients with central nervous system (CNS) relapse compared to non-
CNS-relapsed ALL patients [77]. Furthermore, higher expression of miR-7, miR-198 and miR-
633 was found in patients with CNS relapse compared with non-CNS-relapsed ALL [77]. 
Glucocorticoids can be used to treat ALL because they induce apoptosis in lymphoid lineage 
cells [79]. In ALL patients, sensitivity to prednisone treatment is an important indicator for 
treatment outcome [77]. While miR-16 is lower in ALL patients with low leukocytes and good 
cytogenetic characteristics [80], higher expression of miR-16 is found in patients with 
corticosteroid resistance [80] and is correlated with shorter disease-free survival and overall 
survival. The expression of miR-223 and the miR-15/16 family is increased in ALL patients 
treated with systemic glucocorticoid monotherapy [63, 79]. In contrast, the expression of miR-
548d-1 and miR-106b~93 is reduced after ALL patients are treated with glucocorticoids [79]. 
Differential expression of miR-18a, miR-532, miR-218, miR-625, miR-193a, miR-638, miR-550 
and miR-633 can be used as a marker to predict prednisone response in pediatric ALL 
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patients[77]. For example, high miR-18a but low miR-193a expression is associated with good 
prednisone response. Although up-regulation of miR-128a [81, 82] and miR-128b [63] is 
frequently found in childhood ALL patients, patients with poor prednisolone response are often 
associated with lower miR-128b expression, with higher expression of miR-128b correlated with 
a longer disease-free period [63]. miR-128b expression is higher in the bone marrow of relapsed 
ALL patients compared with the values detected at diagnosis [63]. Increased miR-708 expression 
is detected in childhood ALL with a good response to prednisone and with better remission 
status after 15-day and 33-day chemotherapy protocol [78]. The expression of let-7e is generally 
reduced in pediatric ALL patients [81, 82], but higher expression of let-7e is associated with 
positive minimal residual disease (MRD) at day 14 after treatment [82]. 
 
Acute myeloid leukemia 
Adult acute myeloid leukemia (AML) presents abnormal miRNA expression diversely expressed 
in the different subtypes. Both the t(8;21) and inv(16) chromosomal aberration is associated with 
the formation of novel chimeric fusion genes that involve the core-binding factor (CBF) 
complex, an important regulator of hematopoiesis, providing the designation CBF-AML[83]. 
 
miRNA signature in AML 
A distinct miRNA signature characterized by an alteration of miR-29, miR-125, miR-142, miR-
146 and miR-155 expression has been reported to play a role in AML progression and 
pathogenesis [84]. miR-29 family members miR-29a, miR-29b, and miR-29c act as oncogenes 
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and tumor suppressors in myeloid malignancies [85]. miR-29b targets DNA methyltransferase 
DNMT3A, DNMT3B, and Sp1 (a transcriptional regulator of DNMT1) [86]. Inhibition of miR-
29b promotes DNA hyper-methylation in AML and contributes to methylation status in AML 
cells, suggesting its potential role as a therapeutic target in AML. In addition, miR-29a and miR-
29b affect the expression of genes involved in apoptosis, cell cycle progression, and cellular 
proliferation. Consistently, altered expression of MCL-1 and CDK6 was reported in primary 
AML blasts following ectopic expression of miR-29b [85]. Interestingly, injection of precursor 
miR-29b oligonucleotides in mice engrafted with K562 cells reduce their tumor sizes [84]. The 
miR-125 family includes miR-125a/miR-99b/let-7e, miR-125b-2/miR-99a/let-7c-1, and miR-
125b-1/miR-100/let-7a-2 located on human chromosomes 19, 21, and 11, respectively. The mir-
125 family is involved in self-renewal, both in hematopoietic stem cells (HSC) and 
Megakaryocyte-Erythroid Progenitor Cells (MEC) [87]. Overexpression of miR-125 enhances 
the development of an MPN-like phenotype, which progresses to AML. Based on the cellular 
context, miR-125b can act as a tumor suppressor or an oncogene[88]. In acute myeloid leukemia, 
miR-125b is significantly overexpressed in patient blasts and can promote the transformation of 
normal hematopoietic cells into malignant cells in an in vitro and in vivo model. miR-125b is 
located on chromosome 21 and involved in the development of a rare subtype of AML, acute 
megakaryocytic leukemia (AMKL), especially in patients with Down’s syndrome (DS). The 
trisomy chromosome 21, typical of DS, is associated with overexpression of miR-125b in both 
DS- and non-DS-related AMKL patients [89]. Down-regulation of miR-146a promotes AML 
disease progression by TRAF6-mediated induction of NF-kB [90]. miR-142 promotes the 
development of lymphoid and myeloid leukemia and is found recurrently mutated in AML [91]. 
miR-155 is located on human chromosome 21 in the B-cell integration cluster (BIC) gene[92]. 
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BIC cooperates with c-Myc to induce lymphomas[92]. In addition, miR-155 inhibits the cell-
cycle regulators WEE1 and the mismatch repair genes hMLH1, hMSH2, and hMSH6, resulting 
in an increase in spontaneous mutation rates in hematopoietic stem and progenitor cells (HSPC) 
and solid tumor cell lines [84, 93, 94]. In contrast, other studies suggest that in FLT3-wildtype 
AML cells, miR-155 induces myelomonocytic differentiation and apoptosis[95]. 
 
MicroRNAs in the diagnosis of AML 
Up-regulated let-7a-2-3p is associated with a favorable prognosis, longer overall survival and 
event-free survival in cytogenetically normal AML [96]. The effects of let-7a-2-3p are possibly 
through regulating miRNAs (miR-135a, miR-335 and miR-125b and all members of the miR-
181 family) and genes (FOSB, IGJ, SNORD50A and ZNF502, and FOSB) that are favorable 
signatures in AML. The role of miR-181 in AML is controversial. High miR-181 expression is 
associated with a better clinical outcome in cytogenetically normal acute myeloid leukemia 
patients [97, 98] through reverse regulation of toll-like receptors and interleukin-1β. In addition, 
miR-181 contributes to a better clinical outcome in cytogenetically abnormal AML patients [99] 
by regulation of HOXA7, HOXA9, HOXA11, and PBX3. Drug resistance is the main reason for 
AML relapse and poor prognosis. miR-181b can increase AML drug sensitivity through down-
regulation of HMGB1 and MCL-1. Therefore, miR-181b is found to be down-regulated in 




MicroRNA expression associated with favorable prognosis in AML 
In analysis of the expression of the meningioma 1 (MN1) gene and MN1-associated microRNA 
in Chinese adult de novo acute myeloid leukemia (AML) patients, Xiang found that increased 
expression of MN1 is associated with reduced miR-20a expression and increased miR-181b 
expression. In further analyzing the clinical outcome, miR-20a up-regulation is associated with a 
higher complete remission rate and longer overall survival [101]. In contrast, high miR-181b 
expression is found in patients with a lower complete remission rate, shorter relapse-free survival 
and shorter overall survival [101].  
Cytogenetic risk factors and molecular markers are important factors for AML prognosis [102]. 
Expression signatures of a minimum of two (miR-126/126*), three (miR-224, miR-368, and 
miR-382), and seven (miR-17-5p and miR-20a, along with the aforementioned five) miRNAs 
could correctly distinguish CBF, t(15;17), and MLL-rearrangement AMLs, suggesting that these 
microRNAs may cooperate with specific translocation in leukemogenesis [103]. In fact, KIT-
mediated upregulation of miR-17, which targets RUNX1-3'UTR, mimic the effects of CBF-
AML fusion protein[104]. The expression of miR-29a is lower in the bone marrow of pediatric 
AML patients compared with normal controls [105], and reduced miR-29a expression is 
associated with unfavorable karyotypes and shorter relapse-free and overall survival in pediatric 
AML patients [105]. Importantly, the association of miR-29a and prognosis is more apparent in 
intermediate-risk cytogenetic AML patients [105]. The same is true for miR-29b in that AML 
patients with low miR-29b expression have an unfavorable overall survival [106]. Analyses of 
238 intermediate-risk cytogenetic AML patients, reduced expression of miR-135a and miR-409-
3p is associated with a higher risk of relapse [102]. Higher miR-142 expression was associated 
with a better overall survival in AML patients with intermediate cytogenetic risk [107]. In AML 
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patients with complex karyotype, p53 status plays a role in determining miR-34a’s role in 
clinical prognosis. Up-regulation of miR-34a expression is correlated with unfavorable overall 
survival in TP53 (unaltered)-AML with complex karyotype, but is correlated with favorable 
overall survival and chemotherapy sensitivity in TP53 (biallelic altered)-AML with complex 
karyotype [108]. miR-96 is down-regulated in newly diagnosed AML patients and is associated 
with a higher white blood cell (WBC) count, bone marrow blast count, and lower hemoglobin 
and platelet count. Importantly, the expression of miR-96 increased after patients were treated 
with standard cytarabine plus daunorubicin induction chemotherapy [109]. When analyzing the 
relapse-free survival (RFS) and overall survival (OS), low expression of miR-96 is associated 
with shorter RFS and OS [109]. miR-204 expression is reduced in AML patients and low miR-
204 expression is correlated with short patient survival [110]. After patients received induction 
chemotherapy (daunorubicin plus cytarabine), high expression of miR-204 is associated with 
complete remission [110]. In addition, increased expression of miR-212, miR-25 and/or miR-203 
has been associated with a favorable overall survival, event-free and relapse-free survival in 
AML patients independent of cytogenetic subtypes [66, 111-113].  
 
miRNA expression associated with unfavorable prognosis in AML 
miR-378 is increased in 31% of AML patients and is associated with lower hemoglobin levels 
and shorter relapse-free survival [114]. There is a positive correlation between miR-155 
expression and white blood cell (WBC) count, serum lactate dehydrogenase (LDH), C-reaction 
protein (CRP) value in peripheral blood (PB), and miR25 and miR-196b expression in AML 
[115]. miR-126 is highly expressed in hematopoietic stem cells and leukemic stem-like cells. In 
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AML patients high miR-126 expression is correlated with poor survival, higher chance of relapse 
and expression of stem cell related genes [116, 117]. In vitro, overexpression of miR-126-5p 
increased the phosphorylation of Akt and caused cytarabin resistance. Increased miR-124, miR-
128–1, miR-194, miR-219–5p, miR-220a and miR-320 expression are associated with increased 
risk in AML [97]. The expression of miR-320d is increased in AML patients [118] and higher 
expression of miR-124-1 is associated with shorter overall survival and relapse-free survival 
[119]. AML patients with worse overall and event-free survival are known to have higher 
expression of miR-191 and miR-199a [120]. In de novo AML patients, miR-9-5p and miR-155-
5p are independent unfavorable prognostic factors [112]. miR-155 is up-regulated in AML 
patients compared to normal controls [115, 118]. Consistent with this finding, high miR-155 
expression is associated with an unfavorable prognosis, including lower complete remission rate 
and shorter disease-free survival and overall survival in AML [112, 115, 121]. The deregulation 
of miR-155 is associated with a gene expression profile enriched for genes involved in apoptosis, 
nuclear factor-kappaB activation, and inflammation [121]. Analyzing 53 AML patients, 
increased expression of miR-26a, miR-29b, miR-146a, and miR-196b is associated with an 
unfavorable overall survival [66]. The role of miR-196b was further supported by analyzing 238 
intermediate-risk cytogenetic AML patients, whereby high miR-196b and miR-644 expression is 
associated with shorter overall survival [102]. In 40 non-M3 AML patients, high expression of 
miR-26a, miR-29b and miR-146a is associated with short overall survival [66]. It is worth noting 
that miR-146a expression is reversely correlated with prognosis in both ALL and AML patients 
[66]. The opposite role of miR-29b in AML prognosis has been reported. miR-29b expression is 
inversely associated with MLLT11 expression, which is a poor prognostic biomarker for AML 
patients. Low miR-29b and elevated MLLT11 expression are found in patients with poor overall 
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survival [106]. Whether the cooperation between miR-29b and MLLT11 caused poor prognosis 
needs to be further confirmed. Reduced miR-188-5p expression is associated with favorable 
prognosis as indicated by longer overall survival (OS) and event-free survival (EFS) in 
cytogenetically normal AML patients [96]. The effects of miR-188-5p are possibly through 
regulating miRNAs (miR-135a, miR-335 and miR-125b and all members of miR-181 family) 
and genes (FOSB, IGJ, SNORD50A and ZNF502, and FOSB) that are a favorable signature in 
AML. Up-regulated miR-3151 is found in AML patients with an unfavorable prognosis, such as 
short overall survival and leukemia-free survival, and higher relapse risk [122, 123]. High 
expression of miR-3151 is associated with low expression of genes involved in transcriptional 
regulation, posttranslational modification, and cancer pathways, such as FBXL20 and USP40 
[123]. High miR-3151 expression is associated with high miR-501-5p and low miR-590, miR-
135a, miR-100*, miR-186* and let-7a* expression [122]. The expression of let-7a-3 is increased 
in 25% of de novo AML patients and is associated with shorter overall survival and relapse-free 
survival [124] in AML patients with complete remission. Further studies are needed to confirm 
the opposite role of let-7a-3 and let-7a-2-3p. 
 
miRNA expression and drug response in AML patients 
Higher expression of miR-29b is found in older AML patients with single-agent decitabine 
response compared with non-response patients [125]. The ability of miR-29b to target DNA 
methyltransferases may explain the role of miR-26b in decitabine response. miR-29c expression 
is higher in AML patients compared with healthy controls and is associated with poor survival 
[126]. Reduced miR-29c expression is associated with complete remission after initial treatment 
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(intensive chemotherapy: daunorubicin plus cytarabine or low dose chemotherapy (low dose 
cytarabine or azacitidine)). Higher miR-29c expression was associated with relapse after patients 
achieved complete remission. Importantly, low miR-29c expression is associated with better 
response to azacitidine treatment and remission achievement in elder AML patients who are not 
suitable for intensive chemotherapy [126]. The increased expression of miR-181a is associated 
with a higher complete remission rate, longer overall survival and disease-free survival [98, 99] 
in AML patients treated similarly with intensive induction chemotherapy and consolidation with 
autologous peripheral blood stem-cell transplantation on Cancer and Leukemia Group B 
(CALGB) protocols 9621 and 19808. In addition, after AML patients received double induction 
and one consolidation therapy, increased miR-181b expression was associated with worse 
complete remission rates, relapse-free survival and overall survival in adult patients with de novo 
AML [101]. In contrast, up-regulation of miR-20 is associated with better complete remission 
rates and overall survival [101]. The following drugs are included in the induction therapy and 
consolidation therapy: daunorubicin, cytarabine, idarubicin, and fludarabin [101]. miR-204 
expression is reduced in AML patients and low miR-204 expression is correlated with short 
patient survival [110]. After patients received induction chemotherapy (daunorubicin plus 
cytarabine), high expression of miR-204 is associated with complete remission [110]. miR-331 is 
up-regulated in AML patients. AML patients with longer complete remission after induction 
chemotherapy have reduced miR-331 expression [127]. miR-335 is up-regulated in pediatric 
AML patients both in bone marrow and serum [128]. High serum miR-335 is associated with 
poor relapse-free and overall survival after patients received 10 days of induction chemotherapy 
[128]. However, a separate study reported no association between serum miR-335 expression 
and Ara-C-based chemotherapy response. However, high expression of miR-335 in the bone 
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marrow was indicative of poor Ara-C-based chemotherapy response, lower relapse-free survival 
and overall survival in AML patients [129]. High expression of the miR-10 family is associated 
with complete remission after AML patients received induction chemotherapy [130]. 
 
Adult T-cell Leukemia (ATL): signature and prognosis 
Adult T-cell Leukemia is a fatal malignancy of mature CD4+, CD25+ T lymphocytes induced by 
the retrovirus Human T-cell leukemia virus (HTLV)-1[131, 132]. Several studies have reported 
deregulated microRNAs in ATL patient samples and HTLV-1-transformed cells, among them 
miR-155, miR-146a, miR-150, miR-223 were found up-regulated and miR-31 and miR124a 
down-regulated [133-136]. Interestingly, a recent study demonstrated that virus-encoded protein 
HBZ targets the expression of DICER thereby modulating the expression of a subset of 
microRNAs [137]. Deregulation of miR-146a, miR-155, miR-150 and miR-223 is reported to 
affect cellular proliferation [138-140] and alteration of miR-31, miR-130b and miR-93 are 
involved in apoptosis resistance [141], suggesting a possible role of miRNA expression in ATL 
progression and pathogenesis. Differential analyses of microRNA expression in non-infected 
healthy individuals, chronic ATL patients and acute ATL patients revealed an increased number 
of up-regulated miRNAs in acute ATL patients when compared with chronic ATL patients [142]. 
Among these, increased miR-155 expression correlates with disease progression from HTLV-1 
carrier to chronic ATL and then to acute ATL [142]. Both STAT3 and Myb, which 
transcriptionally up-regulate miR-155, are activated in HTLV-I-transformed cells and ATL 
samples [136, 143, 144]. On the other hand, let-7g is highest in healthy donors and its expression 
is significantly reduced in an HTLV-1 carrier, chronic and acute ATL patient samples [142]. For 
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clinical outcomes, high miR-155 and low miR-126 is associated with a poor prognosis [142]. 
High miR-130b and low miR-145 and miR-223 expression in aggressive-type ATL are 
associated with shorter overall survival. Among miR-130b, miR-145 and miR-223, only miR-
145 can act as an independent risk factor for ATL prognosis by a multivariate prognostic 
analysis. An in vitro study showed that overexpression of miR-145 in ATL cells reduced cell 
proliferation [145]. A recent study demonstrated that epigenetic silencing of miR-124-1 resulted 
in STAT3-mediated Pim1 kinase activation and increased tumorigenic potential [136]. 
 
Table 2. microRNAs deregulated in human leukemia and their predicted target genes 
microRNAs most frequently deregulated in human leukemia (CLL, CML, ALL, AML and ATL) 
and their characterized target genes 
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Role of circulating RNA 
The majority of miRNAs are cellular miRNAs, however an emerging class of circulating 
miRNAs has been described. Circulating miRNAs have been observed in various body 
fluids[146]. They are involved in proliferation and differentiation. Recent evidence shows 
elevated expression of the miR-29 family (miR-29a, miR-29b and miR-29c), miR-150 and miR-
155 in CLL-derived exosomes compared to healthy donors [147]. The plasma expression of 
miR-29a and miR-150 is associated with absolute lymphocyte count in the blood [148]. The 
miR-29 family is significantly down-regulated in a subset of CLL patients and is associated with 
an unfavorable prognosis [12]. miR-150 is highly expressed in cellular and serum samples of 
CLL patients [37]. Interestingly, low cellular expression of miR-150 but high serum expression 
of the same is associated with poor prognosis as indicated by tumor burden, treatment-free 
survival (TFS) and overall survival (OS) [37]. The expression of miR-155 is increased with 
disease progression from monoclonal B-cell lymphocytosis (MBL) to CLL and is higher in MBL 
and CLL than normal controls [20]. In addition, high plasma miR-155 expression is associated 
with CLL patients poorly responding to fludarabine, cyclophosphamide, and rituximab (FCR) 
chemotherapy [20]. Therefore, high expression of miR-155 is associated with more aggressive 
disease and poorer clinical prognosis in CLL [21, 22].  
Consistent with the finding in CLL patients, the expression of miR-150 and miR-155 is higher in 
AML-derived exosomes and can act as a biomarker to distinguish AML patients from normal 
controls [130]. There is a positive correlation between miR-155 expression and white blood cell 
count, serum lactate dehydrogenase (LDH) and C-reaction protein (CRP) value in peripheral 
blood in AML patients [115]. High miR-155 expression is associated with an unfavorable 
prognosis, such as lower complete remission rate and shorter disease-free survival and overall 
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survival in AML patients [112, 115, 121]. However, the role of miR-150 in AML is 
controversial. The expression of miR-150 has been reported to be lower in AML-derived plasma 
compared to healthy donors [149]. Up-regulation of miR-150 after treatment is associated with 
AML patients with complete remission [149]. In addition, circulating miR-155-5p and miR-
181b-5p are up-regulated in AML patients when compared with normal controls [118]. Up-
regulated circulating miR-181b-5p is associated with shorter overall survival [118] and is found 
in patients with a lower complete remission rate, shorter relapse-free survival and shorter overall 
survival [101].  
Other circulating miRNAs can also act as biomarkers for AML prognosis. For instance, miR-210 
is up-regulated in the bone marrow and serum of AML patients compared with normal controls. 
Reduced serum miR-210 expression is found in patients with complete remission, while high 
miR-210 expression is correlated with poor relapse-free survival and overall survival in AML 
patients [150]. Similarly, the expression of miR-375 is higher in the serum and bone marrow of 
pediatric AML patients and is associated with unfavorable karyotypes and poor prognosis as 
indicated by shorter relapse-free survival and overall survival [151]. Like miR-29a [105], the 
association of miR-375 and prognosis is more apparent in intermediate-risk cytogenetic AML 
patients [151]. Plasma miR-511, miR-222, and miR-34a are up-regulated in B-ALL patients 
compared with normal controls, whereas plasma miR-199a-3p, miR-223, miR-221, and miR-26a 
are lower in B-ALL patients [152]. Moreover, the low expression of miRNA-100 and miRNA-
146a is associated with poor clinical outcome in ALL patients [63, 66, 68, 126]. Together these 
studies clearly demonstrate that detection of circulating miRNAs has significant value for 
detection of disease progression and can also serve as indicators of therapeutic response. 
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Clinical significance of other non-coding RNAs: lncRNA and snoRNAs 
In addition to microRNA, other non-coding RNAs have been reported to play a role in human 
leukemias. Long non-coding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides 
with undefined open reading frames involved in gene expression regulation. A small subset of 
lncRNAs have been reported in leukemia and an lncRNA expression profile correlated with 
treatment response and survival in AML patients [153]. The X-inactive specific transcript Xist 
lncRNA, involved in epigenetic regulation of transcriptionally inactive chromatin, is 
overexpressed in some leukemias [154]. NOTCH-regulated lncRNA LUNAR1 (leukemia-
induced non-coding activator RNA) has been shown to have oncogenic effects in T-ALL [155]. 
LUNAR1 has been demonstrated to increase IGF1R mRNA expression and IGF1 signaling 
[155]. Another NOTCH-related lncRNA, RP11-611D20.2 (NOTCH-associated lncRNA in T-
ALL (NALT)), has been found to be overexpressed in pediatric ALL and may play a role in the 
leukemia stem cell compartment [156]. In CML patients with BCR-ABL translocation, 
deregulation of two lncRNAs has been described: the Beta Globin Locus 3 (BGL3) lncRNA 
[157] and the imprinted H19 lncRNA [158]. Little is known about the function of these lncRNAs 
in CML. BGL3 lncRNA has been shown to increase the expression levels of the tumor 
suppressor PTEN by acting as a competing endogenous RNA (ceRNA) [159]. In contrast, 
lncRNA H19, which is transcriptionally activated by the oncogene c-Myc [158], has been shown 
to inhibit the expression of the onco-suppressor let-7 microRNA family [160]. In AML patients, 
lncRNA IRAIN [161], which is transcribed from the IGF1R imprinted locus, is down-regulated 
in patients with high-risk AML, while urothelial carcinoma-associated 1 (UCA1) lncRNA is 
specifically up-regulated in AML [162], although its role in the pathogenesis is unclear. Finally, 
the lncRNA B-ALL-associated long RNAs-2 (BARL-2) was found to affect B-ALL patient 
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response to corticosteroid treatment [163]. Another class of non-coding ncRNAs, the small 
nucleolar snoRNAs, is also affected in cancers and leukemia. Elevated levels of SNORD112–
114 snoRNAs has been found in acute promyelocytic leukemia (APL) [164]. In a different study, 
Affymetrix GeneArray screening identified snoRNA SNORA70F as significantly down-
regulated in poor prognostic subgroups of CLL patients. In addition, high expression of 
SNORA74A and SNORD116-18, and low expression of SNORD56 were associated with shorter 
progression-free survival (PFS) in these patients [165]. Although lncRNA and snoRNA are not 
as greatly studied as miRNA, they are likely to play an increasing role in the future and 
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Chapter IV:" STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the 
Proliferation of HTLV-I-Transformed and ATL Cells."  














We have previously reported on the deregulation of cellular microRNAs involved in 
hematopoiesis and inflammation in human T-cell lymphotropic virus type 1 (HTLV-I)–
transformed cells. In this study, we demonstrate that miR-150 and miR-223 specifically target 
the signal transducer and activator of transcription 1 (STAT1) 3′ untranslated region, reducing 
STAT1 expression and dampening STAT1-dependent signaling in human T cells. The effects of 
miR-150 and miR-223 on endogenous STAT1 were confirmed using inducible cell lines. Our 
studies also showed that miR-150 expression is upregulated by interleukin-2 signaling in adult T 
cell leukemia/lymphoma (ATL) cells. HTLV-I–transformed and ATL-derived cells have reduced 
levels of miR150 and miR223 expression, which coincide with increased STAT1 expression and 
STAT1-dependent signaling. Knockdown of STAT1 by short hairpin RNA demonstrated that the 
constitutive activation of STAT1 is required for the continuous proliferation of HTLV-I–
transformed cells. Our studies further demonstrate that increased expression of STAT1 in ATL 
cells is associated with higher levels of major histocompatibility complex class I expression. 
Previous studies have demonstrated that the pressure exerted by natural killer (NK) cells in 
vivo can edit leukemic tumor cells by forcing an increased expression of major 
histocompatibility complex class I to escape immune clearance. STAT1-expressing tumor cells 
produce more aggressive tumors because they cannot be eliminated by NK cells. Our results 
suggest that therapeutic approaches using combined targeting of STAT1 and MHC class I may 





MicroRNAs (miRNAs) are involved in a wide range of biologic processes, including cellular 
survival, differentiation, immune response, and oncogenesis. miRNAs are short non-coding 
RNAs that target genes through imperfect base pairing with mRNAs, thereby affecting their 
stability and/or their translation. An individual miRNA has numerous cellular gene targets and 
the manner in which to accomplish a coordinated regulation of biologic processes is unclear. The 
role of miR-150 in human cancer is context-dependent as this miRNA can have either oncogenic 
or tumor suppressor activity in cells that originate from different tissues. This is best illustrated 
by upregulated expression of miR-150 in CD19 + B cells from chronic lymphocytic leukemia 
(CLL) [1,2] but downregulated expression in chronic myeloid leukemia [3,4], acute 
lymphoblastic leukemia [5], and mantle cell lymphoma [6]. Additional studies have further 
demonstrated that miR-150 stimulates the proliferation and migration of lung cancer cells by 
targeting SRC kinase signaling inhibitor 1 (SRCIN1) and SRC activity [7]. In contrast, in 
situ hybridization revealed that miR-150 expression levels are reduced in both estrogen receptors 
positive and triple-negative breast cancer samples compared to adjacent normal cells, and miR-
150 expression was shown to inhibit breast cancer cell migration and invasion [8,9]. Some of the 
known validated cellular gene targets of miR-150 include c-MYB, NOTCH3, CBL, EGR2, 
AKT2, and DKC1 [10–14]. Similar to miR-150, miR-223 is also differentially regulated. Studies 
showed that it is frequently repressed in hepatocellular carcinoma [15], B-CLL [16], acute 
myeloid leukemia (AML) [17], gastric mucosa-associated lymphoid tissue lymphoma [18], and 
recurrent ovarian cancer [19]. In contrast, miR-223 is upregulated in T cell acute lymphocytic 
leukemia (T-ALL) [20], EBV-positive diffuse large B-cell lymphoma [21], and metastatic gastric 
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cancer [22,23]. Among validated cellular gene targets of miR-223 are FBXW7/Cdc4, RhoB, 
stathmin 1, E2F transcription factor 1 (E2F1), signal transducer and activator of transcription 3 
(STAT3), CCAAT/enhancer binding protein beta, forkhead box O1, and nuclear factor I/A [22–
27]. 
Human T-cell lymphotropic virus type 1 (HTLV-I) is a human retrovirus present in 20 million 
people worldwide [28]. Infection with HTLV-I is the etiological agent of adult T cell 
leukemia/lymphoma (ATL) [29] and a neurodegenerative disease called tropical spastic 
paraparesis/HTLV-I–associated myelopathy [30,31]. Only a few studies have investigated 
miRNA expression in HTLV-I–mediated T cell transformation and pathogenesis [32–37]. 
HTLV-I–associated disease pathogenesis is still poorly understood [38–40]. Both diseases 
originate from deregulated proliferation of infected CD4/CD25 + T cells. While it is unclear how 
the virus induces cellular transformation, the viral oncoprotein Tax plays an essential role and is 
sufficient to immortalize human primary T cells [41]. Tax expression leads to accumulation of 
DNA double-strand breaks during cellular replication and simultaneously targets DNA repair 
pathways to increase genetic instability [42,43]. In addition, Tax targets many tumor suppressors, 
cell cycle regulators, and survival factors and affects chromosome stability and segregation [44–
48]. The molecular events linked to the switch from immortalization [interleukin-2 (IL-2)–
dependent growth] to transformation (IL-2–independent growth) are largely unknown. A 
common characteristic found in HTLV-I–transformed cells in vivo and in vitro is the constitutive 
activation of the Janus activated kinase (JAK)/STAT signaling [49,50]. In fact, pharmacological 
targeting of the JAK/STAT axis has shown that activation of this pathway is required for 
continuous proliferation and survival of HTLV-I–transformed cells [51–53]. STAT1 plays a role 
in immune modulatory functions, anti-viral responses, apoptosis, and anti-proliferative 
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responses [54]. In contrast, several studies have shown that STAT1 can also act as a potent tumor 
promoter for leukemia development [55] and that many T-ALL leukemic cells are dependent on 
the TYK2-STAT1-BCL2 pathway for continued survival [56]. However, a potential role played 
by STAT1 in HTLV-I pathogenesis has not yet been investigated. 
In this study, we demonstrate for the first time that miRNAs miR-150 and miR-223 directly 
target the STAT1 3′ untranslated region (UTR) gene. Expression of both miR-150 and miR-223 
was significantly reduced in HTLV-I–transformed cell lines and ATL-derived cells, while 
STAT1 protein expression was elevated. Restoring miR-150 and miR-223 expression inhibited 
endogenous STAT1 expression and the activation of STAT1 transcription–dependent genes and 
significantly reduced the proliferation of HTLV-I–transformed cells and ATL cells. A direct role 
of STAT1 on cell cycle and expansion of HTLV-I cells was further confirmed by using short 
hairpin RNA (shRNA) targeting STAT1. We also found that IL-2–dependent ATL cell lines 
express higher levels of miR-150, suggesting that IL-2 signaling may be involved in the 
transcriptional up-regulation of miR-150 expression. Finally, we found that a majority of freshly 
isolated uncultured ATL samples have high expression of STAT1, which correlated with higher 
major histocompatibility complex class I (MHC-I) expression and may help to conceal ATL cells 







miRNA Target Predictions 
STAT1 sequences were obtained from the National Center for Biotechnology Information 
Nucleotide database (http://www.ncbi.nlm.nih.gov/). Sequences of mature human miRNAs were 
obtained from the miRNA Registry at miRBase (http://www.mirbase.org). The prediction 
algorithms Targetscan and PicTar were used to search for miRNA target sites in the human 
STAT1 3′UTR. 
 
Cell Culture and Patient Samples 
A 293T cell line was cultured in complete Dulbecco's modified Eagle's medium with 10% FBS, 
penicillin, and streptomycin. The HTLV-I cell lines, MT-4, MT-2, C8166, C91PL, and human T 
cell lymphoblast cell line, Jurkat, were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA) 
supplemented with 10% FBS, penicillin, and streptomycin. The ATL-like cell lines, MT-1, ATL-
T, ED-40515(−), ALT-25, ATL-43T, LMY1, and ATL-55T, were maintained in RPMI-1640 
supplemented with 10% FBS, penicillin, and streptomycin and IL-2 (50 U/ml) as needed [57–
59]. Patient samples were obtained after informed consent was provided and in agreement with 
regulations for the protection of human subjects according to the National Institutes of Health 
guidelines. RNA was extracted from peripheral blood mononuclear cells (PBMCs) of patients 





Precursors of miR-150 and miR-223 were cloned in pTRIPZ. pTRIPZ lentivirus is an inducible 
vector engineered to be Tet-On. pTRIPZ contains puromycin resistance that was used to select a 
stable cell line. The stable cell lines derived were incubated in the absence or presence of 
doxycycline and subjected to reverse transcription–polymerase chain reaction (RT-PCR) to 
analyze miR-150 and miR-223 expression. Precursors of miR-150 and miR-223 were also cloned 
in the pSIH1-green fluorescent protein (GFP) lentivirus and pcDNA vector. shRNA against 
STAT1 was cloned in the pSIH1-GFP vector. 
 
3′UTR and Luciferase Reporter Assay 
The full-length 3′UTR of the human STAT1 gene was cloned into the luciferase vector, pGL3 
(Promega). STAT1 3′UTR containing the mutated miR-150 target sequence and the mutated 
miR-223 target sequence were generated by QuikChange Site-Directed Mutagenesis kit 
(Stratagene). miR-150 and miR-223 were cloned into the pcDNA expression vector. 293T cells 
were cotransfected using Polyfect Transfection reagent (Qiagen), with 300 ng of the indicated 
luciferase reporter plasmid, 200 ng of pRL-TK–Renilla luciferase plasmid (Promega, for 
normalization), and the indicated miRNAs (125, 250, 500, or 750 ng). Cell extracts were 
prepared 48 hours after transfection. Cell extracts were lysed in 1 × passive lysis buffer 
(Promega) and analyzed using the Luciferase Reporter Assay System (Promega), according to 
the manufacturer’s instructions. Luciferase assays were performed twice from independent 
experiments, and data were normalized for transfection efficiency using Renilla luciferase 
activity. 293T cells were cotransfected with 300 ng of the STAT1 luciferase reporter plasmid, 
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200 ng of pRL-TK–Renilla luciferase, and the indicated miRNAs. Cell extracts were prepared 48 
hours after transfection according to the manufacturer’s instructions. 
293T cells were stimulated with 500 pg/ml human interferon-γ (IFN-γ; PBL Assay Science, 
Piscataway, NJ) or 100 U/ml human IFN-β (ProSpec, East Brunswick, NJ) and cotransfected 
with 300 ng of pISRE-TA-Luc Vector, 200 ng of pRL-TK–Renilla luciferase plasmid, and 500 
ng of the indicated miRNAs by using Polyfect. Cell extracts were prepared 48 hours after 
transfection and luciferase assays were performed as described above. 
 
Transfection, Viruses, and Generation of Stable miR-150 and miR-223 Inducible Cell Lines 
293T cells were infected with lentiviral particles expressing miR-150 and miR-223. Lentiviruses 
were prepared by transfection of 293T cells with 10 μg of pSIH1-miR-150, pSIH1-miR-223, 
pTRIPz/miR-150, or pTRIPz/miR-223, 5 μg of vesicular stomatitis virus G proteins, and 5 μg of 
pDNL6 using calcium phosphate (Invitrogen). The virus was collected in the supernatant for 4 
days, concentrated by ultracentrifugation, and resuspended in phosphate-buffered saline. For 
inducible miR-150 and miR-223 expression assays, MT-4 or Jurkat cells were infected with 
lentiviruses encoding vector control (pTRIPz), miR-150 (pTRIPz/miR-150), or miR-223 
(pTRIPz/miR-223). Cells were selected with 10 μg/ml puromycin for 12 days. Stable cell lines 
derived were incubated in the absence or presence of doxycycline and subjected to RT-PCR to 




RNA Extraction and Real-Time Quantitative PCR 
RNA was extracted using TRIzol (Invitrogen) and treated with DNaseI (Roche Applied Science, 
Indianapolis, IN). RNA was reverse-transcribed using the RNA-to-cDNA synthesis kit (Applied 
Biosystems, Carlsbad, CA). Quantitative real-time PCR was performed using Real-Time SYBR 
Green PCR Master Mix (SABiosciences, Valencia, CA) on the StepOnePlus Real-Time PCR 
System (Applied Biosystems), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression as an internal control. The miScript II RT Kit was used for mature miRNA 
quantification. cDNA generated with the miScript II RT Kit was used as a template for real-time 
PCR to detect the expressive level of mature miR-150 and miR-223 in HTLV-I and ATL cell 
lines. Real-time PCR was performed in duplicate, and samples were normalized to RNU6b (U6) 
expression. 
 
Western Blot Analysis 
Cells were washed with phosphate-buffered saline and lysed in RIPA buffer with phosphatase 
and protease inhibitors (Complete Cocktail; Roche). Protein concentration was determined with 
the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Total protein extracts were resolved by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to Immobilon 
polyvinylidene difluoride membranes (Millipore, Darmstadt, Germany), and probed with STAT1 
(Cell Signaling Technology, Danvers, MA) and Bcl2, p21, p27, or actin (Santa Cruz 
Biotechnology, Santa Cruz, CA) antibodies. Western blot quantification was performed by using 




miRNAs Total sites 8mer 7mer-m8 7mer-1A Aggregate 
PCT 
miR-223 2 1 0 1 0.27 
miR-150 1 0 0 1 0.14 
miR-144 1 1 0 0 < 0.1 
miR-130ac 1 0 0 1 < 0.1 
miR-155 1 0 0 1 < 0.1 
miR-140 1 0 1 0 < 0.1 
miR-203 1 1 0 0 < 0.1 
miR-27abc 1 0 0 1 < 0.1 
miR-200bc 1 0 0 1 < 0.1 
miR-101 1 0 0 1 < 0.1 
miR-146ac 1 0 1 0 < 0.1 
miR-132 1 0 0 1 < 0.1 
miR-26ab 1 0 0 1 < 0.1 
 






miRNAs miR-150 and miR-223 Target the STAT1 3′UTR 
The prediction algorithms Targetscan and PicTar were used to identify common gene targets to 
miRNAs downregulated in HTLV-I–transformed cells. Among potential targets, STAT1 
appeared as a possible target and was selected for further analyses (Table 1). We identified a 7-
mer-1A binding site for miR-150 in position 426-432nt of the STAT1 3′UTR (Figure 1A). To 
demonstrate a direct effect of miR-150 on STAT1 mRNA, the full-length (1667 bp) STAT1 
3′UTR was cloned into a pGL-3 reporter luciferase construct and miR-150 was cloned into the 
pcDNA expression vector. First, we verified the transfection of the mature miR-150 by using 
RT-PCR (Figure 1B). Expression of the STAT1 3′UTR vector along with a different amount of 
miR-150 demonstrated a 50% inhibition of luciferase activity (Figure 1C). To further 
demonstrate specificity, we performed site-directed mutagenesis to modify the seed sequence 
and generate a mutated STAT1 3′UTR vector (Figure 1A). As expected, miR-150 had no 
significant effect on the mutated STAT1 3′UTR construct (Figure 1C). These results 
demonstrated a specific and direct effect of miR-150 on the STAT1 3′UTR. We next wanted to 
validate these results on the endogenous STAT1 gene. To this end, we expressed in 293T cells 
the pSIH1-miR-150 or pSIH1-GFP control vector. Our results confirmed the effect of miR-150 
on the endogenous STAT1 gene at both the RNA and the protein levels (Figure 1, D and E). The 
down-regulation was not as efficient as seen with the 3′UTR luciferase experiment because in the 
latter experiment the transfection efficiency limits the percentage of cells in which an effect can 
be observed. We then investigated the effect of miR-223. The STAT1 3′UTR sequence displays 
two miR-223 target sites positioned at 970-977nt and 1194-1200nt (Figure 2A). We verified the 
transfection of the mature miR-223 by using RT-PCR (Figure 2B). To investigate if one site was 
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more important than the other, we mutagenized each site independently (mutant-UTR 970 and 
mutant-UTR 1194; Figure 2A). These mutants were tested along with wild-type STAT1 3′UTR 
in transient assays. Results indicated that mutation of a single site had no effect and miR-223 
was still able to repress activity from the STAT1 3′UTR (Figure 2C). However, when both sites 
were simultaneously mutated, miR-223 was no longer able to suppress the activity of the STAT1 
3′UTR, suggesting that the effect of miR-223 is specific and requires only one functional binding 
site (Figure 2D). We next validated these results on the endogenous STAT1 gene. We expressed 
in 293T cells the pSIH1-miR-223 or pSIH1-GFP control vector and analyzed by RT-PCR and 
Western blot. Results confirmed the effect of miR-223 on the endogenous STAT1 gene, which 
was observed at the protein level (Figure 2E). RT-PCR analysis shows no significant change in 
STAT1 expression (Figure 2E). That result suggested that miR-223 regulated STAT1 expression 

























Figure 1. STAT1 is a direct target of miRNA miR-150 
(A) A diagram representing the sequence alignment of miR-150 and its target site within STAT1 
3′UTR and the relative mutated version. The mutations made in the STAT1 3′UTR are 
highlighted. (B) Real-time PCR was performed on mature miR-150 from cDNA derived from 
293T cells transfected with pcDNA or miR-150. Real-time PCR was performed in duplicate, and 
samples were normalized to RNU6b (U6) expression. (C) 293T cells were cotransfected with 
wild-type (or mutated) STAT1 3′UTR luciferase reporter plasmids and pTK–Renilla luciferase 
plasmids, together with a control plasmid (pcDNA) or a different amount of miR-150 (0.125, 
0.25, 0.75 μg). After 48 hours, firefly luciferase activity was measured and normalized by 
Renilla luciferase activity. The data are representative from two independent experiments. (D) 
Real-time PCR of STAT1 expression was performed from total cDNA from 293T cells 
transfected with pcDNA or miR-150 (2 μg). Extracts were analyzed 48 hours after transfection 
and normalized to GAPDH expression. P value was < .05. (E) Western blot analysis of STAT1 
expression from total cellular extracts of 293T cells infected with lentivirus expressing miR-150 
or empty lentivirus used as a control. Extracts were normalized to actin expression. 
Semiquantitative analysis of Western blot data demonstrated 24.9% inhibition of STAT1 
expression by miR-150. Western blot quantification was performed by using the Java-based 




















Figure 2. STAT1 is a direct target of miRNA miR-223 
(A) The diagrams represent the sequence alignment of miR-223 and its target sites within the 
STAT1 3′UTR and the relative mutated versions. The mutations made in the STAT1 3′UTR are 
highlighted. (B) Real-time PCR was performed on mature miR-223 from cDNA derived from 
293T cells transfected with pcDNA or miR-223. Real-time PCR was performed in duplicate, and 
samples were normalized to RNU6b (U6) expression. (C, D) 293T cells were cotransfected with 
wild-type (or mutated) STAT1 3′UTR firefly luciferase reporter plasmids and pTK–Renilla 
luciferase plasmids, together with a control plasmid (pcDNA) or miR-223. After 48 hours, firefly 
luciferase activity was measured and normalized to Renilla luciferase activity. The data are 
representative from two independent experiments. (E) Real-time PCR of STAT1 expression was 
performed from total cDNA from 293T cells transfected with pcDNA or miR-223 (2 μg). 
Extracts were analyzed 48 hours after transfection and normalized to GAPDH expression. 
Western blot analysis of STAT1 expression from total cellular extracts of 293T cells infected 
with lentivirus expressing miR-223 or empty lentivirus used as a control is also shown. Extracts 
were normalized to actin expression. miR-223 demonstrated a 38.1% inhibition of STAT1 
expression. Western blot quantification was performed by using the Java-based image processing 
program ImageJ. 
 
miR-150 and miR-223 Decrease STAT1 Protein Expression and STAT1 Signaling 
STAT1 is a transcription factor involved in inflammation and cancer. STAT1 is a central 
mediator of the IFN responses involved in antiviral and immune defense [60]. Since miR-150 
and miR-223 target STAT1, we hypothesized that these miRNAs may hamper the IFN-mediated 
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response by dampening STAT1 activity. To test this hypothesis, we first used the ISRE reporter 
construct plasmid containing four tandem repeats of the IFN-inducible response element. As 
expected, IFN-γ and IFN-β treatment resulted in the induction of ISRE-luciferase reporter gene 
activity. Expression of either miR-150 or miR-223 resulted in significant inhibition, which was 
efficiently rescued by co-expression of a STAT1 cDNA expression vector lacking the 3′UTR 
sequence (Figure 3, A and B). IFN-independent, STAT1-dependent signaling was also inhibited 
by miR-150 and miR-223 as demonstrated by a reduction in STAT1-luciferase reporter construct 
activity when transfected along with miR-150 or miR-223, which was efficiently rescued by co-
expression of a STAT1 cDNA expression vector lacking the 3′UTR sequence (Figure 3C). An 
additive effect of miR-150 and miR-223 was demonstrated in transient transfection inhibition of 
the STAT1-3′UTR construct (Figure 3D). Finally, Western blot analysis demonstrated that 



















Figure 3. miR-150 and miR-223 hamper the IFN-mediated response by inhibition of 
STAT1 activity 
 (A) 293T cells stimulated with 500 pg/ml human IFN-γ and co-transfected with the pISRE 
firefly luciferase reporter plasmid and pTK–Renilla luciferase plasmid, together with a control 
plasmid (pcDNA), miR-150, miR-223, and/or STAT1 cDNA expressing vector lacking the 
3′UTR sequence. After 48 hours, firefly luciferase activity was measured and normalized by 
Renilla luciferase activity. The data are representative from two independent experiments. (B) 
293T cells stimulated with 100U/ml human IFN-β and co-transfected with the pISRE firefly 
luciferase reporter plasmid and pTK–Renilla luciferase plasmid, together with a control plasmid 
(pcDNA), miR-150, miR-223, and/or STAT1 cDNA expressing vector lacking the 3′UTR 
sequence. After 48 hours, firefly luciferase activity was measured and normalized by Renilla 
luciferase activity. The data are representative from two independent experiments. (C) 293T cells 
were cotransfected with STAT1-luciferase reporter plasmid and pTK–Renilla luciferase plasmid, 
together with a control plasmid (pcDNA), miR-150, miR-223, or STAT1 cDNA expressing 
vector. (D) 293T cells were cotransfected with wild-type STAT1 3′UTR firefly luciferase 
reporter plasmid and pTK–Renilla luciferase plasmids, together with a control plasmid (pcDNA), 
miR-150, and/or miR-223. After 48 hours, firefly luciferase activity was measured and 
normalized by Renilla luciferase activity. (E) 293T cells transfected with pcDNA, mir-150, 
and/or mir-223 (1 μg) and 50 ng of pSIH1-puromycin. Forty-eight hours after transfection, the 
cells were treated with puromycin (1 μg/ml) for 7 days. Western blot analyses of STAT1 
expression from total cellular extracts were performed. Extracts were normalized to actin 
expression. Semiquantitative analysis of Western blot data shows 9.7% and 9% inhibition of 
STAT1 expression by mir-150 and mir-223, respectively, compared to the control. Co-
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transfection of mir-150 and mir-223 demonstrate 23% inhibition of STAT1 expression. Western 
blot quantification was performed by using the Java-based image processing program ImageJ. 
 
miR-150 and miR-223 Expression Is Inversely Correlated With STAT1 Expression in 
HTLV-I–Transformed and ATL Cell Lines 
We next investigated the expression of miR-150 and miR-223 in relation to STAT1 in HTLV-I–
transformed cell lines (MT-4, MT-2, and C8166). Jurkat cells were used as a negative control 
since Jurkat cells are human T cells not transformed with HTLV-I. In HTLV-I–transformed cell 
lines, the expression of both miR-150 and miR-223 was significantly reduced when compared to 
Jurkat cells (Figure 4A). In contrast, the expression of STAT1 was increased at both the RNA 
and the protein levels (Figure 4, B and C). We then investigated if such a correlation could also 
be found in ATL-derived cell lines (MT-1, ATL-T, ED-40515(−), ATL-25). Results from these 
studies confirmed that both miRNAs, miR-150 and miR-223, were significantly downregulated 
when compared to Jurkat cells (Figure 4D). Consistent with the above data, STAT1 RNA and 
protein expression was also increased in ATL cells (Figure 4, E and F). These results suggest an 
inverse correlation between miR-150 or miR-223 and STAT1 expression in HTLV-I–
transformed and ATL-derived cells in vitro. Surprisingly, we found that IL-2–dependent ATL-
derived cells (ATL-43T and ATL-55T) displayed elevated levels of miR-150 but not miR-223 
(Figure 4G), suggesting that the former may be regulated through the IL-2 signaling pathway. To 
further investigate this possibility, we withdrew the IL-2 from the culture media of ATL–IL-2–
dependent cells and analyzed the expression of miR-150 after 48 hours. Our results suggest that 
the absence of IL-2 signaling in ATL cells may be associated with decreased expression of miR-
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150 (Figure 4J). To validate the results, we cultured ATL–IL-2–independent cell lines (MT-1, 
ATL-T) in the presence of IL-2 and analyzed the expression of miR-150 after 48 hours. Our 
results show that IL-2 signaling is associated with a significant increase in miR-150 (Figure 4J). 
Next, we analyzed STAT1 expression. The absence of IL-2 signaling in ATL–IL-2–dependent 
cells is not correlated with an increase in STAT1 expression (data not shown). Interestingly, IL-2 
stimulation in MT-1 and ATL-T cells resulted in STAT1 down-regulation (Figure 4K). These 
results may be significant because several studies have reported that in vivo ATL tumor cells can 
produce IL-2 or IL-15 and express the high affinity IL-2 receptor α chain, CD25. We think that 
these observations may, in part, explain the higher levels of miR-150 found in freshly isolated 
uncultured ATL cells compared to in vitro cell lines. Despite higher expression of miR-150 in 
IL-2–dependent cell lines, STAT1 RNA and protein were expressed at higher levels compared to 
















Figure 4. miR-150 and miR-223 expression correlates with STAT1 expression in HTLV-I 
and ATL cell lines.  
(A, D) Real-time PCR was performed on mature miR-150 and miR-223 from cDNA derived 
from HTLV-I–transformed cells (MT-4, MT-2, and C8166) and ATL-derived IL-2–independent 
cell lines (MT-1, ATL-T, ED-40515(−), and ATL-25). The non–HTLV-I Jurkat T cell line was 
used as a control. Real-time PCR was performed in duplicate, and samples were normalized to 
RNU6b (U6) expression. Fold change was calculated by comparing values with Jurkat 
normalized miRNA expression. (B, E) Real-time PCR was performed on STAT1 from cDNA 
derived from HTLV-I cell lines and ATL cell lines. Real-time PCR was performed in duplicate, 
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and samples were normalized to GAPDH expression. Fold change was calculated by comparing 
values with Jurkat-normalized STAT1 expression. P values were < .05. (C, F) Western blot 
analysis of STAT1 expression was performed from total cellular extracts of Jurkat, HTLV-I, and 
ATL cell lines. Extracts were normalized to actin expression. Semiquantitative analysis of 
Western blot data shows 165%, 158%, and 131% increase in STAT1 expression in MT-4, MT-2, 
and C8166, respectively, and 178%, 195%, 166%, and 148% activation of STAT1 in MT-1, 
ATL-T, ED-40515(−), and ATL-25, respectively, compared to Jurkat. Western blot 
quantification was performed by using the Java-based image processing program ImageJ. (G) 
Real-time PCR was performed on mature miR-150 and miR-223 from cDNA derived from ATL-
derived, IL-2–dependent cell lines (LMY1, 55-T, 43T). The non–HTLV-I Jurkat T cell line was 
used as a control. Real-time PCR was performed in duplicate, and samples were normalized to 
RNU6b (U6) expression. (H) Real-time PCR was performed on STAT1 from cDNA derived 
from ATL-derived, IL-2–dependent cell lines (LMY1, 55-T, 43T). Real-time PCR was 
performed in duplicate, and data were normalized to GAPDH expression. (I) Western blot 
analysis of STAT1 expression was performed from total cellular extracts of Jurkat and ATL–IL-
2–dependent cell lines. Extracts were normalized to actin expression. Semiquantitative analysis 
of Western blot data shows 225%, 188%, and 162% increase in STAT1 expression in LMY1, 
ATL-55T, and ATL-43T, respectively, compared to Jurkat. Western blot quantification was 
performed by using the Java-based image processing program ImageJ. (J) Real-time PCR was 
performed on mature miR-150 from ATL-derived, IL-2–dependent cell lines (LMY1, 55-T, 43T) 
cultured with and without IL-2 for 48 hours. Fold change was calculated by comparing values 
with LMY1, 55-T, and 43T cell lines cultured with IL-2. (J) Real-time PCR was performed on 
mature miR-150 from ATL-derived, IL-2–independent cell lines (MT-1, ATL-T) cultured with 
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and without IL-2 for 48 hours. Fold change was calculated by comparing values with MT-1, 
ATL-T cell lines cultured without IL-2. (K) Western blot analysis of STAT1 expression was 
performed from total cellular extracts of MT-1, ATL-T cell lines cultured with and without IL-2 
for 48 hours. Extracts were normalized to actin expression. Semiquantitative analysis of Western 
blot data shows 50.8% and 67.7% inhibition of STAT1 expression in MT-1 and ATL-T cell 
lines, respectively, cultured with IL-2. 
 
Enforced Expression of miR-150 and miR-223 in Human T Cells Decreases STAT1 
Expression and STAT1-Dependent Transcription 
To further demonstrate the effect of miR-150 and miR-223 expression on STAT1, we 
constructed miR-150 and miR-223 Tet-inducible expression vectors. These vectors were used to 
generate stable cell lines expressing pTRIPZ (control line), pTRIPZ-miR-150, or pTRIPZ-miR-
223 in HTLV-I–transformed MT-4 cells. Treatment with doxycycline for 3 days efficiently 
restored expression of miR-150 or miR-223 in MT-4 cells (Figure 5A). In Jurkat T cells, 
induction of miR-223 was more limited. We believe that this is the result of saturation because 
Jurkat cells naturally express high levels of endogenous miR-223 (Figure 6A). Induction of miR-
150 and miR-223 expression was associated with down-regulation of endogenous STAT1 
expression (Figures 5B and and66B). Notably, we also confirmed that expression of several 
STAT1-dependent genes, MAP/microtubule affinity-regulating kinase 3 (MARK3), inositol 
monophosphatase domain containing 1 (IMPAD1), and SET binding protein 1 (SETBP1) [61], in 
the absence of IFN stimulation, was suppressed after induction of miR-150 and miR-223 
(Figures 5, C–E, and 6, C–E). Similar results were obtained in both MT-4 and Jurkat cells. The 
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effects were generally more pronounced in Jurkat and we believe that this may reflect the fact 
that these genes are also transcriptionally regulated by nuclear factor of kappa light polypeptide 
gene enhancer in B-cells, which is constitutively activated in MT-4 cells. SETBP1 was not 
studied after miR-223 overexpression because the 3′UTR for SETBP1 contains a putative miR-
223 target site (data not shown). Overall, these results demonstrate that under physiological 
conditions miR-150 and miR-223 can reduce STAT1 expression and STAT1-dependent 












Figure 5. miR-150 and miR-223 inhibit STAT1 in an HTLV-I line 
(A) MT-4 miR-150 and MT-4 miR-223 stable cell lines were induced with doxycycline (2 
μg/ml) for 72 or 96 hours. Real-time PCR was performed on mature miR-150 and miR-223 to 
verify miRNA induction. Real-time PCR was performed in duplicate, and samples were 
normalized to U6 expression. (B) Western blot analysis of STAT1 expression from total cellular 
extracts of stable cell lines MT-4 miR-150 and MT-4 miR-223 treated with and without 
doxycycline. MT-4 pTRIPZ cells treated with and without doxycycline were used as a control. 
Extracts were normalized to actin expression. Semiquantitative analysis of Western blot data 
shows 73.1% and 71.5% inhibition of STAT1 expression in stable cell lines MT-4 miR-150 and 
MT-4 miR-223, respectively, treated with doxycycline compared to cells treated without 
doxycycline. Western blot quantification was performed by using the Java-based image 
processing program ImageJ. (C–E) Real-time PCR was performed on STAT1 target 
genes SETBP1, MARK3, and IMPAD1 from cDNA derived from MT-4 miR-150 and MT-4 



















Figure 6. miR-150 and miR-223 inhibit STAT1 in the non–HTLV-I cell line, Jurkat 
(A) Jurkat miR-150 and Jurkat miR-223 stable cell lines were induced by doxycycline (2 μg/ml) 
for 72 hours. Real-time PCR was performed on mature miR-150 and miR-223 to verify miRNA 
induction. Real-time PCR was performed in duplicate, and samples were normalized to U6 
expression. (B) Western blot analysis of STAT1 expression from total cellular extracts of Jurkat 
miR-150 and Jurkat miR-223 stable cell lines treated with and without doxycycline. Jurkat cell 
lines treated with and without doxycycline were used as a control. Extracts were normalized to 
actin expression. Semiquantitative analysis of Western blot data shows 78.1% and 79.4% 
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inhibition of STAT1 expression in stable cell lines Jurkat miR-150 and Jurkat miR-223, 
respectively, treated with doxycycline compared to cells treated without doxycycline. Western 
blot quantification was performed by using the Java-based image processing program ImageJ. 
(C–E) Real-time PCR was performed on STAT1 target genes SETBP1, MARK3, 
and IMPAD1 from Jurkat miR-150 and Jurkat miR-223 cDNA treated with and without 
doxycycline. Real-time PCR was performed in duplicate, and samples were normalized to 
GAPDH expression. 
 
STAT1 Is Required for the Proliferation of HTLV-I–Transformed and ATL Cells 
STAT1 expression has been frequently associated with the increased expression of genes with 
anti-proliferative properties, such as p21WAF or p27KIP [62]. We find no correlation between 
STAT1, p21WAF, or p27KIP expression in HTLV-I and ATL cell lines (Figure 9E). However, 
some reports also suggest that increased expression of STAT1 can contribute to rather than 
inhibit transformation and proliferation of breast cancer, head and neck cancer, melanoma, 
lymphoma, and leukemia cells [63]. Hence, the role of STAT1 in different cancer types may 
depend on other genetic alterations and other signaling pathways activated or not in these cells. 
To evaluate the biologic significance of STAT1 in HTLV-I–transformed cells, we first used MT-
4 and MT-4 miR-150 and miR-223 inducible cell lines. Induction of either miR-150 or miR-223 
expression was associated with reduced cell proliferation as determined by cell count and 2,3-
bis-(2-methoxy-4-nitro- 5-sulfophenyl)-2H-tetrazolium- 5-carboxanilide (XTT) assays 
(Figure 7, A and B). In T-ALL, STAT1 has been shown to activate Bcl2 and promote 
proliferation and survival of transformed cells [64]. Consistent with these reports, we found that 
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STAT1 was involved in Bcl2 expression in MT-4 and Jurkat inducible cell lines (Figure 7D). 
Treatment with doxycycline for 3 days significantly increased Bcl2 expression compared to 
untreated cells (Figure 7C). For this reason, we analyzed Bcl2 expression in treated MT-4 miR-
150, MT-4 miR-223, Jurkat-miR-150, and Jurkat-miR-223 cells compared to the treated MT-4 
and Jurkat control. As expected, the induction significantly decreased Bcl2 expression in MT-4 
and Jurkat cell lines (Figure 7D). To verify the specificity of these results, we included Western 
blot analysis of untreated MT-4 and Jurkat inducible cell lines. The results show no change or an 
increased level of Bcl2 expression compared to the control (Figure 7D). Because many T-ALL 
leukemic cells are dependent on the TYK2-STAT1-BCL2 pathway for continued survival, we 
analyzed the sequence of Tyk2 in several ATL samples. However, no mutation was found in the 
kinase domain of Tyk2 in ATL samples, but a high frequency of Tyk2 V362F single nucleotide 
















Figure 7. Exogenous expression of miR-150 and miR-223 inhibits proliferation of HTLV-I 
cells 
(A, B) MT-4 pTRIPZ, miR-150, and miR-223 inducible cell lines were induced with 
doxycycline (2 μg/ml). After 72 hours, cell count and XTT assays were performed; P value was 
< .05. MT-4 pTRIPZ cells induced with doxycycline were used as a control. (C) Western blot 
analysis of Bcl2 expression from total cellular extracts of Jurkat cell lines treated with and 
without doxycycline. Semiquantitative analysis of Western blot data shows a 229% increase in 
Bcl2 expression. Western blot quantification was performed by using the Java-based image 
processing program ImageJ. (D) Western blot analysis of Bcl2 expression from total cellular 
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extracts of MT-4 and Jurkat inducible cell lines treated with and without doxycycline. Extracts 
were normalized to actin expression. Semiquantitative analysis of Western blot data shows 
45.8% and 67.7% inhibition of Bcl2 expression in stable cell lines MT-4 miR-150 and MT-4 
miR-223, respectively, treated with doxycycline compared to MT-4 pTRIPZ cell lines and 50% 
and 62% inhibition in Jurkat miR-150 and Jurkat miR-223, respectively, compared to Jurkat. 
Western blot quantification was performed by using the Java-based image processing program 
ImageJ. 
 
We are aware that miR-150 and miR-223 likely exert some of their effect through STAT1-
independent pathways. To demonstrate a direct function of STAT1 in HTLV-I–transformed 
cells, we next generated a lentiviral vector expressing shRNA to knock down STAT1 expression. 
Functionality was first verified following infection of 293T cells (Figure 8, A and B). shRNA 
STAT1 efficiently reduced STAT1 and Bcl2 expression (Figure 8B). We confirmed a reduction 
in STAT1 expression in the HTLV-I–transformed MT-2 transduced cells by more than 50% 
(Figure 8C), which was associated with a disruption in cell cycle progression, a 24.3% reduction 
in the number of cells in S phase and an accumulation of cells in G2/M (Figure 8D). To confirm 
that these observations were not specific to MT-2 and could be generalized to other HTLV-I–
transformed cells, we transduced MT-2, C91PL, and MT-4 HTLV-I–transformed cells and an 
MT-1 ATL cell line. Transduction of STAT1 shRNA was first confirmed by using RT-PCR 
(Figure 9A). STAT1 down-regulation was associated with reduced cell proliferation as 
determined by cell count, XTT assays, and bromodeoxyuridine incorporation (Figure 9, B–D). 
Together our results demonstrate that STAT1 is required for the proliferation of HTLV-I–











Figure 8. Inhibition of STAT1 expression in the HTLV-I cell, MT-2, results in cell cycle 
disruption 
 (A) Real-time PCR analysis of STAT1 expression was performed from total cDNA from 293T 
cells infected with pSIH1-GFP and pSIH1-GFP-shSTAT1. Extracts were analyzed 48 hours after 
transfection and normalized to GAPDH expression. P value was < .05. (B) Western blot analysis 
of Bcl2 and STAT1 expression from total cellular extracts of 293T cells infected with 
lentiviruses expressing shSTAT1 or empty lentivirus (pSIH1-GFP) used as a control. Extracts 
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were normalized to actin expression. Semiquantitative analysis of Western blot data shows 
70.9% of Bcl2 expression and 70.4% inhibition of STAT1 expression in 293T cells infected with 
shSTAT1, compared to the control. Western blot quantification was performed by using the 
Java-based image processing program ImageJ. (C) Real-time PCR analysis of STAT1 expression 
was performed from total cDNA from MT-2 cells transfected with pSIH1-GFP or pSIH1-GFP-
shSTAT1. Extracts were analyzed 48 hours after transfection and normalized to GAPDH 
expression. P value was < .05. (D) Cell-cycle analysis of MT-2 cells infected with lentiviruses 
encoding vector control (pSIH1-GFP) and shSTAT1. Cell-cycle analysis demonstrated a 24.3% 
reduction in the number of cells in S phase compared to GFP control. 
 
Increased STAT1 and MHC-I Expression in ATL Cells 
Since our results demonstrate an important role of STAT1 in proliferation of HTLV-I–
transformed cells, we then wanted to investigate expression of STAT1 in freshly isolated 
uncultured ATL samples. We next analyzed RNA samples from 35 patients with acute ATL and 
9 HDs by RT-PCR. Our results showed that STAT1 was significantly elevated in patients with 
ATL compared with HD (almost three-fold higher; Figure 10A). Early studies suggest that ATL 
cells originate within the helper-inducer T cell subtype and have a common cytokine production 
profile including IL-1α, IL-1β, tumour necrosis factor alpha, IFN-γ, and granulocyte-macrophage 
colony-stimulating-factor [65]. Among these factors, IFN-γ is a well-known potent inducer of 
MHC class I through activation of the JAK/STAT1/interferon regulatory factor 1 signal 
transduction pathway [66]. Tumor cells with low or no MHC-I cell surface expression may 
escape recognition by anti-tumor T cells but are highly sensitive to NK-mediated killing. In fact, 
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increased expression of MHC-I is one important mechanism that allows for immune escape [67–
70]. We then investigated the expression of MHC-I in ATL and HD samples. Overall, ATL 
















Figure 9. Inhibition of STAT1 expression results in a decrease in cellular proliferation in 
HTLV-I cells 
(A) Real-time PCR analysis of STAT1 expression was performed from total cDNA from MT-2, 
C91PL, MT-1, and MT-4 cells infected with pSIH1-GFP or pSIH1-GFP-shSTAT1. Extracts 
were analyzed 48 hours after infection and normalized to GAPDH expression. P values were < 
.05. (B) MT-2, C91PL, MT-1, and MT-4 cells were infected with lentivirus encoding vector 
control (pSIH1-GFP) or shSTAT1. After 48 hours, cells were counted for proliferation (B) and 
XTT proliferation (C) assays, and bromodeoxyuridine assays were performed (D). P values were 
< .05 (B–D). (E) Western blot analysis of p21, p27, and STAT1expression from total cellular 












Figure 10. STAT1 expression correlates with increased MHC-I expression in ATL patient 
samples 
(A) Real-time PCR analysis of STAT1 expression from cDNA derived from PBMCs of patients 
with ATL. Samples were normalized to GAPDH expression, and the fold change was calculated 
by comparing values to HD's normalized gene expression. (B) Real-time PCR analysis of MHC-I 
expression from cDNA derived from PBMCs of patients with ATL. Samples were normalized to 
GAPDH expression, and the fold change was calculated by comparing values to HD's 
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normalized gene expression. Statistical analysis was performed by using unpaired two-sided 
Student's t test. 
 
Discussion 
In this study, we demonstrate for the first time that miR-150 and miR-223 target the STAT1 
3′UTR, reduce STAT1 expression, and reduce both IFN-dependent and IFN-independent 
STAT1-mediated signaling. We have previously reported that miR-150 and miR-223 are 
differentially regulated in HTLV-I cells transformed in vitro and in vivo ATL samples, 
suggesting that ATL cells and in vitro established HTLV-I cell lines may derive from distinct 
cellular populations. In this study, we have shown that IL-2R–mediated signaling can increase 
miR-150 expression in ATL cells. Previous studies have demonstrated that ATL cells 
overexpress an IL-2Rα chain (CD25). Additional studies have shown that ATL cells may 
produce or respond to IL-2 or other IL-2Rγ chain user cytokines in the microenvironment [71–
75]. In contrast, in vitro transformed cells do express CD25 but do not produce IL-2. With regard 
to miR-223, it has been previously shown that E2F1 represses the miR-223 promoter [26,76]. 
Interestingly, viral HTLV-I bZIP factor mRNA increases the expression and transcriptional 
activity of E2F1 [77]. In contrast to other viral genes, HTLV-I bZIP factor expression is 
consistently increased in ATL cells in vivo [77]. These observations can, in part, explain the 
differential regulation of miR-223 expression between in vitro and in vivo HTLV-I–transformed 
cells. Others have shown that overexpression of miR-150 in bone marrow progenitor cells 
resulted in modest inhibition of cell proliferation [3], suggesting low side effects. Therefore, 
reinstating miR-150 expression may provide an effective therapeutic strategy to treat HTLV-I 
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leukemia. Our studies also revealed that STAT1 expression is inversely correlated to that of 
miR-150 and miR-223 in HTLV-I–transformed and ATL cells and is generally increased in 
HTLV-I–transformed cells. Several studies have shown that an increase in STAT1 expression is 
associated with radio-protection of cancer cells. Since HTLV-I–transformed cells are notoriously 
resistant to high dose radiotherapy, it is possible that increased STAT1 expression plays a role in 
the resistance to high dose radiotherapy and warrants additional studies. STAT1 has been 
associated with both tumor suppressor and tumor promoting activities [78,79]. Our studies 
suggest that in HTLV-I–infected cells STAT1 has a tumor promoting effect since inhibition of 
STAT1 expression and STAT1-dependent transcription through miR-150 or miR-223 or directly 
by shRNA targeting resulted in reduced proliferation of HTLV-I–transformed and ATL cells. In 
addition, STAT1 may play an important role in the immune-suppressive status observed in 
patients with ATL and allow HTLV-I–transformed cells to evade NK-mediated killing. Along 
these lines, knockout mice studies showed that the IFN-α receptor 1 and STAT1 are both 
required for normal tumor Treg frequencies and the release of IL-10, a potent inhibitor of NK 
activity, in the tumor microenvironment. Indeed, high levels of IL-10 in the serum of patients 
with acute ATL have been reported. Furthermore, increased STAT1 as observed in patients with 
ATL may be involved in higher levels of MHC-I expression. Although MHC-I is not a direct 
target for STAT1, previous studies have demonstrated that STAT1 plays an essential role in 
chromatin decondensation of the MHC locus through interactions with the remodeling brahma 
protein-like 1 factor [80]. As indicated above, increased expression of MHC-I on tumor cells has 
been associated with escape from NK-mediated killing of tumor cells and more aggressive tumor 
phenotypes [81,82]. Our results showed that patients with ATL with a higher expression of 
STAT1 displayed higher levels of MHC-I as well. Since STAT1 plays an important role in 
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regulation of inducible nitric oxide synthase activity, it is possible that it participates in 
upregulated expression of inducible nitric oxide synthase in ATL cells. 
There are also some unforeseen observations in our study. First, suppressor of cytokine signaling 
1, a terminator of STAT1-dependent signaling, has been reported to be activated in HTLV-I–
transformed cells through a mechanism involving the Tax oncoprotein [83]. However, it should 
be remembered here that in vivo about half of ATL samples have no detectable Tax 
expression [84], and therefore, the ability of suppressor of cytokine signaling 1 to block STAT1 
may vary greatly among patients and is currently under investigation. In addition, several 
kinases, including cyclin-dependent kinase 8, can phosphorylate STAT1 at serine 727 to restrain 
NK cell cytotoxicity by reducing expression of perforin and granzyme B [85]. Targeted 
inhibition of cyclin-dependent kinase 8-mediated STAT1 phosphorylation at serine 727 may 
represent a possible approach to stimulate NK cell–mediated tumor surveillance in patients with 
ATL. 
Despite expression of both miR-150 and miR-223 in freshly isolated ATL samples, STAT1 did 
not seem to be affected, as both STAT1 RNA and protein were increased in a majority of ATL 
samples. These data suggest that in ATL patient cells miR-150 and miR-223 may not be able to 
efficiently target the STAT1 3′UTR. Although the reason for this deficiency is unclear, it is 
possible that other higher affinity gene targets expressed at higher levels act as competitors and 
sequester miR-150 and miR-223 or that the sequence or the spatial structure/folding of the 
STAT1 3′UTR is altered in ATL cells in vivo and warrants additional future studies. 
Targeted inhibition of STAT1 has been investigated in various types of leukemia. For instance, 
treatment of acute myeloid cells (AML) with retinoic acid resulted in an increased STAT1 
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expression and reduced proliferation [80]. In addition, STAT1 has been shown to play a key role 
in dasatinib-induced differentiation of acute myeloid cells (AML) and in Bryostatin-1–induced 
differentiation of CLL cells [61,86]. The results presented here suggest that STAT1 may 
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HTLV-I is associated with the development of an aggressive form of lymphocytic leukemia 
known as adult T-cell leukemia/lymphoma (ATLL). A major obstacle for effective treatment of 
ATLL resides in the genetic diversity of tumor cells and their ability to acquire resistance to 
chemotherapy regimens. As a result, most patients relapse and current therapeutic approaches 
still have limited long-term survival benefits. Hence, the development of novel approaches is 
greatly needed. 
In this study, we found that a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), 
PJ-34, is very effective in activating S/G2M cell cycle checkpoints, resulting in permanent cell 
cycle arrest and reactivation of p53 transcription functions and caspase-3-dependent apoptosis of 
HTLV-I-transformed and patient-derived ATLL tumor cells. We also found that HTLV-I-
transformed MT-2 cells are resistant to PJ-34 therapy associated with reduced cleaved caspase-3 
activation and increased expression of RelA/p65. 
Since PJ-34 has been tested in clinical trials for the treatment of solid tumors, our results suggest 
that some ATLL patients may be good candidates to benefit from PJ-34 therapy. 
 
Introduction 
Human T-cell leukemia virus type I (HTLV-I) is etiologically linked to the development of an 
aggressive type of peripheral T-cell leukemia known as ATLL [1]. The clinical course varies 
among infected patients and the disease has been classified into four distinct entities: smoldering, 
chronic, acute, or lymphoma [2]. Although many features of HTLV-I biology have been 
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discovered [3], the treatment of the disease remains unsatisfactory, with minimal improvements 
in the overall survival of patients [4]. Overall, the current therapies used for the treatment of 
ATLL patients in the acute phase have limited impact and the overall projected 4-year survival 
rate of acute ATLL is around 5 % [5]. The mechanism by which HTLV-I causes ATLL is still 
not fully understood, but a latency period of several decades before the onset of the disease 
suggests that long-term survival and expansion of virus-infected cells are required. Along these 
lines, we have previously shown that reactivation of telomerase activity is one of the essential 
steps in the transformation process of HTLV-I-infected cells [6]. HTLV-I transformed 
CD4/CD25+ T cells in vivo and in vitro. In early stages, infected cells may rely on an 
autocrine/paracrine IL-2/IL-2R or IL-15/IL-15R cytokine loop for active proliferation [7]. 
During that stage, HTLV-I-infected cells accumulate genetic and epigenetic mutations and are 
prone to genomic instability. At the basis of this phenomenon is the viral oncoprotein Tax, which 
has been shown to inactivate tumor suppressors such as p16ink, p53, RB, and p21WAF [8], 
affect genome stability [9], and activate oncogenic signaling pathways such as NF-κB, Notch, 
and JAK/STAT [10–12]. In addition, Tax also induces DNA breaks during cellular replication 
and inhibits DNA repair pathways, leading to accumulation of genetic alterations [13, 14]. 
Eventually, an infected IL-2-independent transformed cell emerges with a selective growth 
advantage resulting in clonal expansion. The molecular basis for IL-2 independence is still 
unknown although a majority of HTLV-I-transformed cells simultaneously acquire constitutive 
JAK/STAT activation. The transition from IL-2 dependent to IL-2 independent is believed to 
mimic the disease progression from smoldering or chronic to the acute type of ATLL. Recently, 
we showed that Tax can induce genomic DNA double-strand breaks (DDSB) by targeting the 
fork of replication during cell division [13]. Since HTLV-I-transformed cells have a defective 
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homologous recombination repair (HR) pathway [14], we hypothesized that HTLV-I-
transformed and ATLL cells might be particularly sensitive to small drug inhibitors targeting 
DNA replication. Although poly (ADP-ribose) polymerase (PARP) is a single-strand break 
sensing protein, PARP inhibitors (PARPi) have been shown to be selectively effective in cells 
with an HR-defective pathway [15]. Numerous PARPi (PJ-34, MK4827, ABT-888, AZD2281, 
and BSI-201) are in clinical trials for breast cancer, ovarian cancer, and prostate cancer [16, 17]. 
The PARPi PJ-34 has been shown to cause cell cycle arrest in various human cancers, including 
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [18, 19]. 
In this study, we investigated the efficacy of the PARPi PJ-34 in targeting HTLV-I-transformed 
cells and a panel of patient-derived ATLL cell lines. Our results demonstrate that PJ-34 used as a 
single agent is a potent inhibitor of cellular growth in IL-2-dependent as well as IL-2-
independent transformed ATLL cells. We also found that another PARPi (olaparib/AZD2281) is 
also effective against HTLV-I-transformed cells. We further show that cells treated with PJ-34 
reactivated p53 functions and accumulated in G2/M. Tumor cells died from apoptosis as shown 
by annexin V staining but this process appears to be largely p53 - independent since ATLL-
derived cells not expressing p53 (MT-1 and ED) were still efficiently killed by PJ-34. We found 
that HTLV-I-transformed MT-2 and C91PL cell lines were resistant to PJ-34 treatment. We 
found that PJ-34-resistant cells expressed higher basal levels of Bax and were unable to engage 
the cleavage of pro-caspase-3. In addition, resistance of MT-2 cells was independent from 




Materials and methods 
Cell lines and reagents 
HTLV-I-transformed cell lines (MT-4, MT-2, C8166, C91PL) and ATL-like cell lines, IL-2 
independent (MT-1, ATL-T, ED-40515(−), ALT-25), were maintained in RPMI-1640 media 
supplemented with 10 % FBS, penicillin, and streptomycin. ATL-like cell lines, IL-2 dependent 
(ATL-43T, KOB, and ATL-55T), were maintained in RPMI-1640 supplemented with 10 % FBS, 
penicillin, and streptomycin and IL-2 (50 U/mL). PARP-1 inhibitor, PJ-34 (N-(5, 6-Dihydro-6-
oxo-2-phenanthridinyl)-2-(dimethylamino) acetamide, ab120981), was purchased from Abcam. 
Stock solutions (25 mM) were made with dimethyl sulfoxide (DMSO). In all experiments, cells 
were treated with different concentrations of PJ-34 (5, 10, 25, and 50 μM) or DMSO for 3 or 
5 days, as indicated. Olaparib was used at 25 μM for 3 days. Cell Proliferation Kit II (XTT) was 
purchased from Roche Life Science. 
 
Cell cycle and cell proliferation 
HTLV-I-transformed and ATL cells were treated with DMSO or PJ-34 for 3 days. The cells were 
collected and washed with 1× PBS and fixed with 75 % EtOH overnight at −20 °C. The next 
day, cells were washed with ice-cold 1× PBS, followed by treatment with RNase for 15 min at 
37 °C, stained with 100 μg/mL propidium iodine (PI) for 15 min at room temperature, and 
analyzed by flow cytometry. Cell proliferation was measured by the XTT assay. For the XTT 
assay, 100 μL (10,000) cells were seeded in 96-well plates and treated with different 
concentrations of PJ-34 (5, 10, 25, and 50 μM) or DMSO for 5 days. A 50-μL of XTT labeling 
mixture was added to each well and incubated for 6 h. The absorbance was measured at 450 and 
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620 nm by spectrophotometry. Results were plotted as mean ± SD from at least two independent 
experiments. 
 
Cell tracking assay 
CFDA-SE (Molecular Probes, Eugene, OR) was used to label cells according to the 
manufacturer’s protocol. After labeling, 1 × 105 cells were analyzed by FACS assay for 0 h 
control. The rest of the labeled cells were divided into two groups: one treated with DMSO, the 
other one with PJ-34. Every 24 h, 1 × 105cells were taken out for FACS assay until 72 h. 
 
Apoptosis assays and mitochondrial membrane potential 
The cells were collected and washed with 1× PBS then stained with annexin V/propidium iodide 
using the Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit (Molecular Probes, Eugene, 
OR) according to the manufacturer’s instructions. MT-4, C91PL, and MT-2 cells were treated 
with DMSO or PJ-34. Then, the cell mitochondrial membrane potential (ΔΨm) was measured 
using the JC-1 Assay Kit (Invitrogen) according to the manufacturer’s instructions. 
 
Western blotting 
Total cell extracts were prepared with RIPA buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 1 % 
NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS). Samples were separated on SDS-PAGE 
followed by electroblotting to polyvinylidene difluoride membranes. The following antibodies 
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were used: cyclin E (C-19), cyclin A (h432), cyclin B1 (H-20), p21 (C-19), actin (C-11) and p53 
(FL-393), Bcl-2 (100), Bax (N-20), Bcl-xS/L (S-18), caspase-8 (H-134), and caspase-3 (H-60) 
are all from Santa Cruz Biotechnology; Phospho-Histone H2A.X (Ser139) (p-H2AX, 2577) and 
Phospho-p53 (Ser15) (pS15-p53, D4S1H) are from Cell Signaling Biotechnology. 
 
Real-time RT-PCR 
Total RNA was prepared with TRIzol reagent (Invitrogen, Carlsbad, CA). After DNase I 
treatment, the RNA was reverse transcribed and the cDNA was used for PCR and real-time PCR. 
The real-time PCR assay was performed using the iTaq™ Universal SYBR® Green Supermix. 
Real-time PCR was used to detect the expression of Bax, MDM2, GADD45α, XIAP, FLIP, 
p53BP1, BRCA1, p65/RELA, and PARP1. Real-time PCR was performed in duplicate, and data 
were normalized to GAPDH expression. 
 
Results 
PJ-34 induces cell cycle arrest in HTLV-I-transformed and ATLL-derived cell lines 
HTLV-I-transformed and ATLL cells are characterized by excessive chromosomal instability 
associated with defects in HR DNA repair pathways. We, therefore, hypothesized that these cells 
might be particularly sensitive to PARPi. HTLV-I-transformed T-cell lines MT-2, MT-4, C8166, 
and patient-derived ATLL cell lines ED and ATL-25 were treated with PJ-34 for 3 days and cell 
cycle was analyzed by propidium iodide staining and DNA content analyses on live gated cells 
by FACS. Our results revealed a marked increase of cells in the G2/M phase of cell cycle 
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following treatment (Fig. 1a, b). These results are consistent with previous findings that the 
mitotic spindle checkpoint is functional in HTLV-I-transformed and Tax-expressing cells, which 
arrest in G2/M following treatment with NU7026, Taxol, or Nocodazole [20, 21]. We next used 
carboxyfluorescein succinimidyl ester (CFSE) incorporation and confirmed that HTLV-I-
transformed MT-2 cells treated with PJ-34 are no longer dividing (Fig. 1c), suggesting that these 
cells are arrested in all the different phases of the cell cycle. Consistent with these results, we 
observed a significant increase in cyclin-dependent kinase inhibitor (CDK) p21WAF expression 
in MT-2, C91PL, and MT-4 cells after treatment with PJ-34 (Fig. 1d). Cyclin A associates with 
CDK2 and is involved in the initiation and completion of DNA replication during S phase [22]. 
Our experiments revealed a significant decrease in cyclin A expression after treatment with PJ-
34. Since cyclin A is also important for centrosome replication and G2/M transition [23], these 
data may provide an explanation for G2/M arrest observed in most cells after treatment with PJ-
34. In contrast, cyclin E, involved in G1 exit and initiation of S phase [24], was downregulated 
by PJ-34 in C91PL cells only (Fig. 1d). We next investigated the expression of Cyclin B1 
because of its role in mitosis [25]. We found that cyclin B1 expression was significantly reduced 
in MT-2 and C91PL but not in MT-4 transformed cells (Fig.(Fig.1d).1d). Overall, our results 
suggest that PARPi PJ-34 affects multiple cyclins and is effective in preventing proliferation of 
HTLV-I-transformed cells. 
Next, we measured quantitative inhibition of cellular proliferation using XTT assays, a 
colorimetric assay for the quantification of cellular proliferation. These assays were performed in 
four HTLV-I-transformed cells and seven ATLL-derived cell lines and a dose increase of PJ-34 
(5–50 μM) or DMSO vehicle as a control (Fig. 2). To demonstrate specificity of PJ-34, we used 
human PBMCs from a HTLV-I-negative healthy donor. These studies demonstrate that IC50 for 
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most HTLV-I-transformed or ATL cells is around 10 μM (MT-1 and C91PL 20 μM) (Fig. 2). 
Even at 50 μM of PJ-34, PBMCs present less than 25 % inhibition when most HTLV-I-
transformed cells had more than 80 % inhibition (Fig. 2). 
 
 
Figure 1. PJ-34 induces S/G2M cell cycle arrest 
a Cell cycle analysis of HTLV-I-transformed and ATL cells after DMSO or PJ-34 
treatment. b Cell cycle profile of DMSO- or PJ-34-treated cells. c Cell tracking of MT-2 with 
CFDA-SE after DMSO or PJ-34 treatment. Representative results are shown here. d Western 
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blot of cyclin E, cyclin A, cyclin B1, and p21 in MT-2, MT-4, and C91PL cells after DMSO or 




Figure 2. Antiproliferative effect of PJ-34 
a PBMCs, HTLV-1-transformed (C8166, MT-2, C91PL, MT4), and (b) ATL cells (ATL-MT-1, 
ATL-ED, ATL-KOB, ATL-T, ATL-43T, ATL-25, ATL-55T) were treated with DMSO or 
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different concentrations of PJ-34 (5, 10, 25, 50 μM) for 5 days; cell proliferation was measured 
using XTT assay. Results were plotted as mean ± SD from at least two independent experiments 
PJ-34 induces p53-dependent and p53-independent apoptosis in HTLV-I-transformed and 
ATLL-derived cell lines. 
 
PARPi have been used to induce apoptosis in breast cancer and ovarian cancer cells [26–28]. The 
lack of effective therapy for ATLL prompted us to investigate the cytotoxicity of PJ-34 in four 
HTLV-I-transformed and seven ATLL-derived cell lines. Cells were treated for 5 days and 
analyzed by annexin V staining. Our results demonstrated a significant level of apoptosis in all 
patient-derived ATLL cell lines and most HTLV-I-transformed cell lines, with the exception of 
C91PL and MT-2 which appear to be resistant to PJ-34-induced apoptosis (Fig. 3a, b). These 
results were confirmed using a dose-dependent increase of PJ-34 on HTLV-I-transformed MT-4 
cells (Fig. 3c). To confirm specific effects of PJ-34 on HTLV-I-transformed cells, we used a 
dose-dependent increase of PJ-34 and normal human PBMCs as a negative control (Fig. 4). 
Overall, these studies confirmed our previous observations and showed that HTLV-I-
transformed cells are more sensitive than PBMC controls (Fig. 4). Also in agreement with above-
mentioned data, C91PL had kinetics similar to PBMC and MT-2 was resistant to PJ-34 even at a 
dose of 50 μM (Fig. 4). Interestingly, another PARPi, olaparib (AZD2281), also induced 
apoptosis in HTLV-I-transformed MT-4 and ATL-ED resulting in only 34 and 10 % live cells, 
respectively, after 3 days of treatment. In contrast, similar to PJ-34, MT-2 cells were more 





Figure 3. PJ-34 induces cell apoptosis in most HTLV-I-transformed and ATL cells except 
for C91PL and MT-2 cells.  
a HTLV-1-transformed and (b) ATL cells were treated with 25 μM PJ-34 for 3 days. Cells were 
subsequently stained for annexin V and PI and analyzed for apoptosis by FACS analysis. c MT-4 
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cell line was treated with DMSO or different amounts of PJ-34 (5, 10, 25 μM). Cells were 
subsequently stained for annexin V and PI and analyzed for apoptosis by FACS analysis. 
 
 PJ-34 treatment leads to reactivation of p53 functions in HTLV-I-transformed cells 
As a result of PARP inhibition by PJ-34, unrepaired single-strand DNA breaks (SSB) are 
converted into double-strand breaks (DDSB) at fork replication and result in accumulation of 
DDSB and p-H2AX foci. Consistent with this notion, we found an increased p-H2AX expression 
in cells treated with PJ-34 (Fig. 6a). Accumulation of p-H2AX is known to result in ATM/ATR 
activation and downstream Chk1-p53 pathway. Indeed, treatment of HTLV-I-transformed cells 
with PJ-34 caused an increased p-p53 at serine 15 and p21WAF (Fig. 6a), suggesting that p53 
may be active in these cells. Drug cytotoxicity is often associated with activation of p53-
dependent apoptosis, and tumors with mutated inactive p53 are frequently resistant to radio- and 
chemotherapy. HTLV-I-transformed cells in vitro and in vivo have been shown to express high 
levels of p53 that is genetically or functionally inactivated [29–31] but can be reactivated leading 
to either apoptosis or senescence of HTLV-I-transformed cells [32]. We compared activation of 
p53-mediated transcription in MT-4 (PJ-34 sensitive) and C91PL or MT-2 (PJ-34 resistant). Our 
results suggested that p53 was functionally reactivated in all HTLV-I-transformed cells 
following treatment with PJ-34, as demonstrated by an increase in p53 (Fig. 6b) and increased 
mRNA expression of the p53 target genes Bax, MDM2, p21, and GADD45α (Fig. 6c–e). One 
common target of both p53-dependent G1 arrest and p53-independent G2 arrest is p21WAF, 
whose expression was consistently increased after PJ-34 treatment of HTLV-I-transformed cells. 
However, our studies suggest that the sensitivity of HTLV-I-transformed cells to PJ-34-induced 
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apoptosis may not be dependent upon p53 signaling since both MT-2 and C91PL cells were 
resistant to PJ-34-mediated apoptosis despite reactivation of p53 in these cells. In addition, some 
ATLL-derived HTLV-I-transformed cells such as ED or MT-1 have no detectable expression of 




Figure 4. PJ-34 induces cell apoptosis in most of HTLV-1-transformed and ATL cells 
except for C91PL and MT-2 cells.  
a PBMCs, HTLV-1-transformed (C8166, MT-2, C91PL, MT4), and (b) ATL cells (ATL-MT-1, 
ATL-ED, ATL-KOB, ATL-T, ATL-43T, ATL-25, ATL-55T) were treated with DMSO or 
different concentrations of PJ-34 (5, 10, 25, 50 μM) for 5 days. Cells were subsequently stained 
for annexin V and PI and analyzed for apoptosis by FACS analysis. Percentage of increased 
apoptotic and necrotic cells in HTLV-1-transformed cells and ATL cell treatment with different 
amounts of PJ-34 were graphed. 
 
Resistance of HTLV-I-transformed cells to PJ-34-induced apoptosis is associated with 
defective caspase-3 activation 
Disruption of the mitochondrial membrane potential, ΔΨm, represents a critical step in the 
activation process of apoptosis cell death. Therefore, we measured ΔΨm in MT-4, MT-2, and 
C91PL cells treated with PJ-34. Our results suggested that the ΔΨm collapse was pronounced 
when HTLV-I-transformed cells were treated with PJ-34, and MT-4 cells were significantly 
more affected than MT-2 (Fig. 7a). The collapse of the ΔΨm is usually associated with activation 
of caspases. Caspase-9 is activated immediately downstream of the mitochondria following 
cytochrome C release and apoptosome formation. In contrast, caspase-8 is traditionally activated 
by death receptor signaling. These are referred to as canonical and non-canonical apoptosis 
pathways [33]. Caspase-3 is a central mediator in the caspase pathway and poly (ADP-ribose) 
polymerase (PARP) is a substrate of caspase-3 protease activity and its processing is usually 
associated with apoptotic cell death. To gain further insight into the mechanism used by MT-2 
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and C91PL-transformed cells to resist PJ-34 toxicity, we analyzed different markers associated 
with pro-apoptotic and anti-apoptotic activities. Although Bcl-xL is overexpressed and an 
important anti-apoptotic factor in HTLV-I cells [34], the surge in levels of Bax expression 
cannot be counteracted by high levels of Bcl-xL, since the latter does not prevent Bax-mediated 
apoptosis [35]. Expression of anti-apoptotic Bcl-2 was largely unchanged after treatment with 
PJ-34 (Fig. 7b). We then evaluated whether the observed apoptotic phenotype of HTLV-I-
transformed cells treated with PJ-34 was dependent upon the mitochondrial pathway by 
assessing Bax activation and activation of caspase-3. Surprisingly, active caspase 3 cleaved 
products were readily detected in MT-4-treated cells but not detected in MT-2 and C91PL cells 
after exposure to PJ-34 (Fig. 7c). Therefore, we investigated levels of FLIP and XIAP since these 
are known to affect activation of caspase-3, but no difference was detected for MT-2 and C91PL 
cells (Fig. 7d). We amplified and sequenced the cDNA of the caspase-3 gene, but it was wild 
type in both MT-2 and C91PL. The reason for the lack of active caspase-3 in MT-2 and C91PL 
















Figure 5. PARPi olaparib (AZD2281) 
PARPi olaparib (AZD2281) was used at 25 μM for 3 days on HTLV-I-transformed MT-4, 






Figure 6. PJ-34 causes DNA damage and p53 pathway activation even in MT-2 and C91PL 
cells 
a Western blot of p-H2AX, pS15-p53 and p21 in MT-4 cells treated with DMSO or PJ-34. Actin 
was used to confirm equal loading. b Western blot of p53 in MT-2, MT-4 and C91PL cells after 
treatment with DMSO or PJ-34. c–e Cells were treated with DMSO or PJ-34 and the changes of 
p53 target genes Bax (c), MDM2 (d), and GADD45a (e) were analyzed using real-time RT-PCR. 
Real-time PCR was performed in duplicate, and data were normalized to GAPDH expression. 





Figure 7. The defect of caspase-3 activation in MT-2 and C91PL contributes to the 
resistance of PJ-34 in MT-2 and C91PL cells 
a MT-4 and MT-2 were treated with DMSO or PJ-34. Cells were subsequently stained with JC-1, 
and mitochondrial membrane potential (ΔΨm) was measured by FACS analysis. Representative 
results of two experiments are shown here. b Western blot of analysis of Bcl-2, Bax, and Bcl-xL 
in MT-2, C91PL, and MT-4 after treatment with DMSO or PJ-34. c MT-2, MT-4, and C91PL 
were treated with DMSO or PJ-34 for 3 days. Then, total cell extracts were probed for caspase-8, 
caspase-3, and PARP-1 expression. d Relative expression of FLIP and XIAP were compared 
using real-time RT-PCR among resistant cell lines MT-2, C91PL, and other sensitive cell lines. 
Results were presented as mean ± SD from two independent experiments. 
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Resistance to PJ-34 in HTLV-I-transformed MT-2 cells coincides with increased expression 
of RelA/p65 
We next wanted to understand the molecular mechanism involved in the resistance of HTLV-I-
transformed cells MT-2 and C91PL. This has direct and important implications for treatment of 
ATLL patients with PJ-34, and identification of resistance biomarkers could also provide new 
insights for PARPi treatment of breast, ovarian, and prostate cancer patients. Acquisition of 
resistance to PARPi can be achieved by genetic alterations that restore HR functions [36]. 
Frequently, increased expression of BRCA1 or p53BP1 has been shown to correlate with 
resistance to PARPi [37, 38]. However, expression levels of p53BP1 or BRCA1 were not 
affected in HTLV-I-transformed MT-2 or C91PL before or after PJ-34 treatment (Fig. 8a, b). 
Increased expression of miR-107 was associated with PARPi sensitivity [39]. However, analyses 
of mature miR-107 expression revealed a significant increased expression in both resistant and 
sensitive HTLV-I-transformed cells (except for ED) when compared with HTLV-I-negative 
Jurkat T cells (data not shown). Similarly, the expression of PARP1 was not affected in MT-2-
treated cells (Fig. 8c). In contrast, a significant increase in RelA/p65 was detected specifically in 
MT-2 but not MT-4 or C8166 cells following treatment with PJ-34, suggesting that canonical 
NF-κB activation may play an important role in resistance to PARPi in these cells. 
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Figure 8. The expressions of known resistant markers in MT-2 and sensitive cell lines 
a, b Relative expression of p53BP1 (a) and BRCA1 (b) was compared using real-time RT-PCR 
among resistant cell lines MT-2, C91PL, and other sensitive cell lines. Real-time PCR was 
performed in duplicate, and data were normalized to GAPDH expression. Results were presented 
as mean ± SD from two independent experiments. c Relative expression of p53BP1, p65/RELA, 
BRCA1, and PARP-1 was compared using real-time RT-PCR among MT-4, C8166, and MT-2 
treated with DMSO or 25 μM of PJ-34 for 5 days. Real-time PCR was performed in duplicate, 





ATLL has a poor clinical outcome and current therapies have limited long-term benefits, in 
addition to most patients with acute or lymphoma ATLL having a short relapse-free survival. 
Patients diagnosed with chronic or smoldering forms of ATLL have a longer life expectancy but 
current treatments are ineffective and patients eventually progress to the acute type. Numerous 
studies have established that cancers with a dysfunction of the HR DNA repair pathway, also 
referred to as “BRCAness,” share characteristics with BRCA1- or BRCA2-mutated cancer cells 
and are very sensitive to PARPi [40, 41]. We have previously reported that HTLV-I-transformed 
cells have pronounced defects in the homologous recombination (HR) DNA repair pathway. 
Additional studies demonstrated that tumor cells with a defective base excision repair (BER) 
pathway are prone to DDSB accumulation and hypersensitive to PARP targeting [42]. Notably, 
HTLV-I-transformed cells expressing the viral oncoprotein Tax have a defective BER pathway 
[43, 44]. These observations prompted us to investigate the potential benefits of PARPi therapy 
for ATLL. 
In this study, we found a potent anti-proliferative effect of PARP small inhibitor PJ-34 against 
HTLV-I-transformed cells and patient-derived ATLL cells. Reduced tumor cell proliferation was 
demonstrated using XTT and CFSE staining assays. We showed that HTLV-I-transformed cells 
arrested in the G2/M phase of the cell cycle following treatment with PJ-34 was consistent with 
alterations in cyclins and cyclin-dependent kinase inhibitor (CDKI) expression. The effect of PJ-
34 was time- and dose- dependent and affected both IL-2-dependent and IL-2-independent 
HTLV-I-transformed cells. We further demonstrated that PJ-34 is very effective against a panel 
of patient-derived ATLL cell lines, suggesting therapeutic potential. In general, anti-proliferative 
effects were associated with apoptotic cell death as shown by annexin V staining and the 
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activation of caspase-3. We detected a loss of the mitochondrial membrane potential in HTLV-I 
cells following PJ-34 treatment, supporting the notion that PJ-34 induces cell death via the 
intrinsic mitochondrial pathway. Interestingly, treatment with PARPi PJ-34 resulted in 
accumulation of DNA breaks and reactivation of the tumor suppressor p53 transcriptional 
functions, as demonstrated by an increased expression of target genes p21WAF, MDM2, BAX, 
and GADD45. However, reactivation of p53 was not critical for PJ-34’s effects since ATLL ED 
cells do not express p53 and were still sensitive to PJ-34. Interestingly, our studies identified two 
HTLV-I-transformed cell lines that were resistant to PJ-34 treatment: MT-2 and C91PL. We then 
investigated differences between MT-4 (PJ-34 sensitive) and MT-2 and C91PL (PJ-34 resistant). 
We found no specific pattern of expression for p53BP1 or BRCA1 in PJ-34-resistant versus 
sensitive cells. We then investigated expression of pro- and anti-apoptotic factors. Overall, anti-
apoptotic proteins were not differentially affected but only MT-4 cells showed an increase in 
pro-apoptotic Bax expression. Bcl-xL, a pro-survival member of the Bcl-2 family, cannot 
directly inhibit Bax and specifically inhibits certain upstream BH3-only proteins. This supports 
our observation that the upregulation of Bcl-xL seen in MT-4 cells is unable to inhibit PJ-34-
induced apoptosis and Bax activation, leading to apoptosis. We found that PJ-34-resistant cells 
were unable to activate caspase-3. This was unexpected because we and others previously 
demonstrated that MT-2 cells can activate caspase-3-dependent apoptosis [45–47]. 
Recently, PARP1 and PARP2 were found to play a role in sensing stalled or collapsed 
replication forks and to recruit the Mre11-Rad50-NBS1 (MRN) complex for resection and 
single-stranded DNA (ssDNA) formation, which allows RAD51 binding onto resected DNA to 
initiate HR [48, 49]. Thus, PARP is also involved in HR repair at replication forks and inhibition 
of PARP leads to increased DNA lesions that can cause stalling and collapse of the DNA 
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replication machinery. These observations suggest that targeting PARPi may be a good approach 
for ATLL patients. Combination therapy using PJ-34 and DNA-damaging agents such as 
cisplatin has shown promising results in other cancers and may be considered for a phase I trial 
of HTLV-I-associated ATLL. The reproducible growth arrest in cells from different genetic 
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Chapter VI:" WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce 
apoptosis in HTLV-1-transformed adult T-cell leukemia cells”  













Human T-cell leukemia virus type 1 (HTLV-1) infection is associated with adult T-cell 
leukemia/lymphoma (ATLL), a lymphoproliferative malignancy with a dismal prognosis and 
limited therapeutic options. Recent evidence shows that HTLV-1-transformed cells present 
defects in both DNA replication and DNA repair, suggesting that these cells might be 
particularly sensitive to treatment with a small helicase inhibitor. Because the "Werner syndrome 
ATP-dependent helicase" encoded by the WRN gene plays important roles in both cellular 
proliferation and DNA repair, we hypothesized that inhibition of WRN activity could be used as 
a new strategy to target ATLL cells. 
Our analysis demonstrates an apoptotic effect induced by the WRN helicase inhibitor in HTLV-
1-transformed cells in vitro and ATL-derived cell lines. Inhibition of cellular proliferation and 
induction of apoptosis were demonstrated with cell cycle analysis, XTT proliferation assay, 
clonogenic assay, annexin V staining, and measurement of mitochondrial transmembrane 
potential. 
Targeted inhibition of the WRN helicase induced cell cycle arrest and apoptosis in HTLV-1-
transformed leukemia cells. Treatment with NSC 19630 (WRN inhibitor) induces S-phase cell 
cycle arrest, disruption of the mitochondrial membrane potential, and decreased expression of 
anti-apoptotic factor Bcl-2. These events were associated with activation of caspase-3-dependent 
apoptosis in ATL cells. We identified some ATL cells, ATL-55T and LMY1, less sensitive to 
NSC 19630 but sensitive to another WRN inhibitor, NSC 617145. 
WRN is essential for survival of ATL cells. Our studies suggest that targeting the WRN helicase 
with small inhibitors is a novel promising strategy to target HTLV-1-transformed ATL cells. 
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Background 
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that infects over 20 million people 
worldwide and is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) [1, 2], an 
aggressive malignancy of mature activated T cells. HTLV-1 is associated with transformation of 
T lymphocytes and the development of ATLL in approximately 1–4% of infected individuals 
following a long latency period [3]. The diversity in clinical presentation and response to therapy 
of ATLL patients leads to classification into four subtypes: acute, lymphoma, chronic, and 
smoldering, based on organ involvement, lactate dehydrogenase (LDH), and calcium values [4]. 
Patients with aggressive forms of ATLL, the acute and lymphoma types, display a poor 
prognosis, with a median survival of approximately 1 year [5], and resistance to aggressive 
combined chemotherapy. Several clinical trials show that first-generation polychemotherapy 
containing doxorubicin (CHOP) has a limited effect on ATLL patients [6], while other 
approaches have yielded limited long-term benefits to ATL patients with acute or lymphoma 
type. In general, HTLV-1-associated disease has a poor clinical outcome, with 4-year survival 
rates for acute and lymphoma subtypes at 5 and 5.7%, respectively [7, 8]. The mechanism by 
which HTLV-1 induces T-cell transformation remains unclear; however, the viral Tax protein 
plays an essential role in the immortalization of human T lymphocytes [9, 10]. HTLV-1 activates 
an oncogenic signaling pathway, such as NF-kB and Jak/STAT [11, 12], and affects the 
expression of cellular miRNAs [13–16]. In addition, HTLV-1 infection leads to inactivation of 
several tumor suppressors and epigenetic regulators, including p16ink, Rb, p53 and p21waf, 
TET2, and MLL3 [17, 18]. HTLV-1-transformed cells are characterized by an increase of 
phospho-ATM and accumulation of ɣ-H2AX, suggesting a high level of DNA damage in those 
cells [19, 20]. Consistently, Tax was found to induce DNA double-strand breaks (DDSB), in an 
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NF-kB-dependent manner, and is responsible for alteration of DNA repair machinery. Tax 
induces DDSB during the S-phase of the cell cycle, which are normally repaired through error-
free Homologous Recombination repair (HR); however, in HTLV-1-transformed cells, the DNA 
damage is preferentially repaired by the error-prone non-homologous end joining (NHEJ) 
pathway [21, 22]. Overall, this evidence shows that Tax, by inducing DDSB and altering the 
DNA repair, promotes genetic instability that might be involved in the initiating events leading 
to transformation. Furthermore, our recent study shows that Tax-expressing cells display DNA 
replication issues. The replication fork progression was found to be slower and stalls more 
frequently in the presence of the viral protein Tax [23], suggesting that these cells might be 
sensitive to a DNA replication inhibitor. 
Targeting DNA replication and repair machinery has been proposed as a promising strategy to 
combat cancer [24, 25]. Helicases are highly conserved enzymes that unwind nucleic acid 
duplexes during DNA replication and repair [26]. WRN mutations of the gene lead to Werner 
syndrome, which is characterized by genetic instability and hematological disease [27]. WRN 
helicases are generally highly expressed in human leukemia [28] and depletion of the gene 
results in mitotic catastrophe, leading to cancer cell death [29]. Interestingly, evidence shows that 
treatment with a WRN inhibitor (NSC 19630) significantly affects cellular proliferation of 
leukemia cell lines [30]. WRN helicases are involved in replication fork progression and 
participate in DNA double-strand break repair through homologous repair and the non-
homologous end joining pathway [21]. Defects in DNA replication and DNA damage response 
in the HTLV-1 context lead us to hypothesize that ATL cells may be sensitive to treatment with 
a WRN inhibitor. Here, we demonstrate that two small WRN inhibitors, NSC 19630 and NSC 
617145, induce cell cycle arrest and apoptosis in HTLV-1-transformed ATL cells. 
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Methods 
Cell lines and reagent 
HTLV-1-transformed cell lines (MT-4, C8166, C91PL, and 1186.94 [31–33]) and ATL-derived 
cell lines, IL-2-independent (ED-40515(−), TL-Om1, and ATL-25 [34, 35]), were maintained in 
RPMI-1640 media supplemented with penicillin, streptomycin, and 10% fetal bovine serum 
(FBS). ATL-derived cell lines, IL-2-dependent (LMY1, ATL-55T, ATL-43T SO4, KK1 [36–
42]), were maintained in RPMI-1640 media supplemented with IL-2 (50 U/mL), penicillin, 
streptomycin, and 10% FBS. Peripheral blood mononuclear cells (PBMCs) were isolated from 
healthy donors by using Ficoll-Paque PLUS reagent (GE Healthcare Life Sciences). PBMCs 
were maintained in RPMI-1640 media supplemented with penicillin, streptomycin, and 20% 
fetal bovine serum (FBS). WRN inhibitor NSC 19630 was purchased from EMD Millipore’s 
Calbiochem® and NSC 617145 was purchased from Tocris Bioscience. Cells were treated with 
different concentrations of WRN inhibitors, and cells exposed to DMSO were used as a control, 
as indicated in figure legends. 
 
Cell cycle and proliferation  
Cells were treated with the WRN inhibitor or DMSO as a control. After 72 h, cells were 
collected and washed twice with phosphate-buffered saline (PBS) and then were fixed with 80% 
EtOH overnight at −20 °C. The following day, cells were washed twice with PBS, incubated 
with RNase for 15 min at 37 °C, stained with 100 μg/mL propidium iodide (PI) for 20 min, and 
analyzed on an LSR II flow cytometer. Cell proliferation was measured by microscopic cell 
count, Cell Proliferation Kit II (XTT) (Roche), the XTT assay, according to the manufacturer’s 
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instructions. Clonogenic assay was used to study cell proliferation. Briefly, cells were washed 
twice with PBS, fixed with cold Methanol (MeOH), and then stained with crystal violet dye 
(0.5% MeOH) for 20 min at room temperature. 
 
Apoptosis assay and mitochondrial membrane potential 
Inhibitor-treated and control cells were collected and washed twice with PBS then stained with 
annexin V/propidium iodide using the Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit 
(Molecular Probes, Eugene, OR) according to the manufacturer’s instructions. Mitochondrial 




Cell lysates were separated on SDS-PAGE followed by electroblotting to polyvinylidene 
difluoride membranes and probed with cyclin D1 (M-20), cyclin E (C-19), cyclin A (h432), 
cyclin B1 (H-20), actin (C-11), Bcl-2 (100), Mcl-1 and caspase-3 (H-60), Tax mouse monoclonal 
antibody (NIH AIDS Reagent Program, HTLV-I Tax Hybridoma (168B17)), and appropriate 






Cells were centrifuged on slides at 800 rpm for 10 min. Slides were fixed in 4% 
paraformaldehyde (PFA) for 15 min at room temperature and then permeabilized with 0.5% 
Triton X-100 for 5 min on ice for 5 min. Slides were blocked for 1 h in PBS with 0.5% gelatin 
and 0.25% bovine serum albumin at room temperature. For γ-H2AX and PCNA staining, slides 
were incubated with anti-γ-H2AX (Ser139) antibody FITC conjugated (Millipore Sigma) and 
PCNA antibody (DAKO, Agilent Technologies) 1/200 in PBS for 2 h, washed three times in 
PBS-0.2% gelatin for 10 min each time, and incubated with the appropriate Alexa Fluor 
secondary antibody (Molecular Probes, Invitrogen) in PBS-0.2% gelatin for 1 h at room 
temperature. Cells were washed three times in PBS-0.2% gelatin for 10 min each time and 
mounted by using DABCO mounting medium (2.5% DABCO from Sigma, 200 mM Tris-HCl 
pH 8.6 and 90% glycerol). Fluorescent images were captured with Nikon TE2000E 
epifluorescence microscope by using the ×100 objective. 
 
Statistical analysis 
Experiments in Figs. 1, ,2,2, ,3,3, and and44 were performed multiple times in duplicate. 
Representative results were shown in the final figures. P values were calculated by using paired 






NSC 19630 inhibitor induces S-phase cell cycle arrest 
HTLV-1-derived cell lines and Tax-expressing cells display impaired DNA replication and 
repair, leading us to hypothesize that these cells may be sensitive to treatment with a small 
helicase inhibitor. In order to determine if the small inhibitor NSC 19630 affects cellular 
proliferation, we exposed in vitro HTLV-1-transformed cell lines (MT4, C8166, and C91PL) and 
patient-derived ATLL cell lines (ED) to 3 μM of NSC 19630 or DMSO control for 48 h. Cells 
were stained with propidium iodide and DNA content was analyzed by FACS. Consistent with 
the fact that WRN helicases are required to unwind double-stranded DNA to single-stranded 
DNA during DNA replication [43], NSC 19630 treatment showed significant accumulation of 
cells in the S-phase when compared with DMSO-exposed cells (Fig. 1a, ,b).b). Previous studies 
demonstrated that cells expressing a WRN-specific shRNA displayed a reduction in cellular 
growth [44]. In fact, WRN-depleted human fibroblasts show a marked delay in completing the 
cell cycle by spending more time in late S- and/or G2-phases of the cell cycle [45]. Consistent 
with these observations, perturbation of cell cycle progression was noted in HTLV-1-
transformed and ATL-derived cell lines (Fig. 1a, ,b).b). We included Western blot of the Tax 
viral protein in cellular lysates derived from MT4, C8166, C91PL, and ED (Fig. 1c). As 
previously reported, our analysis identified ED as Tax-negative and MT4, C8166, and C91PL as 
Tax-positive cell lines. [23, 46]. Our analysis shows that NSC 19630 induces perturbation of cell 












Figure 1. NSC 19630 inhibitor induces S-phase cell cycle arrest 
a HTLV-1-transformed cell lines (C8166, C91PL, and MT4) and patient-derived cell lines (ED) 
were treated with 3 μM of NSC 19630 and DMSO vehicle has a control. After 48 h, cells were 
stained with propidium iodide (PI) and DNA content was analyzed by FACS to distinguish the 
different phases of the cell cycle (G0/G1, S, G2/M). The cell cycle analysis indicated an 
accumulation of the percentage of cells in S-phase, suggesting that exposure to the helicase 
inhibitor induced accumulation of cells in the S-phase in HTLV-1-transformed and ATL-derived 
cell lines. Experiment was performed multiple times in duplicate. Representative results are 
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shown in the final figures. b Graphic representation of the different percentages of G0/G1-, S-, 
and G2/M-phase cells treated with 3 μM of NSC 19630 compared to DMSO control. c Western 
blots of Tax viral protein in ED, C8166, C91PL, and MT-4 cell lines. d Western blots of cyclin 
D1, cyclin A, cyclin E, and cyclin B1 in ED and C8166 cells following 72 h of treatment with 
DMSO or 3 μM of NSC 19630. Actin was used to confirm equal loading. 
 
The expression of cell cycle progression regulatory proteins was studied by Western blot in ED 
cells exposed to 3 μM of WRN inhibitor for 72 h. We compared the protein level of cyclins D1, 
E, A, and B1 in ED cells treated with NSC 19630 versus DMSO-treated controls (Fig. 1d). 
Cyclin E has a critical role in the control of the G1- and S-phase transitions and in the initiation 
of DNA replication [47]. Cyclin D1 levels vary during the cell cycle, with an elevated level of 
cyclin D1 maintained through G1-phase and required for the initiation of S-phase, while levels 
are reduced to allow DNA synthesis in S-phase [48]. However, increased levels of cyclin D1 are 
required to exit S-phase [48]. Similarly, cyclin A is accumulated during S-phase and is degraded 
before metaphase, while cyclin B1 is accumulated during the G2/M-phase [49]. Treatment of 
ATL cells with the WRN inhibitor NSC 19630 was associated with a decrease in the expression 
of cyclin D1, which may prevent treated cells from S-phase exit and result in accumulation of 
cells in S-phase (Fig. 1d). While there was no significant change in cyclin A expression in NSC 
19630-treated cells, expression of cyclin E and cyclin B1 was significantly reduced (Fig. 1d). We 
believe that a relative decreased population in G2/M as a result of S-phase arrest accounts for the 
decrease in cyclin B1. 
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In addition, we decided to include Western blot of cyclins D1, E, A, and B1 in Tax-expressing 
cell line lysate C8166 extracted from cells exposed to NSC 19630 compared to DMSO-treated 
controls. Our analysis shows a reduction of cyclins E, D1, and B1 in Tax-positive cells (Fig. 1d), 
suggesting that cells arrested during the S-phase of the cell cycle. Overall, our data revealed a 
profound alteration of the cyclin expression profile in ATL cells exposed to the WRN helicase 








Figure 2. NSC 19630 inhibits cellular proliferation in patient-derived cells 
a C91PL cells were exposed to increasing amounts of the WRN helicase inhibitor NSC 19630 (0, 
0.2, 2, and 20 μM). After 72 h, cells were stained with annexin V to determine the percentage of 
apoptosis. The figures include the percentage of cells in the four quarters: Q1, Q2, Q3, and Q4. 
Q3 included the live cells that are annexin V and PI negative. Q4 included early apoptotic cells, 
which are annexin V positive and PI negative. Q2 included cells in late apoptosis, which are both 
annexin V and PI positive. Finally, Q1 included necrotic cells, which are PI positive and annexin 
V negative. A dose-dependent effect was noted. Experiment was performed multiple times in 
duplicate. Representative results are shown in the final figures. b Normal resting PBMCs and 
C91PL were exposed to increasing amounts of the WRN helicase inhibitor NSC 19630 (0, 0.2, 2, 
and 20 μM). After 72 h, cells were stained with annexin V and survival cells were graphed. 
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Experiment was performed in duplicate. P values were calculated comparing NSC-treated cells 
to DMSO control by using paired and two-tailed Student’s t test and indicated in the figure. c 
HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) and ATL-derived (ED, TL, ATL-25, 
ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) cell lines and normal resting PBMCs with 
increasing doses of NSC 19630 (0.2, 2, and 20 μM) show inhibition of cellular growth as 
measured by using cell count. Experiment was performed multiple times in duplicate. 
Representative results are shown in the final figures. d, e Patient-derived cell lines ATL-25 and 
LMY1 were treated with DMSO or 3 μM of NSC 19630 for 72 h and stained with crystal violet 
to test the anti-proliferative property of the WRN helicase inhibitor. The results were confirmed 
with XTT assay and cell counts. Experiment was performed multiple times in duplicate. 
Representative results were shown in the final figures. P values were calculated by using paired 
and two-tailed Student’s t test and indicated in the figure. 
 
NSC 19630 inhibits cellular proliferation and induces apoptosis in HTLV-1-transformed 
and patient-derived cells 
Recent evidence shows that treatment with the WRN inhibitor NSC 19630 significantly affects 
the cellular growth of different leukemia cell lines [30]. We next exposed HTLV-1-transformed 
C91PL to increasing logarithmic doses (0.2, 2, and 20 μM) or DMSO vehicle as a control 
(Fig. 2a, ,b).b). Induction of cell death was measured by using annexin V/PI staining. Apoptotic 
cells were scored as annexin V+, necrotic dead cells as PI+, versus live cells, which were 
annexin V-/PI-. We calculated the IC50 by using logarithmic transformation and we compared it 
to normal PBMCs isolated from healthy donors. Resting PBMCs were treated with the same 
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concentrations of NSC 19630, 0.2, 2, and 20 μM, and induction of apoptosis by using annexin 
V/PI staining was measured (Fig. 2b). The IC50 in normal cells is higher compared to the 
HTLV-1-transformed cell line, C91PL (9.28 ± 0.23 and 2.76 ± 0.29, respectively), showing that 
resting PBMCs isolated from a healthy donor are less sensitive to the drug. 
We expanded our analysis by testing the HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) 
and ATL-derived (ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, and KOB) cell 
lines with increasing doses of NSC 19630, 0.2, 2, and 20 μM. Inhibition of cellular growth was 
measured by using cell count and reported in Fig. 2c. We calculated the IC50 for every cell line 
by using logarithmic transformation, and the values are indicated in Table 1. Interestingly, 
LMY1 and ATL-55T displayed a limited reduction of cellular growth when cells were treated 
with 2 μM of WRN inhibitor (Fig. 3c). Consistently, the IC50 was found to be higher in those 
lines compared to the other cell lines tested in our study, suggesting that LMY1 and ATL-55T 
are less sensitive to the drug (Table 1). We included normal PBMCs isolated from healthy 
donors in our analysis as a negative control. As expected, limited inhibition of proliferation was 
noted in resting PBMCs treated with WRN inhibitor (Fig. 2c) even at high concentrations. 
Our analysis shows a dose-dependent inhibition of cellular proliferation, suggesting that 
targeting WRN activity represents a promising strategy to kill ATL cells. These results were 
further confirmed by clonogenic assay. Two patient-derived ATL cell lines with adherent 
characteristics were exposed to 3 μM of NSC 19630 or DMSO for 72 h, washed, and then 
stained with crystal violet. A significant reduction in the number of cells was noted in ATL-25 
(Fig. 2d); however, no significant changes were observed in LMY1, suggesting that these cells 
are resistant to the WRN inhibitor (Fig. 2e). To confirm these results, the anti-proliferative effect 
of NSC 19630 was quantified by measuring cleavage of XTT to an orange formazan dye using 
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an ELISA reader at 450 nm and confirmed by microscopic cell count. Consistently, our analysis 
identified LMY1 as less sensitive to NSC 19630 (Fig. 2e). In contrast, ATL-25 was sensitive to 
the anti-proliferative effect of the WRN inhibitor (Fig. 2d). 
The lack of effective therapeutic treatment for ATL patients led us to investigate the cytotoxicity 
of NSC 19630. WRN inhibitor is reported to induce cell death through accumulation of DNA 
double-strand breaks (DDSB) [30]. A previous article published from our laboratory shows that 
Tax affects the DNA repair machinery, more specifically by inhibiting Homologous 
Recombination (HR) repair [21]. That evidence leads us to speculate that NSC 19630 might 
induce cell death more prominently in Tax-expressing cells. To verify our hypothesis, we tested 
NSC 19630’s apoptotic effect on a Tax-expressing cell line (MT-4) versus a Tax-negative cell 
line (ED). Evident induction of cell death was noted in both Tax-positive and Tax-negative cells 
(Fig. 3a). Then we investigated if the compound affects Tax expression in three Tax-positive cell 
lines (C8166, MT-4, and C91PL); an ED-negative cell line was included in our analysis. Tax 
expression was found to be unchanged in NSC-treated cells compared to a DMSO control 
(Fig. 3b), suggesting that Tax expression is not a marker of drug sensitivity. A possible 
explanation of our finding is that Tax inhibits Homologous Recombination repair in an NF-κB-
dependent manner [21]; however, constitutive activation is described in ATL cells that do not 
express detectable Tax [50]. 
Our preliminary data show that a WRN helicase inhibitor induces apoptosis in vitro (Fig. 3a), so 
we decided to include additional cell lines (MT-4, C8166, C91PL, and 1186.94) and nine ATL 
patient-derived cell lines (Fig. 3c). Previous studies suggest that IL-2-dependent ATL cell lines 
represent a model of smoldering and chronic forms of ATL, while IL-2-independent lines may 
better relate to the acute form of ATL. To investigate the potential use of WRN in various stages 
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of ATL disease, we selected ATL-IL-2-independent (ED, TL, and ATL-25) and ATL-IL-2-
dependent (ATL-43T, ATL-55T, LMY1, KK1, SO4, and KOB) cell lines for study. These cells 
were exposed for 72 h to the WRN helicase inhibitor and analyzed by annexin V/PI staining to 
measure the percentage of apoptosis induced by the compound (Fig. 3c). Significant levels of 
apoptosis were detected in IL-2-dependent and IL-2-independent ATL cell lines (Fig. 3c). These 
results suggest that HTLV-1-transformed ATL cells are highly sensitive to the WRN inhibitor 
NSC 19630 and that patients with the chronic, smoldering, or acute form of ATL are potential 
candidates for this therapeutic agent. 
To gain some insights into the molecular mechanisms involved in NSC 19630’s effects on ATL 
cells, we next investigated disruption of the mitochondrial transmembrane potential (ΔΨm) 
(Fig. 3f). Activation of mitochondrial pathway cell death leads to the opening of the 
mitochondrial permeability transition (MPT) pore. The major consequences of this event are the 
disruption of ΔΨm and the release of pro-apoptotic proteins. Our analyses show that treatment 
with the NSC 19630 inhibitor resulted in the collapse of mitochondrial transmembrane potential 
in ED cells (Fig. 3f). Since the loss of mitochondrial transmembrane potential is associated with 
the activation of the caspase pathway [51], we investigated the activation of caspase-3, an 
essential mediator of apoptosis activated by proteolytic cleavage. Our data indicate that cleaved 
caspase-3 products were readily detected in ED-treated cells when compared to DMSO-treated 
control cells (Fig. 3d). We then analyzed the expression of B-cell lymphoma 2 (Bcl-2) (Fig. 3d), 
a protein that prevents apoptosis either by sequestering caspases or by preventing the release of 
mitochondrial apoptogenic factors, such as cytochrome c, and an apoptosis-inducing factor, AIF, 
into the cytoplasm [52]. Consistent with results from annexin V/PI, the treatment with the WRN 
helicase inhibitor led to decreased Bcl-2 expression in ED-treated cells (Fig. 3d). Previous 
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studies showed that an increased expression of Mcl-1 significantly inhibits progression through 
the S-phase of the cell cycle [53]. Consistent with our cell cycle results demonstrating that 
exposure to the WRN helicase inhibitor results in S-phase arrest (Fig. 1a), increased levels of 
Mcl-1 were detected in ED-treated cells (Fig. 3d). Moreover, we performed Western blot of 
caspase-3, Bcl-2, and Mcl-1 on protein lysates of ATL-55T and LMY1 treated with DMSO or 
NSC 19630. As expected, no significant change of expression was noted (Fig. 3d), confirming 
that these lines are less sensitive to the drug. 
The WRN helicase stabilizes and maintains the replication fork during DNA replication. Failure 
to stabilize the fork induces DNA double-strand breaks (DDSB); in fact, treatment with 
replication inhibitors induces fork collapse, leading to serious DNA damage and cell death [54]. 
Consistent with this concept, M. Aggarwal et al. demonstrated that a WRN inhibitor, NSC 
19630, induces DDSB and accumulation of PCNA foci, which is associated with stalled 
replication forks [30]. In order to investigate if apoptosis is WRN-dependent in an HTLV-1 
context, we dual-stained ɣ-H2AX (a specific marker of DDSB) and PCNA in cells exposed to 
NSC 19630 compared to DMSO-treated cells. Our analysis shows accumulation of PCNA and ɣ-
H2AX foci, suggesting that the treatment induces DNA replication issues and, consequentially, 























Figure 3. NSC 19630 induces apoptosis in HTLV-1-transformed and patient-derived cells 
a ED and MT-4 cells were exposed to WRN helicase inhibitor NSC 19630 (3 μM) or DMSO. 
After 72 h, cells were stained with annexin V. The figures include the percentage of cells in the 
four quarters: Q1, Q2, Q3, and Q4. Q3 included the live cells that are annexin V and PI negative. 
Q4 included early apoptotic cells, which are annexin V positive and PI negative. Q2 included 
cells in late apoptosis, which are both annexin V and PI positive. Finally, Q1 included necrotic 
cells, which are PI positive and annexin V negative. b Western blots of Tax viral protein in ED, 
C8166, C91PL, and MT-4 cells exposed to NSC 19630 compared to DMSO-treated controls. c 
HTLV-1-transformed cell lines (MT-4, C8166, C91PL, and 1186.94) and patient-derived cell 
lines (ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, and KOB) were treated for 72 
h with 3 μM of NSC 19630. Cells were stained with annexin V to measure the apoptotic effect of 
the WRN helicase inhibitor. The percentage of apoptosis and necrosis was graphed. HTLV-1-
transformed, ATL-derived IL-2-dependent cell lines and IL-2-independent cell lines are 
represented in blue, yellow, and red, respectively. Tax viral protein is expressed in MT-4, C8166, 
C91PL, 1186.94, and ATL-25 cell lines [23]. Experiments were performed multiple times in 
duplicate. Representative results are shown in the final figures. d Western blot of Caspase-3 and 
apoptotic markers Bcl-2 and Mcl-1 was performed in ED, ATL-55T, and LMY1 cells exposed to 
DMSO or 3 μM of NSC 19630. Our analysis shows the activation of caspase-3 after treatment 
with the WRN helicase inhibitor. e Immunofluorescence of ɣ-H2AX and PCNA in ED cells 
exposed for 72 h with 3 μM of NSC 19630 compared to DMSO control. Fluorescent images 
were captured by using the ×100 objective f Distraction of mitochondrial transmembrane 
potential in ED cells treated with NSC 19630 compared to DMSO control.  
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NSC 19630-resistant ATL-55T and LMY1 cell lines are sensitive to NSC 617145 
Data presented above suggest that NSC 19630 is a promising agent for the treatment of ATL. 
However, our analyses show that the apoptotic effect of the WRN helicase inhibitor was very 
limited in two ATL lines, namely LMY1 and ATL-55T (Fig.(Fig.3c),3c), suggesting potential 
resistance mechanisms that warrant further investigations. We studied the endogenous 
expression of WRN helicases in HTLV-1-transformed and ATL-derived cell lines. Consistent 
with previously published studies, our analyses show no direct correlation between levels of 
WRN protein expression and sensitivity to the WRN inhibitor (data not shown). 
We then investigated NSC 617145, a WRN inhibitor identified as a close structural analog of 
NSC 19630 but with more potent inhibition of WRN helicase activity. We next exposed HTLV-
1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL, 1186.94, ED, TL, ATL-25, ATL-
43T, ATL-55T, LMY1, KK1, SO4, KOB) and resting PBMCs isolated from healthy donors to 
increasing doses of NSC 617145 (0.02, 0.2, 2, and 20 μM), and inhibition of cellular growth was 
measured by cell count (Fig. 4a). We calculated the IC50 for every cell line by using logarithmic 
transformation and the values are reported in Table 2. Our analysis clearly shows that NSC 
617145 was found to be more potent in inhibiting cellular growth compared to NSC 19630. In 
fact, ATL-55T cells were sensitive when exposed to increasing concentrations of NSC 617145, 
which inhibited cellular growth, as shown by cell count and XTT proliferation assay (Fig. 4b, c) 
Next, we exposed LMY1 cells to 0.25 μM for 4 days then stained with crystal violet. 
Consistently, again, a significant reduction in the number of cells was observed in LMY1, which 
was confirmed by cell count and XTT assay (Fig. 4d). Finally, we performed apoptosis assay and 
found that low concentrations of NSC 617145 induced high levels of cell death in both ATL-55T 
and LMY1 cell lines (Fig. 4e). Interestingly, limited inhibition of proliferation was noted in 
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normal PBMCs (Fig. 4a). To confirm the limited effect of WRN inhibitor on normal cells, we 
estimated the IC50 in an HTLV-1-transformed cell line, C91PL, and in resting PBMCs based on 
induction of apoptosis. C91PL and normal resting PBMCs were exposed to increasing 
logarithmic doses (0.02, 0.2, and 2 μM) or DMSO vehicle as a control. Induction of cell death 
was measured by using annexin V/PI staining (data not show). Our analysis shows that the IC50 
in normal cells is higher compared to the HTLV-1-transformed cell line C91PL (0.32 ± 0.013 
and 0.13 ± 0.047, respectively), suggesting that NSC 617145 might be suitable for treating ATL 
patients. 
Overall, our data suggest that HTLV-1-transformed ATL cells are very sensitive to the anti-





























Figure 4. ATL-55T and LMY1 cell lines are sensitive to NSC 617145  
a HTLV-1-transformed (MT-4, C8166, C91PL, 1186.94) and ATL-derived (ED, TL, ATL-25, 
ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) cell lines and normal resting PBMCs were 
treated with increasing doses of NSC 617145 (0.02, 0.2, 2, and 20 μM). Inhibition of cellular 
growth was measured by using cell count. Experiment was performed multiple times in 
duplicate. Representative results are shown in the final figures. b Patient-derived cell line, ATL-
55T, was exposed to increasing amounts of NSC 617145 for 4 days, and the anti-proliferative 
effect was evaluated by cell count and XTT assay. Representative results are shown in the final 
figures. P values were calculated using paired two-sided Student’s t test. c LMY1-ATL-derived 
cells were treated with 0.25 μM of NSC 617145 for 96 h and stained with crystal violet. Cell 
count and XTT assay were used to measure the cellular growth of NSC 617145-treated cells 
compared to DMSO control cells. Experiment was performed multiple times in duplicate. 
Representative results are shown in the final figures. P values were calculated by using paired 
and two-tailed Student’s t test and indicated in the figure. d ATL-55T and LMY1 cells were 
stained with annexin V to measure the apoptotic effect of the WRN helicase inhibitor NSC 
617145. Cells were treated for 92 h with 0.25 μM of NSC 617145. e The figures include the 
percentage of cells in the four quarters: Q1, Q2, Q3, and Q4. Q3 included the live cells that are 
annexin V and PI negative. Q4 included early apoptotic cells, which are annexin V positive and 
PI negative. Q2 included cells in late apoptosis, which are both annexin V and PI positive. 
Finally, Q1 included necrotic cells, which are PI positive and annexin V negative. Experiment 
was performed multiple times in duplicate. Representative results are shown in the final figures. 
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Table 1. Estimated IC50 of NSC 19630 in HTLV-1-transformed and patient-derived cells 
We tested the HTLV-1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL, 1186.94, 
ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) with increasing doses of NSC 
19630 (0.2, 2, and 20 μM), and inhibition of cellular growth was measured by using cell count. 
We calculated the IC50 for every cell line by using logarithmic transformation and the values are 
reported in the table. Our analysis shows that ATL-55T and LMY1 were found to be less 




Table 2. Estimated IC50 of NSC 617145 in HTLV-1-transformed and patient-derived cells 
We tested the HTLV-1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL, 1186.94, 
ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) with increasing doses of NSC 
617145 (0.02, 0.2, and 2 μM), and cell count was used to measure the inhibition of cellular 
growth. We calculated the IC50 for every cell line by using logarithmic transformation and the 
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values are reported in the table. Our analysis clearly shows that NSC 617145 is more potent in 
inhibiting cellular proliferation compared to NSC 19630. 
 
Discussion 
In the absence of effective chemotherapy treatments, most patients with aggressive forms of the 
disease have a poor clinical outcome. Patients with the lymphoma type also have an unfavorable 
prognosis, with a median survival of 10.2 months, while patients with acute ATLL present a 
median survival of 6.2 months [55]. The projected 4-year survival rates of patients with the acute 
and lymphoma forms are only 1–5% [56]. DNA repair inhibitors induced cell death in different 
human leukemias [57, 58], and in the absence of an effective treatment for ATLL, we decided to 
test the cytotoxicity of a WRN helicase inhibitor. WRN helicases are involved in HR DNA repair 
and helicase activity is required during DNA replication. Previous studies showed that both DNA 
repair and DNA replication are impaired in HTLV-1-transformed cells. 
In this study, we investigate small inhibitors of WRN as a potential therapeutic agent for ATLL. 
NSC 19630 targets WRN helicase activity but does not affect other DNA helicases (Bloom 
syndrome (BLM), Fanconi anemia group J (FANCJ), RECQ1, RecQ, UvrD, or DnaB) [30]. Our 
results demonstrate an apoptotic effect induced by the WRN helicase inhibitor in HTLV-1-
transformed cells in vitro and in a majority of ATL-derived cell lines tested. Inhibition of cellular 
proliferation and induction of apoptosis were demonstrated with XTT proliferation assay, 
clonogenic assay, and annexin V staining. Consistent with previous studies, we observed an S-
phase delay in ATL cells following treatment with NSC 19630. All the cyclins tested (cyclins E, 
B1, and D1) were found to be downregulated after the treatment, except for cyclin A, which is 
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specific to the S-phase of the cell cycle. The effect of the WRN inhibitor was found to be dose- 
and time-dependent. Exposure to 3 μM of NSC 19630 shows significant caspase-dependent 
apoptosis in HTLV-1-transformed and patient-derived cells, both IL-2-dependent and IL-2-
independent. We found a disruption of the mitochondrial potential, suggesting that the WRN 
inhibitor induces cell death through an intrinsic apoptotic pathway. Consistently, expression of 
Bcl-2 intrinsic anti-apoptotic factor was reduced in ED cells exposed to the WRN inhibitor. Our 
study shows that the WRN inhibitor efficiently kills HTLV-1-transformed and patient-derived 
cells. In addition, non-cancerous cells are resistant to the anti-proliferative and apoptotic effects 
of NSC 19630 [30], suggesting that NSC 19630 may represent a suitable strategy for initiation of 
phase I clinical trials. Our study also identified two cell lines less sensitive to NSC 19630, ATL-
55T and LMY1. Nonetheless, these cells were efficiently killed by an NSC 19630 analog, NSC 
617145, with more potent inhibitory effects on WRN helicase activity. In addition, a possible 
explanation of the different sensitivities to WRN helicase inhibitors in different ATL cells is that 
the compounds act on different domains of the enzyme. NSC 19630 is reported to inhibit the 
helicase domain and mildly reduce the ATPase and exonuclease activities of WRN. On the other 
hand, NSC 617145 reduces mainly the ATPase domain in a dose-dependent manner [59]. 
 
Conclusions 
The WRN inhibitors NSC 19630 and NSC 617145 efficiently kill HTLV-1-transformed and 
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Chapter VII: “Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-
I-induced acute adult T-cell leukemia.”  
Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C. Molecular 















Epigenetic regulators play a critical role in the maintenance of specific chromatin domains in an 
active or repressed state. Disruption of epigenetic regulatory mechanisms is widespread in cancer 
cells and largely contributes to the transformation process through active repression of tumor 
suppressor genes. While mutations of epigenetic regulators have been reported in various 
lymphoid malignancies and solid cancers, mutation of these genes in HTLV-I-associated T-cell 
leukemia has not been investigated. 
Here we used whole genome next generation sequencing (NGS) of uncultured freshly isolated 
ATL samples and identified the presence of mutations in SUZ12, DNMT1, DNMT3A, 
DNMT3B, TET1, TET2, IDH1, IDH2, MLL, MLL2, MLL3 and MLL4. 
TET2 was the most frequently mutated gene, occurring in 32 % (10/31) of ATL samples 
analyzed. Interestingly, NGS revealed nonsense mutations accompanied by loss of 
heterozygosity (LOH) in TET2 and MLL3, which was further confirmed by cloning and direct 
sequencing of DNA from uncultured cells. Finally, direct sequencing of matched control and 
tumor samples revealed that TET2 mutation was present only in ATL tumor cells. 
Our results suggest that inactivation of MLL3 and TET2 may play an important role in the 







Human T-cell leukemia virus type I (HTLV-I) is associated with fatal lymphoproliferative 
disorders known as adult T-cell leukemia/lymphoma (ATL) [1, 2]. The disease is classified into 
distinct subtypes - smoldering, chronic, acute and lymphoma - that differ in their clinical 
presentation and in their response to treatment [3]. Since the clinical subtypes of ATL have 
distinct genomic alterations and different clinical progression, these diseases require a different 
approach for treatment [4]. However, current therapies for ATL do not result in long-term 
remission and even the clinically less aggressive forms ultimately evolve to the acute. The 4 year 
survival rate for acute-, lymphoma-, chronic- and smoldering-type ATL is 11, 16, 36, and 52 %, 
respectively [5, 6]. The viral oncoprotein Tax plays an important role in initiation of events 
leading to cellular transformation [7, 8]. However, the fact that the disease has a low penetrance 
and is observed after a long latency period of several decades has led to the hypothesis that the 
virus initiates oncogenic events but is not sufficient for cellular transformation [9, 10]. In support 
of this notion epigenetic alterations are required for the development of ATL. Promoter hyper-
methylation associated with loss of SHP1 expression coincides with the IL-2-independent 
transformation of T cells by HTLV-I in vitro [11]. SHP1 is one of the most frequently altered 
genes in ATL patients, with an overall hyper-methylation rate of 90 % [12]; other tumor 
suppressor genes inactivated by methylation in ATL include p53-related p73, CDKN2A and 
p21CIP1/WAF1 [13]. The fact that histone methyl-transferase EZH2 has been demonstrated to 
repress p57KIP2 expression through histone H3 lysine 27 trimethylation (H3K27me3) [14], and 
that p57KIP2 is methylated in nearly 50 % of newly diagnosed ALL patients [15], prompted us 
to analyze the status of cellular genes involved in chromatin silencing. In this study we use next 
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generation sequencing (NGS) to characterize the genetic mutations in EZH1, EZH2, EED, 
SUZ12, DNMT1, DNMT3A, DNMT3B, TET1, TET2, TET3, IDH1/2, MLL, MLL2, MLL3, 
MLL4 and ASXL1. Our study revealed a high frequency of mutation in epigenetic regulators in 
ATL samples, suggesting that chromatin remodeling by some of these genes may play a role in 




Figure 1. HTLV-1 proviral load in cell lines and patients 
a A set of standard samples was prepared through dilution of HTLV-I transformed cell line DNA 
(TL) containing a single copy of integrated HTLV-I with HTLV-I negative 293 T cell DNA. 
Real time PCR was performed with 100 ng of mixed DNA. Both GAPDH and gag were detected 
and ΔCt was calculated by Ct gag - Ct GAPDH. The standard curve was created with ΔCt (X) 
and the percentage of HTLV-I viral load relative to TL cell (Y). b Proviral load was calculated in 
DNA samples isolated from high grade ATL lymphoma and matched-control B cells by real time 




ATL patient samples 
All patient samples were obtained after informed consent was provided and in agreement with 
regulations for the protection of human subjects according to the National Institutes of Health 
(NIH) guidelines. As for the samples from the Japanese material bank, they were provided from 
the biomaterial bank of the Japanese nationwide cohort study (Joint Study of Predisposing 
Factors for ATL Development, JSPFAD) that is approved by the ethical committee of the 
University of Tokyo (No. 14-15, No. 07-07 and No. 10-50). Genomic DNA was extracted using 
DNAZol (Invitrogen) from uncultured acute and lymphoma ATL samples. DNA samples 1–7, 10 
and 11 were isolated from patients diagnosed with acute ATL. DNA samples 8, 9, 12 and 13 
were isolated from patients with lymphoma ATL. HTLV-I proviral load was calculated by 
TaqMan real time PCR and compared with a standard curve established using C91PL HTLV-I 
transformed cell line harboring one proviral copy (Fig.(Fig.1a).1a). High tumor grade lymph 
node biopsy was used for ATL lymphoma patients as confirmed by real time PCR compared 
with B cells isolated from matched patient (Fig.(Fig.1b1b). 
 
Next generation sequencing (NGS) 
Exome Sequencing was performed by Perkin Elmer. DNA samples were evaluated using an e-
gel and PicoGreen fluorometry to measure quality and quantity, respectively. DNA samples were 
then physically sheared to the desired size using a Covaris E220 Focused-ultrasonicator. Library 
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preparation and enrichment were carried out using an Agilent SureSelectXT All Exon V3 kit and 
an automated sample preparation method derived from the manufacturer’s protocol. All 
subsequent steps were based on sequencing by Next Generation Sequencing methods on the 
Illumina Hiseq 2000 platform. Basecall files (*.bcl) were generated by the Illumina instruments 
and de-multiplexed and converted to fastq.gz format using CASAVA v1.8.2. Each pair of 
fastq.gz files was then aligned against human reference build 37 using BWA, v0.6.2. The 
resulting SAM files were converted to BAM format, sorted and indexed using SamTools 
v0.1.18. Duplicate reads in the sorted BAM file were marked using PicardTools v1.86. The 
duplicate marked BAM files were processed using GATK v1.6–13, following their “Best-
Practices V3”. Each BAM was realigned around known INDELs and base quality scores were 
recalibrated, resulting in a recalibrated BAM file. Variants for each recalibrated BAM file were 
called using GATK Unified Genotyper, with SNPs and INDELs saved to separate files. These 






Figure 2. Schematic representation of the MLL3 protein and distribution of mutations 
found in ATL patients  
a Schematic representation of the MLL3 protein. Nonsense and missense mutations found in 
ATL patients are shown in red and blue, respectively. b Chromatogram of the sequence of MLL3 
from normal PBMC DNA (top) and MLL3 from ATL DNA with amino acid 904 nonsense 
mutation (bottom). c Alignment of ATL patient DNA KOE with MLL3 demonstrates the 
presence of a stop codon TGA in position 904. SNPs identifying the MLL3 sequence (different 




Direct PCR-sequencing and TA cloning for analyses 
Direct sequencing of ATL DNA was performed after PCR amplification using specific primers 
described below. In the case of MLL3 primers were located in introns surrounding exon 16. 
Primers amplify genome sequence from 152235498 to 152236241 of chromosome seven which 
encompass the MLL3 Exon16 nucleotide 2653 to 2769 (amino acid 884 to 923). MLL3 F: 
CAGGCTATAGTTGTTGTCGTCACCAAG; MLL3 R: 
CATAACATGATAGTAAGCAAATATCTATC. TET2-414 primers amplify nucleotide 842 to 
1379 exon1 of TET2, which correspond to TET2 amino acid 281 to 459. TET2 Q414-F: 
ACTCTGAGCTGCCTCCAAAG; TET2 Q414-R: GAAGGTGGTGCCTCAGGTTT. TET2-876 
primers amplify nucleotide 2403 to 2866 exon1 of TET2, which correspond to amino acid 801 to 
955. TET2 Q876-F: TGTCCAAATGGGACTGGAGG; TET2 Q876-R: 
GATGCCACCTTAGAGCAGCA. Individual clones were obtained by TA-cloning (Invitrogen) 










Figure 3. Schematic representation of TET2 protein and distribution of mutations found in 
ATL patients 
(a) Schematic representation of TET2 protein. (b and c) Somatic LOH Q414* and LOH Q876* 
were confirmed by direct sequencing and analyses of TA clones from high grade tumor and 





Despite profound epigenetic alterations in the genome of ATL cells, the genetic status of 
chromatin modifiers has not been investigated. In this study we performed next generation 
exome sequencing (NGS) to identify novel mutations in epigenetic regulators in ATL samples. 
The polycomb repressive complex 2 (PRC2) has histone methyltransferase activity and primarily 
trimethylates histone H3 on lysine 27 (H3K27me3), a mark of transcriptionally silent chromatin 
[16]. The PRC2 complex has four subunits: SUZ12, EED, EZH1 and EZH2. LOH mutations of 
EZH2 or SUZ12 have been reported in 25 % of T-ALL [17]. In addition, the loss of PRC2 
activity cooperates with mutated Notch1 by allowing recruitment of the intracellular domain of 
Notch onto the promoter of target genes [17]. Along these lines, activated Notch is also required 
for ATL cell growth and tumor formation in an ATL mouse model [18]. While the EZH2 gene 
was not mutated in our study, 1/13 ATL sample had a mutation in SUZ12 (Additional file 1: 
Table S1). It will be interesting in future studies to investigate if there is any cooperation of 
EZH2 and/or SUZ12 with activated Notch in a larger cohort of acute ATL patients. The coding 
sequence of the other two subunits, EED and EZH1, was not mutated in any of the ATL samples 
tested. The possibility that some members of PRC2 may be regulated post-transcriptionally by 
microRNA or LncRNA in ATL cells is under investigation. Similarly, miR101, miR-26 and 
miR208b have been shown to target EZH2, miR-323-3p to target EED, and miR-200b to target 
SUZ12. An earlier study demonstrated that decreased expression of miR-101, but not MiR-26b, 
in acute ATL is in part responsible for elevated expression of EZH2 in these cells [19]. 
Consequently, increased expression of the EZH2 protein induced the silencing of miR-31, 
resulting in NIK-mediated activation of NF-kB in ATL cells [20]. Additional sex combs like 
transcriptional regulator 1 (ASXL1) interact with PRC2 and are likely involved in a cross-talk 
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between chromatin silencing systems, PRC1/PRC2, the HP1α/CBX5 heterochromatin repressive 
complex and the polycomb repressive deubiquitinase (PR-DUB) complex. Mutation of ASXL1 
has been reported in AML and chronic myelomonocytic leukemia (CMML) patients [21]. Our 
study revealed mutations of ASXL1 in 2/13 ATL samples (Additional file 1: Table S1). 
Interestingly, an ASXL1 somatic mutation, V1092M, detected in one ATL patient has also been 
reported in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) [22]. 
We next analyzed DNA (cytosine-5)-methyltransferases (DNMT1, DNMT3A and DNMT3B), 
which catalyze the transfer of methyl groups to specific CpG islands in DNA and are involved in 
maintenance or de novo methylation. Somatic mutations in DNMT3A have been reported as 
nonsense, frameshift, and missense mutations throughout the open-reading frame in 5–20 % of 
AML and MDS [23]. These studies suggested a potential gain-of-function that did not require the 
presence of a wild type copy of DNMT3A for altered function. Our analyses identified mutations 
in 7.5 % (1/13) of DNMT1 (isoform a) and DNMT3A (isoform b) and 15 % (2/13) of DNMT3B 
(isoform 1) of ATL samples. Interestingly, the same mutation at position N442K of DNMT3B 
was identified in two different unrelated ATL patients and has been reported in prostate cancer 
cells and the Cosmic Database. 
The Mixed Lineage Leukemia (MLL) family of genes (also known as lysine (K)-specific 
methyltransferases (KMT2)) plays an important role in histone methylation and transcriptional 
activation and is involved as a regulator of growth of hematopoietic precursor cells. Mutation of 
MLL and MLL2 was observed in 7.5 % (1/13) of ATL patients. The MLL3 gene, which encodes 
a component of a histone H3 lysine 4 methyltransferase complex named the ASC-2- and Mll3-
containing complex (ASCOM), has been implicated as a tumor suppressor gene due to its 
frequent mutations in multiple types of human tumors [24]. Exome sequencing has recently been 
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used to identify an MLL3 germ line mutation in a pedigree of colorectal cancer and acute 
myeloid leukemia [25]. Mutations and LOH in MLL3 has been reported in various human 
cancers [26]. Our initial NGS analyses identified a high rate of nonsense mutations in MLL3 at 
position R904* of ATL samples (Fig.(Fig.2a).2a). This was interesting because early termination 
of MLL3 is predicted to produce a dominant negative form with oncogenic activities [27]. The 
presence of R904* on a highly conserved sequence homologous to MLL3 present on 
chromosome 13 likely contributed to the wrong assignment of a snp (rs200662726) in position 
R904* of the MLL3 gene in the NCBI database (Additional file 2: Table S2). Nevertheless, 
direct sequencing for all ATL DNA samples confirmed LOH for MLL3 in one ATL patient 
(Fig.2b and c). 
 
Ten-eleven translocation methylcytosine dioxygenase genes (TET1-3) are involved in DNA 
demethylation. Our investigations reveal mutation in the coding sequence of TET1 in 15 % 
(2/13). The mutation I1229M has been reported in the cosmic database. We also noticed the 
presence of TET1 single nucleotide polymorphism (snp rs3998860) I1123M. This snp has a 
global minor allele frequency (MAF) of 0.3067/1536 but was detected in all ATL samples tested 
(Additional file 1: Table S1). A larger cohort study is needed to confirm these data. No mutations 
were detected for TET3 (Additional file 1: Table S1). Interestingly, TET2 was mutated at a high 
frequency of 38 % (5/13) in ATL patients. These results are in line with the high rate of somatic 
TET2 inactivation observed in MDS, MPN, chronic myelomonocytic leukemia (CMML) and 
AML [28], and they suggest that TET2 may play an important role in ATL pathogenesis. TET2 
LOH was found in two ATL patients with nonsense mutations at positions Q876* and Q414* 
(Fig.(Fig.3a),3a), two mutations previously reported in CML patients. For these two ATL 
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patients, we PCR amplified the TET2 region overlapping these mutations and cloned and 
sequenced five clones for high tumor grade and matched samples. ATL12 DNA was extracted 
from a high grade lymph node biopsy from megakaryocytes as a tumor negative control. For 
ATL11 DNA was extracted from high proviral load (high grade tumor sample) samples before 
therapy and control sample DNA obtained after complete remission. Proviral loads were 
confirmed by quantitative real time RT-PCR for all samples (Fig. 1). Both mutations, Q876* and 
Q414*, were somatic mutations found in TET2 of ATL cells and not detected in control samples 
(Fig.3b and c). We then analyzed an additional 18 acute ATL patients by direct PCR, cloning 
and sequencing and found 6/18 (30 %) with the mutation (Fig. 4). Among missense ATL 
mutations only a mutation in position Q414R has previously been reported, although it was 
Q414L (COSM1618223). Of note, we found another unrelated ATL patient with a Q876* 










In this study we report a high frequency of TET2 missense mutations (8/31 (25 %)) and LOH of 
TET2 (3/31 (10 %)) in acute ATL patients. These data suggest that TET2 may be involved in 
HTLV-I pathogenesis and warrant additional studies. Studies have shown that the TET2 
mutation results in global low levels of 5hmC compared with normal controls, supporting a 
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functional relevance of TET2 mutations in leukemogenesis. Activating mutations of IDH1/2 
have been shown to be mutually exclusive with mutations of TET2 [29]. Although mutations of 
IDH1/IDH2 have the same final epigenetic effect as TET2 inactivation, mainly a global promoter 
hypermethylation, mutation in IDH1/2 was not observed in any ATL samples tested here. 
Consistent with this notion, increased methylation of CDKN2A promoter has been associated 
with the progression of ATL disease [30]. Wilms tumor (WT1) mutant AML patients have 
reduced 5hmC levels similar to the TET2/IDH1/IDH2 mutant in AML, suggesting that WT1 may 
also play an important role in control of the epigenome [31]. WT1 and TET2 interact with one 
another. Although there are no reports regarding the genetic status of WT1 in ATL cells, we have 
previously shown PI3K-dependent cytoplasmic retention and inactivation of WT1 in HTLV-I 
transformed cells [32]. It will be interesting to evaluate the role of cytoplasmic WT1 in the 
regulation of TET2 functions in HTLV-I transformed T cells. Although a number of genes have 
been shown to be hypo- or hypermethylated in ATL cells, a direct implication of these genes in 
cellular transformation and/or ATL pathogenesis is lacking. In this study, we also found LOH in 
1/13 ATL patient for MLL3. ASCOM-MLL3 has a redundant but crucial role in transactivation 
of p53 and participates in DNA damage-induced expression of p53-targeted genes [33]. Notably, 
p53 transcriptional functions are impaired in ATL patients in the absence of genetic mutations in 
p53 [34] and the possibility that loss of MLL3 participates in this process for some ATL patients 






In summary, this report used both next generation sequencing and classic direct sequencing 
methods to identify mutations of epigenetic regulators in freshly isolated uncultured ATL 
samples. This study identifies for the first time mutations in multiple genes involved in the 
maintenance of the epigenome. Notably, a high frequency of mutation was detected in the TET2 
gene with the presence of nonsense mutations leading to LOH in ATL patients. Our data suggest 
that TET2 and possibly MLL3 LOH may be involved in ATL pathogenesis and larger clinical 















Table 1. Novel mutations identified in epigenetic regulators EZH1, EZH2, EED, SUZ12, 
DNMT1, DNMT3A, DNMT3B, TET1, TET2, TET3, IDH1/2, MLL, MLL2, MLL3, MLL4 
and ASXL1 in ATL patients 
The mutations previously reported as SNPs are not included. Novel mutations are labeled in blue 
(missense) or in red (nonsense). Samples 1–7, 10 and 11 were isolated from patients diagnosed 
with acute ATL. Samples 8, 9, 12 and 13 were isolated from high proviral load tissues (Fig. 1) 







Table 2. Sequence alignment of MLL3 gene and genome regions of very high homology 
found in chromosome 1, 2, 3, 13 and 21 
Nucleotide differences specific to MLL3 are highlighted in red. TGA snp rs200662726 
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MicroRNAs are non-coding RNAs reported to be involved in critical biological processes. In 
past years, deregulation of miRNAs has been documented in several pathological conditions, 
including cancer. Overexpression and suppression of miRNA expression affect cellular pathways 
and contribute to carcinogenesis and tumor progression. This evidence makes miRNAs a suitable 
candidate for therapeutic applications and results in the development of strategies to manipulate 
their expression. There are different approaches that can be used to restore or reduce miRNA 
expression [1, 2].  
Restoring miRNA expression could represent a successful strategy for cancer treatment. The 
reintroduction of miRNA function can be obtained by using double-stranded RNA mimics. 
MiRNA-mimics present a strand that is identical to the miRNA of interest, with the other strand 
conjugated with a molecule, promoting cellular uptake. Synthetic RNA duplexes are currently 
modified to improve stability and cellular uptake. [3, 4]. Moreover, chemical modifications can 
be used to prevent the processing of miRNA-mimics RISC and nucleases to avoid degradation 
and increase the stability. [5]. Importantly, potential issues can occur by using synthetic RNA 
duplexes, for example, activation of non-specific interferon response through Toll-like receptors 
and overexpression of the miRNA of interest over the `normal` level of expression [6].  
Moreover, enforced delivery of miRNA mimics might have off-target effects due to the 
expression of the miRNAs of interest not only in target cells but also other cell types. 
Consistently, alteration of miRNA expression in normal tissues can generate potential side 
effects. To avoid this possibility, lenti-, adeno- or adeno- associated viruses can be used. [3].  
Alternatively, suppression of miRNA expression can be achieved by antisense miRNAs, which 
present a complementary binding site of the miRNA of interest to repress its function. Several 
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chemical modifications have been developed to promote the stability and the pharmacokinetics 
of anti-miRNA oligonucleotides, such as 2`-O-Methyl (2`-O-Me) and 2`-O-Methoxyethyl (2`-
MOE) and bicyclic locked nucleic acid (LNA) sugar modifications. These changes improve the 
resistance of anti-miRNA oligonucleotides to nuclease and increase the melting temperature 
(Tm) [7, 8].  
The first strategy used to suppress miRNA function in vivo was to link the cholesterol to 
antagomirs or chemically modified antimiRs [3]. However, the effect was found to be limited. 
More recent studies show that a nanoparticle encapsulated with antimiRs efficiently inhibits 
miRNA function both in vitro and in vivo, indicating that they might represent the most efficient 
methodology to suppress miRNA expression [9-11].  
In cancer therapy, miRNA-based therapeutics are finalized to restore or reintroduce miRNA 
expression. Based on preclinical and clinical studies, miRNA therapeutics appear to be a novel 
promising strategy for human diseases. Importantly, the first phase II clinical trial testing anti-
miR-122 in chronic HCV patients showed it to be a promising and well-tolerated therapy, 
supporting the notion that pharmacological modulation of miRNA activity might represent a new 
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HTLV-I-associated diseases have limited therapeutic options. The four-year survival average for 
acute and lymphoma types of ATL is 5 and 5.7%, respectively [1-14], because HTLV-1-
transformed cells are resistant to conventional chemotherapy. Therefore effective therapy for 
ATL is lacking and development of more efficient treatments is essential.  
The genomic instability induced by the viral protein Tax is reported to be involved in cellular 
transformation [15-25]. In addition, Tax has been shown to constitutively activate NF-kB [26-
32], which promotes the proliferation and survival of the infected cells [33-45]. The mechanisms 
that the oncoprotein Tax used to lead to celluar transformation are different. Tax prematurely 
activates the anaphase promoting complex [46-49], inhibits nucleotide excision repair [50-52] 
and affects the topoisomerase activity [53;54] and beta-polymerases [55]. Tax has been reported 
to interfere with the DNA replication fork and induces DNA double-strand breaks (DDSB).  
As discussed in the previous section, Tax inhibits homologous recombination repair (HR) in 
HTLV-I-transformed cells. Based on these observations we hypothesized that HTLV-I-
transformed and ATL cells might be particularly sensitive to small PARP inhibitors, which have 
been shown to induce selective apoptosis in HR-deficient cell lines, such BRCAness cells. 
Consistently, our studies have shown that HTLV-1-transformed and ATL-derived cell lines are 
sensitive to the treatment with PARP inhibitor PJ-34. In the absence of a curative therapy for 
ATL, our preclinical study has validated the PARP inhibitor PJ-34 as a potential novel 
therapeutic approach for patients. The future prospective of this project is to study the efficacy of 
several PARP inhibitors as monotherapy or in combination therapy in vitro and in vivo.  
In order to investigate the therapeutic efficiency of PARPi we want to investigate the apoptotic 
effect of additional PARP inhibitors currently in phase II/III clinical trials, such as Olaparib, 
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Veliparib, ABT-888, Talazoparib, BMN-673, and Niraparib, MK-4827. For every inhibitor we 
want to test dose-dependent and time-dependent toxicity in HTLV-1 and ATL-derived cell lines. 
Interestingly, our study has shown that PJ-34 has a superior apoptotic effect on ATL cells 
compared to Olaparib. We believe these types of experiments are important to individuate among 
the different PARP inhibitors which is more efficient for ATL patients. In addition, we will 
include activated isolated and unstimulated PBMCs isolated form HTLV-1 negative donors to 
confirm absence of PARPi toxicity at the drug concentration selected above for ATL cells.  
Combination therapy using a DNA damaging agent along with PARPi might represent a 
promising approach because it would lead to the accumulation of DDSB in ATL cells, which 
might enhance the apoptotic effect of PARPi. The DNA damaging agents Paclitaxel, 
Doxorubicin or Vincristine have been shown to induce apoptosis in HTLV-I-transformed cells 
[64-67]. We want to investigate the potential synergistic effects of PARPi in combination with 
Paclitaxel, Doxorubicin or Vincristine.  
Alternatively, we will investigate the effect of small inhibitors of signaling pathways involved in 
DNA repair or typically activated in cancer cells. Activation of the PI3K pathway is reported in a 
wide range of tumors and promotes cellular growth and the survival. More importantly, the PI3K 
pathway plays an essential role in the sensing of DDSB during the S-phase of the cell cycle [68]. 
Consistently, activation of the PI3K was noted in ATL cells and is involved in cellular 
proliferation [69-71]. Moreover, the treatment with BKM120, a PI3K inhibitor, has significantly 
reduced the expression of BRCA1, BRCA2 and, consequently, the efficiency of HR DNA repair.  
In addition, an interesting study published by our laboratory shows that Ku80 and DNA-PK 
specifically co-localized with γ-H2AX foci on DNA breaks in HTLV-I-transformed cells, 
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suggesting that these cells preferentially repair the DDSB by using Non-homologous End Joining 
repair (NHEJ). Consistently, when these cells are exposed to NU7026, a specific DNA-PK 
inhibitor, a significant inhibition of proliferation and survival of HTLV-I-transformed cells were 
noted [72]. Based on this evidence we would like to test BKM120 or NU7026 alone and in 
combination with each PARPi on HTLV-I-transformed and ATL-derived cells to evaluate the 
synergistic effects. Alternatively, since drug synergies can be manifested through concomitant 
blockade of parallel signaling pathways or dual inhibition of the same pathway at distinct nodes, 
combination therapies can be better understood (and predicted) by monitoring gene and protein 
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